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Abstract 
 
Huntington’s disease (HD) is an adult-onset, autosomal dominant neurodegenerative 
disease characterised by progressive movement disorder, psychiatric and cognitive 
symptoms. The causative genetic mutation is an abnormally expanded CAG triplet 
repeat near the N-terminus of exon 1 of the huntingtin gene (HTT), and longer CAG 
repeat lengths are associated with earlier age of disease onset. The aim of this thesis 
was to create a HTT allelic series cell model of HD in which the effects of increasing 
CAG repeat length, against a stable genetic background, could be observed within 
human neurons.  
 
Initially, recombinant adeno-associated virus (rAAV) was used to knock-in different 
CAG expansions into an immortalised human neural stem cell line (ReNcellVM), but 
due to low rates of homologous recombination, this was not successful. Instead, work 
was undertaken to optimise and characterise a transgenic HTT exon 1 allelic series in 
the ReNcellVM line; there is much evidence to suggest that HTT exon 1 is the 
pathogenic species in HD and generates phenotypes over a faster timescale than full-
length HTT models. In ReNcellVM neurons the expression of pathogenic HTT exon 1 
led to the formation of mutant HTT aggregates in a proportion of cells, in a manner that 
was related to CAG-repeat length and levels of HTT exon 1 expression. No overt cell-
death phenotypes were seen but subtle differences between control and mutant lines 
were observed. 
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To complement the HTT exon 1 model, an induced pluripotent stem cell (iPSC) model 
was generated from an HD family who carried a range of CAG-repeat length mutations. 
These cells were differentiated into medium spiny neurons (MSNs) and both models 
were used to study the trafficking of huntingtin within cells; whilst differences were 
observed between the trafficking of control and mutant HTT exon 1, these were not 
apparent in the MSNs which express full-length HTT.  
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Impact statement 
 
This thesis describes the production and optimisation of two novel cell models of 
Huntington’s disease. The first is a human neural stem cell allelic series that 
overexpresses HTT exon 1 with increasing CAG-repeat lengths. This model displays 
robust differentiation into neurons within two weeks and is amenable to high content 
imaging as demonstrated in chapter four of this work. The model therefore lends itself 
to high content screening of therapeutic compounds and has been used in industrial 
collaborations with Takeda (now Cerevance) to advance this purpose. The model was 
also used in collaboration with Proteostasis Therapeutics Inc (PTI) to assess the ability 
of various compounds (USP14 inhibitors) to clear pathogenic mutant HTT exon 1 from 
neurons, as described in chapter five. This model continues to be available for further 
therapeutic research within industry or academia, and to the wider academic 
community for basic science research in HD and general neuroscience.  
 
An induced pluripotent stem cell (iPSC) cell model of HD has also been generated from 
a family of HD patients as described in chapter three. These cells differentiate into 
medium spiny neurons and have been used to study the trafficking of HTT protein, as 
discussed in chapter six. This model is unique as the genetically related background of 
the donors goes some way to eliminating the genetic heterogeneity that can affect 
comparisons between control and mutant HD iPSC cells. This model forms the basis of 
ongoing work in the HD research group at UCL. The fibroblasts derived from the 
patients’ skin biopsies have been used to demonstrate the presence of pathogenic HTT 
exon 1 protein, as described in the publication “The pathogenic exon 1 HTT protein is 
produced by incomplete splicing in Huntington's disease patients” (Neueder, Landles, 
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Ghosh et al 2017; Sci Rep 7(1):1307). This model is also a useful tool for the wider HD 
research community both in academia and industry.  
 
A manuscript entitled “Expression of mutant huntingtin exon 1 fragments in human 
neural stem cells and neurons causes inclusion formation and mitochondrial 
dysfunction”, which describes work in chapters four and five of this thesis is being 
prepared for publication in FASEB journal, and in addition aspects of this work have 
been presented at the European Huntington’s Disease Network (EHDN) meeting in 
Sept 2016, which is attended by scientists, clinicians and patients. In this way, the main 
findings of this thesis have been disseminated to a broader audience.  
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1 Introduction 
 
 
1.1 Huntington’s disease 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease, 
characterised by a triad of motor, cognitive and psychiatric features. There is typically 
adult onset, with irreversible progression of symptoms over 10-15 years (Ross & 
Tabrizi, 2011). It was first described by an American doctor, George Huntington, in 
1872 (Huntington, 1872). He noted that certain families were affected by a hereditary 
condition marked by chorea and psychiatric symptoms and that the disease was “one 
of the incurables”. Almost 150 years later we now know much about the genetics and 
the pathogenesis of HD, and international collaborative research efforts continue with 
the hope of finding an effective therapy. Studies in HD basic science research remain 
essential in realising this goal.   
 
1.1.1 Epidemiology of HD 
 
The prevalence of HD varies across the globe. In Western and European populations, 
it has typically been quoted at around 4-10/100,000 people (Harper, 2002), however a 
more recent study from the UK suggests it may be closer to 12.3/100,000 population 
(Evans et al, 2013; Rawlins, 2010). This makes it among the more common of the 
inherited neurological diseases. There has traditionally been great stigma attached to 
the diagnosis of HD (Wexler, 2010); from accusations of witchcraft to the more recent 
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and disturbing eugenics movement of the last century, families affected by HD may feel 
pressured into hiding their condition – often at the expense of getting medical help. 
This is believed to have led to an underestimation of the true prevalence of the 
disease.  
 
HD was originally thought to have migrated from North-West Europe to other parts of 
the world. Although migration is undoubtedly a major contributor of HD prevalence, de 
novo genetic mutations also make a significant contribution. In some communities, the 
prevalence of HD is exceptionally high. One of the best studied of these is the 
population living near the edge of Lake Maracaibo in Venezuela, where 700/100,000 
people have HD. In 1983, genetic linkage studies in this group of people paved the way 
for the identification of the genetic mutation causative of Huntington’s disease ten years 
later (1993; Gusella et al, 1983; Huntington's Disease Collaborative Research Group, 
1993)  
 
1.1.2 Genetics of HD 
 
Huntington’s disease is caused by an expanded CAG triplet repeat in exon 1 of the 
gene encoding huntingtin protein, which lies on the short arm of chromosome 4. This 
creates an elongated polyglutamine (polyQ) stretch at the N-terminus of the mutated 
protein. HD displays autosomal dominant inheritance and so the presence of the gene 
mutation on either allele leads to the disease state. The wild type gene carries 10-35 
CAG repeats, with a mean value of 18 repeats across the UK population (Snell et al, 
1993). The mutation is fully penetrant at 40 or more repeats. Those who inherit 36-40 
repeats have a reduced penetrance form of the disease – they may develop symptoms 
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of HD in older age, or they may never become symptomatic (Rubinsztein et al, 1996). 
Individuals with 27-35 CAG repeats are said to carry an “intermediate allele”, and have 
long been thought to remain asymptomatic. However, a recent study suggests that 
there may be a behavioral phenotype in this group of people (Killoran et al, 2013). 
Intermediate alleles can expand during meiosis, leading to the potential acquisition of a 
disease gene carrying 36 or more repeats in the offspring. A recent PCR analysis of 
sperm cell DNA suggests that the highest risk of this is where the CAG repeat lengths 
are 34 or 35, with the risk of a new pathogenic mutation being 2.4% and 21% 
respectively (Semaka et al, 2013).  
 
Seemingly sporadic cases of HD can arise when there has been misdiagnosis of the 
condition in other family members, or death has occurred by some other means before 
symptoms of HD have developed in prior generations. Occasionally non-paternity also 
leads to “sporadic” cases of HD. This highlights the importance of taking a detailed and 
complete family history when considering the diagnosis of HD. Approximately 6-8% of 
cases of newly diagnosed HD arise in families with no apparent family history (Almqvist 
et al, 2001; Siesling et al, 2000).  
 
1.1.2.1 Anticipation 
 
There is inherent instability of the CAG repeat during meiosis, which can lead to 
expansions (and sometimes contractions) in the number of CAG repeats inherited by 
successive generations (Zühlke et al, 1993). Longer CAG repeat lengths correlate with 
an earlier age of onset of disease, and so as the condition is passed down the family 
symptoms can develop at progressively younger ages. This is a phenomenon known 
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as anticipation. Anticipation is more likely to occur when inherited down the paternal 
bloodline. This is hypothesized to be due to differences in spermatogenesis and 
oogenesis (Kremer et al, 1995). In rare instances, large increases in CAG repeat occur 
leading to juvenile HD (JHD) when the age of onset is <20 years old. Paternal 
inheritance is seen in 90% of JHD cases (Barbeau, 1970; Kremer, 2002).  
 
1.1.2.2 Effects of CAG repeat length 
 
As stated above, longer CAG repeat lengths correlate with an earlier age of disease 
onset. Studies at a population level have shown that 50-70% of the variability in age of 
onset is determined by the CAG repeat length. Recent studies have shown that genetic 
variants in DNA repair proteins account for some of the remainder of the variability 
(Consortium, 2015). It is important to emphasize that it is not possible in a clinical 
setting to predict an individual’s age of onset of disease from their CAG repeat length, 
particularly as the majority of patients with HD have CAG repeats ranging from 40-50, a 
range at which great unpredictability is observed.  
 
A conditional probability model developed by Langbehn et al takes into account not 
only the CAG repeat length, but also the number of disease-free years already lived 
(Langbehn et al, 2004; Langbehn et al, 2010). It is based on data from a large cohort of 
3000 patients and is more accurately able to estimate the percentage chance of 
disease free survival over a set number of years (usually 5 years). However, even this 
more sophisticated model is based on population data and so cannot be extrapolated 
to apply in a clinic setting. Patients often experience psychiatric and cognitive 
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symptoms for many years before their official disease onset (as defined by the 
presence of definitive motor signs), further complicating the issue.  
 
The rate of clinical disease progression after motor onset has also shown some 
correlation with CAG repeat length (Rosas et al, 2011; Rosenblatt et al, 2012), and 
again variants in DNA repair proteins contribute (Hensman Moss et al, 2017). It is 
worth noting that CAG repeat length does not predict the exact disease phenotype; for 
example, it is much less strongly correlated to the age at onset of psychiatric symptoms 
than motor symptoms. The duration of disease from diagnosis to death is also 
independent of CAG repeat length.  
 
1.1.3 Clinical aspects of HD 
 
Huntington’s disease is characterized by motor, cognitive and psychiatric symptoms. 
Generally the disease develops in adult life with an average age of onset of 40 years, 
though cases of HD have been diagnosed in patients as young as 2 years old, ranging 
up to 87 years. From the time of disease onset, symptoms progress over 15 to 20 
years; the most common cause of death is pneumonia (Lanska et al, 1988). 
 
1.1.3.1 Natural history and disease progression 
 
Patients are said to have onset of “manifest” disease only when there is the presence 
of unequivocal motor signs (e.g. chorea, dystonia, bradykinesia, rigidity) that have no 
explanation other than HD; however it is quite common to have psychiatric or cognitive 
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symptoms and subtle motor signs for many years before this (Ross & Tabrizi, 2011). 
This prodromal phase of HD corresponds to neurobiological changes including striatal 
atrophy and loss of corticostriatal connectivity (Tabrizi et al, 2012; Tabrizi et al, 2013).   
 
 
Figure 1.1: The natural history of Huntington disease, showing premanifest and 
manifest disease with corresponding clinical changes. (Reproduced from Ross CA, 
Aylward EH, Wild EJ, et al. (2014) Huntington disease: natural history, biomarkers and 
prospects for therapeutics. Nat Rev Neurol 10: 204–216, with permission from Springer 
Nature) 
 
Patients who are known to carry the HD gene mutation but who have not yet developed 
motor onset of disease are defined as “premanifest”, however it does not necessarily 
follow that they are completely asymptomatic (although generally up to 10-15 years 
prior to disease onset they are clinically indistinguishable from controls) (Ross et al, 
2014). More recently, the term “perimanifest” disease has been used to describe that 
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group of patients with prodromal HD who are felt by their clinician to be developing the 
motor signs that will lead to a diagnosis of “manifest” HD in the near future.  
 
1.1.3.2 Clinical presentation 
 
Motor Features 
Motor symptoms of HD consist of involuntary movements seen predominantly in early-
moderate stage typical adult onset disease, and impaired voluntary movements that 
are more common in advanced disease and JHD. More subtle motor changes also 
occur many years prior to disease onset. The TRACK-HD study found differences in 
speeded tapping over 36 months between control and premanifest patients who were 
predicted to be over 10.8 years from disease diagnosis (Tabrizi et al, 2013). 
 
Chorea is one of most striking features of HD.  Indeed, the disease was initially named 
Huntington’s chorea before this was changed to give recognition to the wide range of 
non-motor features. Chorea comprises involuntary, excessive movements, which are 
short lived and may appear semi-purposeful. Other motor symptoms include dystonia, 
myoclonus and tics. Gait and postural reflexes are affected and walking aids may be 
needed. As the disease progresses, hyperkinetic movements decrease and instead 
bradykinesia, akinesia and rigidity dominate.  
 
Cognitive features 
Cognitive symptoms are universal in HD and may emerge years before disease onset 
(Paulsen et al, 2008; Stout et al, 2011). Symptoms range from subtle deficits to frank 
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dementia later in the course of disease. Executive functioning i.e. high-level processing 
that controls other more basic aspects of cognitive function is commonly affected in 
HD. There may also be general cognitive slowing, impaired short-term memory (with 
problems learning and retrieving new material) and poor emotion recognition (Peavy et 
al, 2010; Stout et al, 2012; Stout et al, 2011). There is some overlap with psychiatric 
symptoms in terms of disinhibition and impulsive behaviours, with accompanying lack 
of insight (Duff et al, 2010). Semantic memory remains relatively preserved (Craufurd 
D, 2002). Some patients with advanced disease may develop a severe frontal and 
subcortical dementia. 
 
Psychiatric features 
Psychiatric symptoms can be the most distressing aspect of HD for both patients and 
their carers and are common (affecting 33-76% of patients (van Duijn et al, 2007)). 
Indeed suicide is the second most common cause of death in HD (Lanska et al, 1988). 
Symptoms occur in both prodromal and manifest HD and arise not only as a response 
to the diagnosis, but due to the underlying neurobiology of the disease. Depression is 
the most common condition, followed by anxiety (Paulsen et al, 2005). Apathy is also a 
common and disabling feature of HD that tends to worsen over time. Other 
neuropsychiatric symptoms include irritability and aggression, obsessive, compulsive 
thoughts and behaviours, and psychosis. 
 
Other neurological symptoms 
Speech difficulties arise from a combination of dysarthria and word finding difficulties 
secondary to cognitive dysfunction. Swallowing problems similarly arise from a 
combination of incoordination of oral and pharyngeal muscles, and cognitive 
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impairment. This can cause choking and in more severe cases lead to aspiration and 
subsequent pneumonia (the leading cause of death in HD). Sleep disturbance is a 
common complaint of patients (Videnovic et al, 2009), resulting from low mood, anxiety 
or night-time chorea or intrinsic circadian rhythm dysfunction.  
 
Systemic symptoms 
Though the most dramatic effects of HD are on the nervous system, a range of 
systemic symptoms can also be observed (van der Burg et al, 2009). Severe weight 
loss often occurs, greater than that seen in other hyperkinetic movement disorders, and 
may lead to cachexia. It is thought to be secondary to an underlying catabolic state as 
part of the disease pathology and not simply due to feeding or swallowing difficulties or 
chorea. This may begin during the prodromal phase of HD and there is an association 
between higher body mass index at disease onset and slower rate of disease 
progression (Myers et al, 1991). In addition, heart failure is seen in 30% of patients, 
compared to 2% of age-matched controls (Lanska et al, 1988). Both osteoporosis and 
skeletal muscle atrophy are observed, despite the muscle hyperactivity secondary to 
chorea. Endocrine problems with thyroid dysfunction and impaired glucose tolerance 
occur. Testicular atrophy with reduced numbers of germ cells and abnormal 
seminiferous tubules is noted. Despite reduced levels of testosterone in men, fertility 
remains unaffected.  
 
There is evidence for widespread activation of the immune system in HD as plasma 
samples from patients show increased levels of IL-6 and IL-8 (Bjorkqvist et al, 2008), 
which may contribute to the peripheral phenotype described. The range of peripheral 
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effects is perhaps not surprising given that cells throughout the body, and not just in the 
nervous system, express huntingtin protein. 
 
Juvenile Huntington’s disease 
Juvenile HD (JHD) generally arises in those who have inherited >55 CAG repeats 
(Andrew et al, 1993), and is defined by an age of onset less than 20 years old. The 
clinical presentation of JHD varies from the adult form in that rigidity, bradykinesia and 
akinesia are present from disease onset, rather than the hyperkinetic presentation 
commonly seen in adult onset HD. There may also be learning difficulties and 
behaviour disturbance whilst at school. Seizures occur in 30-50% of patients (Kremer, 
2002). This rigid phenotype of HD is also known as the Westphal or akinetic-rigid 
variant and on rare occasions presents as adult onset disease. 
 
1.1.3.3 Diagnosis of HD 
 
Diagnosis relies on clinical findings, which must include unequivocal motor signs, in 
combination with a positive family history suggestive of an autosomal dominant pattern 
of inheritance. The role of neuroimaging and CSF testing is only for the investigation of 
other causes of chorea. Genetic testing to determine the CAG repeat length in the HD 
gene confirms the diagnosis (Craufurd et al, 2014).  
 
Diagnostic tests are carried out on those people who are displaying motor signs 
consistent with HD; generally they are requested by neurologists to confirm a 
suspected diagnosis. Predictive tests are carried out in asymptomatic individuals with a 
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positive family history of HD and must be carried out in accordance with international 
guidelines (1994; Craufurd & Tyler, 1992; Went, 1990). Overall just under 20% of 
patients at risk of HD proceed with predictive genetic testing (Baig et al, 2016).  
 
1.1.3.4 Management of HD 
 
The clinical management of HD requires a multidisciplinary approach. There are 
currently no disease-modifying treatments available, and so treatments aim to alleviate 
symptoms and optimize function (Bonelli & Hofmann, 2007; Frank, 2014; Mason & 
Barker, 2009). Anti-chorea medication should be considered if there is functional 
impairment, for example in terms of manual dexterity or falls. A Cochrane review of 
studies for the symptomatic treatment of HD examined 22 studies and concluded that 
only tetrabenazine (TBZ) showed clear efficacy for the control of chorea (Mestre et al, 
2009), although in practice, atypical neuroleptics such as olanzapine, risperidone and 
quetiapine are also used, especially if there are psychiatric comorbidities. The 
benzodiazepine clonazepam may be used if there is dystonia, rigidity or myoclonus. 
Tizanidine and baclofen can help with spasticity and rigidity that develop in later stages 
and botulinum toxin injections can be effective in the treatment of muscle spasm 
(Novak & Tabrizi, 2010).  
 
There is a lack of evidence base to guide specific treatment of psychiatric symptoms, 
however depression often responds well to non-stimulating selective serotonin 
reuptake inhibitors (SSRIs) such as citalopram. If insomnia is also a problem, 
mirtazapine, which is a sedating antidepressant, can be used. Cognitive behavioural 
therapy (CBT) can also be useful for appropriately selected patients. Other psychiatric 
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symptoms such as anxiety, irritability, aggression, obsessive-compulsive behaviours 
and psychosis may also respond to treatment with both typical and atypical 
neuroleptics (Novak & Tabrizi, 2010). 
 
 
1.1.4 Therapeutics research in HD 
 
1.1.4.1 Disease-modifying therapies 
 
Over 30 years have passed since the discovery of the causative gene mutation in HD, 
but there remains an urgent and as yet unmet need for treatments. However a number 
of promising avenues to disease modification have been identified recently (Wild & 
Tabrizi, 2014), many of which are proceeding to clinical trials in the near future (figure 
1.2). 
 
Reducing huntingtin expression 
Huntingtin (HTT) lowering through gene silencing is an approach that has seen 
enormous advances in recent years. Mutant HTT is known to primarily cause disease 
through a dominant toxic effect, and so any reduction in its expression should reduce 
its downstream pathological effects. Strategies to lower HTT levels include both post-
transcriptional inhibition such as RNA interference (RNAi) and anti-sense 
oligonucleotides (ASOs), and genome editing techniques such as zinc finger proteins 
(ZFPs).  
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Administration of complementary small interfering RNA molecules (siRNAs) results in 
Argonaut-2 mediated cleavage and degradation of mature, spliced HTT mRNA in the 
cytosol. ASOs have a more upstream site of action and recruit RNaseH1, an 
endogenous enzyme that recognises RNA/DNA duplexes and degrades HTT pre-
mRNA (Keiser et al, 2016).  
 
 
Figure 1.2: Schematic depicting current priority preclinical therapeutic targets under 
investigation for Huntington’s disease. BDNF, brain-derived neurotrophic factor; 
HDAC, histone deacetylase; HTT, huntingtin; KMO, kynurenine monooxygenase; 
NMDA, N-methyl-D-aspartate; PDE, phosphodiesterase; Trk, tyrosine receptor kinase. 
(Reproduced from Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in 
Huntington’s disease: what’s in the pipeline? Mov Disord 29: 1434–1445.) 
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Both siRNAs (Harper et al, 2005; Stanek et al, 2014)  and ASOs (Kordasiewicz et al, 
2012) designed to lower total HTT levels have been shown to improve disease 
symptoms in rodent models. A potential concern in humans is the long-term effect of 
reducing wild-type HTT, although reduction in endogenous wild-type HTT has been 
shown to be well tolerated in non-human primates (Grondin et al, 2012; McBride et al, 
2011). Allele-specific lowering of mutant HTT only (without affecting wild-type HTT) has 
been challenging. However ASOs complementary to the expanded CAG have recently 
been produced which have selectivity for mHTT over HTT, and have led to phenotypic 
improvement in two different mouse models of HD (Datson et al, 2017).	 siRNAs 
designed to target single nucleotide polymorphisms (SNPs) that reside only on the 
mutant HTT allele could also be used to achieve allele specific suppression (Miller et 
al, 2017; Pfister et al, 2009). ASOs targeting mutant-allele linked SNPs have also been 
designed that lead to even greater (up to 50-fold) selectivity of the mHTT allele over the 
normal allele (Carroll et al, 2011; Southwell et al, 2014). Such compounds are 
proceeding to clinical trials in the near future, and will involve screening potential trial 
subjects for the presence of specific SNPs before drug administration.  
 
Gene suppression can also be achieved at the transcriptional level, using effectors that 
bind to specific DNA sequences. Zinc finger proteins (ZFPs) contain a zinc finger 
domain that can be synthetically manipulated to bind HTT DNA, fused to a functional 
domain such as a nuclease. Delivery of such agents is through the use of viral vectors, 
and this approach will also be proceeding into clinical trials soon. Another recently 
discovered genome editing technique is through manipulation of the endogenous 
clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas9 system 
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which recognises and destroys foreign DNA in prokaryotic cells. Incorporation of a 
synthetic guide RNA (gRNA) strand that targets a particular DNA location for cutting, 
followed by the insertion of a desired DNA sequence (for example stop codons), is 
used to inactivate the mutant allele (Cox et al, 2015). The technique has been 
successfully demonstrated in HD patient-derived fibroblasts, leading to the dramatic 
reduction of mutant HTT RNA and mHTT protein (Shin et al, 2016). 
 
A seminal Phase 1/2a clinical trial (IONIS-HTTRx) has recently been undertaken by 
Ionis Pharmaceuticals to test the safety and tolerability of an ASO targeting human 
HTT, delivered by lumbar intrathecal bolus administration to early stage HD patients. 
The trial included neuroimaging assessments and exploratory endpoints to assess the 
effect on cognitive, motor, and neuropsychiatric symptoms. Encouragingly, results from 
this trial have confirmed target engagement, with a reduction in mHTT seen in the CSF 
of trial subjects (Tabrizi et al, 2018). Intrathecal delivery of ASO treatment has shown 
dramatic benefit in patients with spinal muscular atrophy (SMA) (Finkel et al, 2017; 
Mercuri et al, 2018) with trials of ASOs in amyotrophic lateral sclerosis (ALS) also 
demonstrating the safety and tolerability of this general approach (Miller et al, 2013). 
 
Stem cell therapy 
Over the last 15 years there have been a number of small trials of foetal striatal 
transplantation in patients with HD carried out in the United Kingdom (Barker et al, 
2013; Reuter et al, 2008; Rosser et al, 2002), France (Bachoud-Lévi et al, 2006; 
Bachoud-Lévi et al, 2000), Germany (Capetian et al, 2009), Italy (Gallina et al, 2010), 
and the United States (Hauser et al, 2002), but the conclusions so far have been 
mixed. Some have reported improvement or stabilization in motor, functional, and 
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neuropsychological scores (Bachoud-Lévi et al, 2006), but this has not been found 
consistently across groups (Barker et al, 2013; Hauser et al, 2002). This may be due to 
the small numbers of patients treated at each centre, and also the differences in patient 
selection in terms of disease stage between the studies. In addition there were subtle 
differences in methodology with respect to the tissue type transplanted (cells from 
whole ganglionic eminence compared to lateral ganglionic eminence, and also different 
foetal gestation) as well as the preparation of the donor tissue and numbers of cells 
transplanted (Barker et al, 2013). Post-mortem studies, where available, have revealed 
poor long-term graft survival. This may be due to allograft immunoreactivity, 
excitotoxicty, or microglial responses directed against donor tissue (Wijeyekoon & 
Barker, 2011). A more recent study has shown the presence of mHTT aggregates in 
the genetically normal, unrelated grafted donor cells, thus raising questions regarding 
the spread of mutant protein between neurons (Cicchetti et al, 2014) and the long-term 
success of any foetal striatal transplantation therapy. 
 
Small molecule approaches to disease modification 
Basic science research carried out in cellular, mouse, and mammalian models of 
disease has identified a role for huntingtin protein in several different cellular pathways. 
Thus a plethora of potential targets for disease modification exist. Approaches that 
have been shown to be beneficial in animal models, and in some cases are in clinical 
trials are summarised in Table 1.1. 
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Table 1.1: Targets for small molecule approaches to disease modification in 
Huntington’s disease. 
Target Mechanism 
Histone deacetylases 
(HDACs)  
HDAC4 reduction delayed cytoplasmic aggregate formation, restored 
BDNF transcript levels, rescued synaptic function and improved 
phenotype and lifespan in HD mouse models. (Butler & Bates, 2006; 
Mielcarek et al, 2013). 
Post-translational 
modifications 
Phosphorylation of mHtt by ganglioside GM1 at specific residues 
attenuates huntingtin toxicity, and restores normal motor function in 
already symptomatic HD mice (Di Pardo et al, 2012). Acetylation of 
mHTT promotes its clearance by autophagy, and the inhibition of the 
deacetylase sirtuin 1 by selisistat has been shown to have benefit in 
various HD models and is safe and tolerable for patients (Süssmuth 
et al, 2015). 
Phosphodiesterase 
(PDE) 10A 
PDE 10A is expressed in the striatum and regulates cAMP and 
cGMP signalling, synaptic plasticity, and the response to cortical 
stimulation. Inhibition has beneficial effects in animal models 
(Giampà et al, 2010). However, the recently completed Pfizer 
“Amaryllis” trial of PDE10A inhibition in patients has not found any 
beneficial effect on motor function, or other HD symptoms that were 
tested (NCT02197130). 
Brain-derived 
neurotrophic factor 
(BDNF) 
Administration of BDNF improved neurological dysfunction and 
survival in R6/2 mice (Giampà et al, 2013).  Small molecule agonism 
of TrkB, through which BNDF acts, also improved striatal pathology 
and symptoms in HD mouse models (Simmons et al, 2013). However 
cysteamine, which is also thought to act through increasing BDNF 
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levels, has not demonstrated efficacy in a recent clinical trial (CYST-
HD) (Verny et al, 2017). 
Immune modulation 
 
Peripheral modulation through inhibition of kynurenine 3 
monooxygenase extends life span, prevents synaptic loss, and 
decreases microglial activation in R6/2 mice (Zwilling et al, 2011). 
Central modulation with laquinimod (an immunomodulatory drug with 
unknown mechanism of action), has been shown to reduce NF-kB 
activation in astrocytes (Brück et al, 2012) and has demonstrated 
potential in the treatment of multiple sclerosis (Comi et al, 2012). The 
effect of laquinimod on motor function and brain imaging in early HD 
is currently being assessed in LEGATO-HD (NCT02215616).  
Chaperone proteins Upregulation of chaperone proteins reduces potential misfolding of 
mHTT and subsequent aggregate formation (Labbadia et al, 2012; 
Sontag et al, 2013). 
Autophagy Induction of autophagy with rapamycin (an mTOR inhibitor) aids the 
clearance of mHTT and its cleavage products, and reduces toxicity in 
fly and mouse models of HD (Ravikumar et al, 2004). 
Mitogen-activated 
protein kinases 
(MAPKs) 
MAPK signalling regulates a variety of cellular functions, and has 
been found to be abnormal in HD. Over-activation or upregulation of 
ERK and MKP-1 has been found to be neuroprotective (Apostol et al, 
2006; Taylor et al, 2013), whereas inhibition of MLK2, JNK, and p38 
has beneficial effects (Apostol et al, 2008; Taylor et al, 2013). The 
role of MAPKs in HD is not completely understood. 
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Cellular metabolism 
 
Cellular metabolism is known to be affected in HD. The 
administration of rosiglitazone, an agonist of transcription factor 
peroxisome proliferator-activated receptor γ (which has a key role in 
regulating genes involved in energy metabolism) has been shown to 
attenuate mHTT-induced toxicity in striatal cells and improve motor 
function in HD mice (Jin et al, 2013).. 
Excitotoxicty Excitotoxicity is a known pathogenic mechanism in HD. 
Administration of ceftriaxone, which upregulates expression of the 
EAAT2 glutamate transporter, has been shown to be beneficial in HD 
mouse models (Miller et al, 2008). 
 
 
1.1.4.2 Biomarkers 
 
Assessing the impact of any potential treatment can be difficult due to the 
heterogeneity of motor/psychiatric and cognitive problems in HD and the natural 
variation in rates of progression. Therefore biomarkers are needed to objectively and 
accurately reflect disease status. Furthermore, genetic testing allows us to identify 
premanifest HD patients, in whom the goal would be to introduce medication to delay 
onset of or even prevent neurodegeneration from occurring; biomarkers are essential in 
helping to decide on the timing of such interventions when they become available. 
 
Thanks to large-scale longitudinal studies such as TRACK-HD (Tabrizi et al, 2009; 
Tabrizi et al, 2012; Tabrizi et al, 2011; Tabrizi et al, 2013) and PREDICT-HD (Biglan et 
al, 2013; Harrington et al, 2012; Paulsen et al, 2008), we now have a much clearer idea 
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of the natural progression of HD from premanifest through to manifest disease. 
Structural magnetic resonance imaging has demonstrated significantly faster rates of 
decline in striatal volume in premanifest and manifest individuals compared with age-
matched controls, even in those estimated to be >15 years from estimated disease 
onset (Aylward et al, 2011). Other imaging modalities that may serve as potential 
biomarkers of disease include diffusion tensor imaging, which has shown abnormalities 
in neuronal fibre orientation and integrity in white matter and subcortical grey-matter 
structures in both premanifest and manifest HD, functional magnetic resonance 
imaging techniques, and 18F-fluorodeoxyglucose positron emission tomography (Ross 
et al, 2014). Clinical measures that have been found to track decline in premanifest 
individuals include performance on the speeded tapping task and deterioration in 
emotion recognition; in those with early HD, performance on the Stroop test and 
indirect circle tracing also tracked clinical decline (Tabrizi et al, 2013). 
 
An ultrasensitive single-molecule counting mHTT immunoassay has been developed 
that can quantify very low levels (in the femtomolar range) of mHTT in the 
cerebrospinal fluid. The level of mHTT detected was associated with proximity to 
disease onset and diminished cognitive and motor function, and is a promising 
biomarker being taken forward into clinical trials (Wild et al, 2015). Levels of tau in the 
cerebrospinal fluid also show promise as a biomarker in HD (Rodrigues et al, 2016). 
Recently the level of neurofilament light protein (NfL) in plasma, which can be obtained 
through a simple blood test, has demonstrated potential as a prognostic blood 
biomarker of disease onset and progression in Huntington’s disease (Byrne et al, 
2017). 
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1.2 Pathogenesis of HD 
 
1.2.1 Wild type HTT structure and function 
 
Huntingtin is a very large protein with an estimated molecular weight of 348kDa 
(Hoogeveen et al, 1993). The first exon consists of an N-terminal alpha helix, followed 
by a polyQ stretch, and then a polyproline helix. X-ray crystallography has shown the 
PolyQ stretch to be flexible, adopting alpha helix, random coil and extended loop 
structures (Kim et al, 2009). This flexibility of the PolyQ region is thought to allow the 
flanking N17 domain (the first 17 amino acids of exon 1) and downstream polyproline 
region to come into close spatial proximity, and is impaired with expanded PolyQ tracts 
(Caron et al, 2013).  A recent cryo-electron microscopy study has found that full length 
HTT is largely alpha-helical and consists of 3 major domains; the N- and C-terminal 
domains contain HEAT (huntingtin, elongation factor 3, protein phosphatase 2A and 
lipid kinase TOR) repeats arranged in a solenoid fashion, connected by a smaller 
bridge domain containing different types of tandem repeats (Guo et al, 2018). It has 
many interaction sites suggesting that it is a scaffolding protein that helps to co-
ordinate other proteins and cellular functions (Zuccato et al, 2010).  
 
The protein undergoes extensive post-translational modifications, including 
phosphorylation, SUMOlyation, ubiquitination, palmitoylation and acetylation. HTT is 
also subject to cleavage by a variety of caspases, calpains and cathespins and MMPs 
(matrix metalloproteases). These modifications are all thought to play a role in the 
regulation of HTT activity (Zuccato & Cataneo, 2014). 
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HTT is ubiquitously expressed throughout the body, but the highest concentrations are 
found in the CNS and testes (Li et al, 1993). Knocking out Htt prior to neural 
development is embryonic lethal in mice (Nasir et al, 1995; Zeitlin et al, 1995). A 
developmental role for HTT has also been recently suggested by the finding that HTT 
knockout in human ESCs undergoing neuronal differentiation results in chromosomal 
instability that impairs neurogenesis (Ruzo et al, 2018). A broader systemic role for 
HTT is suggested by the peripheral phenotype seen in patients with HD, and by a study 
that shows conditional knockout of Htt in young mice leads to death from acute 
pancreatitis (Wang et al, 2016). HTT has also been shown to have a neuroprotective 
function through its anti-apoptotic activity (Rigamonti et al, 2001; Zhang et al, 2006).  
 
HTT enhances BDNF production at the level of gene transcription through stimulatory 
action on Bdnf promoter II (Zuccato et al, 2001), and also promotes BDNF vesicular 
trafficking in neurons (Gauthier et al, 2004). BDNF is important for the survival of 
striatal and cortical neurons. Subsequently it has been shown that through its 
interaction with a complex of proteins, wild-type Htt causes retention of the 
REST/NRSF transcriptional regulator in the cytoplasm, thus reducing the activity of 
RE1/NRSE within the Bdnf promoter II. The RE1/NRSE site is present on over 1300 
genes, thus implicating wild type HTT more broadly in transcriptional regulation 
(Zuccato & Cataneo, 2014). HTT also plays a role in vesicular (Velier et al, 1998) and 
axonal transport (Gunawardena et al, 2003), trafficking of organelles such as 
mitochondria (Trushina et al, 2004), and control of synaptic activity in neurons (Smith et 
al, 2005). Thus wild type HTT seems to have a variety of functions; a recent study has 
shown that the reduction of mHTT in cortical or striatal neurons in mice improves 
different aspects of the disease phenotype, suggesting distinct roles for the protein in 
these neuronal populations (Wang et al, 2014). 
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1.2.2 Overview of HD pathology 
 
Compared to the wild-type protein, the mutant protein contains an expanded CAG 
(polyglutamine) repeat in exon 1, immediately following the N17 domain. PolyQ 
expansion increases the α-helical properties of huntingtin, and alters the intramolecular 
interactions between the remaining HTT protein domains (Vijayvargia et al, 2016). 
Ultimately aggregates of abnormal HTT form in neuronal nuclei (intra-nuclear inclusion 
bodies are considered the pathognomic signature of HD), and also to a lesser extent in 
the cytoplasm, dendrites and axon terminals. The definitive role of these aggregates 
(whether toxic or protective) has not yet been established (Arrasate & Finkbeiner, 
2012; Ross & Tabrizi, 2011) (see section 1.4.1 for further detail). At a macroscopic 
level, post-mortem studies have revealed massive neuronal degeneration in the 
striatum of brains from patients with advanced HD. Up to 95% of the GABAergic 
medium spiny neurons (MSNs) that project to the globus pallidus and substantia nigra 
are lost, and there is atrophy (though less so) of the cerebral cortex, subcortical white 
matter, thalamus and hypothalamic nuclei (Halliday et al, 1998). 
 
HD is thought to arise predominantly from a gain of toxic function, as suggested by 
dominant genetic transmission, and data from HD models (Dragatsis et al, 1998; 
Hodgson et al, 1996). A myriad of different mechanisms, both cell autonomous and 
non-cell autonomous, have been shown to play a role but the relative contribution of 
most of these pathways to HD pathogenesis is not fully understood. 
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Figure 1.3: Postulated intracellular pathogenesis of Huntington disease. ATP, 
adenosine triphosphate; BDNF, brain-derived neurotrophic factor; HTT, huntingtin; 
PGC1a, the transcription factor peroxisome proliferator-activated receptor g, 
coactivator 1a; ROS, reactive oxygen species. (Reproduced from Ross CA, Tabrizi SJ 
(2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet 
Neurol 10: 83–98, with permission from Elsevier.) 
 
 
1.2.3 Cell autonomous mechanisms of HD pathogenesis 
 
1.2.3.1 Generation of mutant HTT fragments  
 
Multiple lines of evidence support the “toxic fragment hypothesis” that proteolytic 
cleavage of mutant HTT liberates toxic N-terminal fragments containing the expanded 
polyQ tract, which contribute to cell death through accumulation and the additional 
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activation of further proteolytic caspases (Zuccato et al, 2010). Recent evidence also 
shows that these short N-terminal fragments arise from alternative splicing of exon 1 of 
HTT (Sathasivam et al, 2013). Mutant HTT transcripts allow read through into intron 1 
which has a stop codon at its start, and so on translation an exon 1 fragment is 
produced (Sathasivam et al, 2013). The smallest N-terminal HTT fragment detected in 
a mouse model of HD was exactly equivalent to an exon 1 product and exon 1 proteins 
are known to be highly neurotoxic (Landles et al, 2010). 
 
1.2.3.2 Clearance of mHTT 
 
Two major cellular pathways for degradation of misfolded proteins are the ubiquitin-
proteasome system (UPS) and autophagy. Impairment of the UPS has been noted in 
HD mouse models and human post-mortem brain tissue (Bennett et al, 2007a). In 
addition, mHTT can interfere with target recognition and impair autophagic clearance 
(Martinez-Vicente et al, 2010; Qi et al, 2012) (see section 1.4.2.1 for further detail). 
 
1.2.3.3 Post-translational modification of mutant HTT 
 
The expanded PolyQ tract affects the post-translational modification events that are 
known to occur in wild-type HTT, and these in turn affect mHTT toxicity. Their full 
significance, interdependence and exact role in any pathogenic mechanism remains 
largely unknown (Hughes & Jones, 2014). 
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1.2.3.4 Transcriptional dysregulation 
 
Transcriptional dysregulation occurs before symptom onset in HD, and affects a large 
number of different transcription factors and regulatory DNA target sequences (e.g. the 
CREB-binding protein (CBP) (Steffan et al, 2000) and repressor element 1 transcription 
factor (REST) (Zuccato et al, 2003)). This has been confirmed by DNA microarray 
studies (Hodges et al, 2006). Mutant HTT has also been shown to inhibit histone 
acetyltransferase activity, thus leading to the condensation of chromatin and a 
downregulation of gene transcription. This paves the way for histone deacetylase 
(HDAC) inhibitors as a potential therapy (Butler & Bates, 2006). 
 
1.2.3.5 Somatic instability and impaired DNA repair 
 
Somatic expansion of the CAG repeat has been shown to occur in the human striatum 
(Kennedy et al, 2003) and is associated with younger onset, thus may contribute to 
disease pathogenesis (Swami et al, 2009). Impairment of DNA repair pathways has 
been implicated in this (Dragileva et al, 2009), and large cohort genetic studies in HD 
patients have shown that variants in DNA repair proteins affect age of onset 
(Consortium, 2015) and rate of HD progression (Hensman Moss et al, 2017). 
 
1.2.3.6 RAN translation 
 
A phenomenon known as repeat-associated non-ATG (RAN) translation leads to the 
expression of expansion proteins from all three reading frames, without an AUG start 
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codon. Four novel, homopolymeric expansion proteins (polyAla, polySer, polyLeu and 
polyCys) have been shown to accumulate in HD human brains, particularly in the 
striatum and white matter. These proteins have been shown to be toxic to neural cells 
(Bañez-Coronel et al, 2015). 
 
1.2.3.7 Mitochondrial dysfunction 
 
Mutant HTT affects the axonal transport of mitochondria and also has a direct effect on 
mitochondrial function. Mitochondrial calcium handling is impaired, and transcription of 
nuclear genes responsible for the proper functioning of this organelle is affected, 
leading to impaired respiration (Jin & Johnson, 2010). An increase in mitochondrial 
DNA mutations has also been found in neurons from the cortex of HD patients 
(Siddiqui et al, 2012; Wang et al, 2013). 
 
1.2.3.8 Excitotoxicity 
 
Injection of quinolinic acid (an NMDA receptor agonist) into the striatum of mouse 
models recapitulates many aspects of the HD phenotype (Beal et al, 1986). In addition 
it has now been shown that alterations in glutamatergic signalling occur through 
changes in glutamate release (Joshi et al, 2009), over activity of glutamate receptors 
(Benn et al, 2007), decreased levels of glutamate transporters and reduced glutamate 
uptake (Huang et al, 2010). Increased MSN excitability has also been shown to result 
from decreased potassium channel expression in mHTT expressing astrocytes (Tong 
et al, 2014). 
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1.2.3.9 Cytoskeleton signalling and vesicular trafficking 
 
Through its interactions with huntingtin-associated protein 1 (HAP1), huntingtin-
associated protein of 40 kDa (HAP40) and dynein, HTT regulates vesicle transport and 
recycling (Pardo et al, 2010). Expression of mHTT disrupts this transport, including 
vesicular trafficking of BDNF (Gauthier et al, 2004; Roux et al, 2012). mHTT 
aggregates can also physically obstruct subcellular transport due to their large size (Li 
et al, 2003). 
 
 
1.2.4 Non-cell autonomous mechanisms of HD pathogenesis 
 
1.2.4.1 Loss of neurotrophic (BDNF) support 
 
Loss of BDNF support from cortico-striatal projections may be responsible for the 
selective MSN degeneration seen in HD, as mHTT is known to interfere with both the 
expression and trafficking of BDNF (Zuccato et al, 2008).  
 
1.2.4.2 Loss of glial support 
 
Specific astrocytic expression of mHTT leads to a neurological phenotype in mice 
(Bradford et al, 2009). Furthermore, co-culture experiments have shown that glial 
Chapter 1 
 
54 
 
expression of mHTT causes the death of neurons which do not express mHTT (Shin et 
al, 2005). 
 
1.2.4.3 Trans-neuronal spread 
 
Recently evidence for the non-cell autonomous, trans-neuronal spread of mHTT has 
come to light. Mutant HTT was shown to spread to wild-type human neurons within an 
HD mouse model. This was blocked by botulinum neurotoxins, suggesting the 
involvement of synaptic machinery (Pecho-Vrieseling et al, 2014). Furthermore, post-
mortem studies of HD patients who have received experimental treatment with neural 
stem cell transplantation have revealed the presence of huntingtin inclusions in the 
grafted donor tissue (Cicchetti et al, 2014). 
 
1.2.4.4 Inflammation 
 
Microglial activation has been demonstrated in HD patients, both in manifest (Pavese 
et al, 2006) and premanifest disease (Tai et al, 2007). Recent evidence suggests that 
this is at least in part a cell-autonomous effect, as microglia that express mHTT have 
been shown to have enhanced transcription of pro-inflammatory factors (Crotti et al, 
2014). A peripheral inflammatory response has also been shown with raised levels of 
pro-inflammatory cytokines found in blood samples of manifest and premanifest HD 
patients (Bjorkqvist et al, 2008).  
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1.3 Models of Huntington’s disease 
 
Research on animal and cell models have given us enormous insights into the 
pathogenesis of HD. Models also provide an invaluable platform on which to develop 
and test potential therapeutics. The wide ranges of models available for HD research 
are detailed below, with particular emphasis on in vitro systems. 
 
1.3.1 Animal models of HD 
 
Mouse models are among the most common animal models in HD, with the R6/2 
mouse the most widely used (Mangiarini et al, 1996). This is a transgenic model which 
expresses human HTT exon 1 carrying around 150 CAG repeats. Its early phenotype 
onset and rapid disease progression are advantageous. Other N-terminal mouse 
models include the short-stop line (Slow et al, 2005), the N171-82Q line (Schilling et al, 
1999) and the HD line (Laforet et al, 2001). Full length human HTT expressing mouse 
models include the transgenic YAC128 (Slow et al, 2003) and BACHD (Gray et al, 
2008) mice. Knock-in mouse models have been generated by inserting expanded CAG 
repeats into the endogenous mouse Htt gene (such as the “Detloff” lines (Heng et al, 
2010; Lin et al, 2001)), or by replacing the mouse exon 1 Htt with mutated human exon 
1 HTT, creating a chimera (the “Zeitlin” lines (Menalled et al, 2012; Menalled et al, 
2003)). Other mammalian models of HD include transgenic rats expressing truncated 
(von Hörsten et al, 2003) and full-length (Yu-Taeger et al, 2012) HTT, pigs (Yang et al, 
2010), sheep (Jacobsen et al, 2010) and rhesus macaques (Gray et al, 2008). 
Numerous invertebrate HD models in Caenorhabditis elegans and Drosophila 
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melanogaster have been designed, which are useful for high-throughput analyses with 
genetic screens or the testing of compound libraries (Bates & Landles, 2014).   
 
1.3.2 Cell models of HD 
 
In vitro models have also helped to decipher new pathways of pathogenesis in HD, and 
have been useful in validating findings in animal models. Advantages of cell- based 
experimental systems are the ready supply of cells, the ability to work on human tissue, 
and suitability for high-throughput and high content analysis. There are a wide range of 
HD cell models available to the HD community, derived from both animal and human 
tissue, expressing both full length and exon 1 of the huntingtin gene. A few examples of 
these are listed in table 1.2. Arguably, the most useful cell models should recapitulate 
the main features of HD as closely as possible. Although mHTT is expressed 
throughout the body and causes systemic effects, the main site of pathology is in 
neuronal cells. Human neural cell models of HD are therefore of particular value, both 
in terms of elucidating disease mechanisms and testing therapeutics. 
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Table 1.2: Cell models used in Huntington’s disease. 
Cell line Construct Pathogenic insights 
Animal cells 
PC12: Rat 
phaeochromocytoma  
Full length 16Q, 
48Q, 89Q 
mHtt expression leads to cell morphology 
changes and disruption of cell signalling, 
mediated by NGF and EGF (Song et al, 2002). 
ST14A: Rat striatal 
progenitors 
Htt exon 1 25Q, 
47Q and 72Q, 
with GFP tag 
Probability of a cell remaining aggregate free 
drops exponentially with time (Colby et al, 
2006). 
HC2S2: Immortalised 
rat neural progenitors 
Htt exon 1-28Q 
or 74Q, with 
eGFP tag 
mHtt-expressing cells show time-dependent 
nuclear fragmentation and neuritic 
degeneration (Dong et al, 2011). 
COS-7: Monkey kidney eGFP-tagged 
Htt exon 1 with 
25Q, 46Q and 
97Q 
Aggregate/inclusion formation is dynamic, four 
phase process (Ossato et al, 2010). 
Human cells 
HEK293T: Human 
embryonic kidney 
548 and 151 
amino acid 
fragments of 
HTT with 15Q 
and 128Q 
Toxicity is more affected by the rate of 
aggregation than the localization (Hackam et 
al, 1999). 
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SK-N-SK: Human 
neuroblastoma 
pFlag-GFP exon 
1 21Q and 72Q 
with full length 
HTT co-
transfection. 
Full length HTT reduces cell death in mHTT 
expressing cells but has no effect on inclusion 
formation (Ho et al, 2001). 
SH-SY5Y: Human 
neuroblastoma 
Full length 60Q 
and 150Q-eGFP  
ATP synthase alpha suppresses the formation 
of insoluble inclusions and reduces toxicity 
(Wang et al, 2009). 
hESC: human 
embryonic stem cell 
HTT exon 1 with 
23Q, 73Q and 
145Q 
Demonstrates quantitative relationship 
between neurodegeneration and soluble 
monomeric mHTT levels (Lu & Palacino, 
2013). 
 Full length 
(knock-in) with 
45, 50, 58, 67 
and 74Q 
Disrupted neurogenesis during development 
occurs in a CAG-length dependent fashion 
(Ruzo et al, 2018). 
iPSC: induced 
pluripotent stem cell 
14 lines 
generated from 
controls and HD 
patients 
(ranging up to 
180Q). 
Changes in electrophysiology, metabolism, 
cell adhesion and cell death occur in HD iPSC 
derived neural cells (The Hd Ipsc Consortium, 
2012).  
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1.3.2.1 Fragment and full length mHTT cell models 
 
Both full-length and N-terminal HTT expressing models are useful. Full-length mHTT 
expressing models more closely reflect the actual cellular physiology of HD. However, 
N-terminal or exon 1 models give rise to disease phenotypes, for example aggregate 
formation, on a time-scale more compatible with in vitro experiments. There is also 
good evidence to suggest that mutant HTT exon 1 is the pathogenic species in HD. 
Post-mortem studies of human brain tissue demonstrate that nuclear and cytosolic 
inclusions are composed primarily of N-terminal fragments (DiFiglia et al, 1997). The 
R6/2 mouse over-expressing human HTT exon 1 has the fastest and most aggressive 
HD phenotype, and has been used extensively in HD research (Mangiarini et al, 1996), 
and the transgenic expression of mHtt exon 1 has also been shown to produce an HD-
like phenotype in non-human primates (Yang et al, 2008). The smallest N-terminal 
fragment detected by western blotting using a panel of HTT antibodies in a full length 
mouse model of HD was exactly equivalent to an exon 1 product (Landles et al, 2010). 
A study in transgenic Drosophila engineered to express one of seven naturally 
occurring N-terminal HTT fragments against a constant genetic background, revealed 
that the exon 1 peptide is particularly toxic in terms of survival and degeneration of 
photoreceptor neurons (Barbaro et al, 2015).  
 
A mechanism for generation of mutant HTT exon 1 has been demonstrated in mouse 
models expressing full length mutant Htt (mouse) and HTT (human) (Sathasivam et al, 
2013), and also in patient derived fibroblasts and post-mortem human brain tissue 
(Neueder et al, 2017); abnormal splicing in the presence of an expanded CAG repeat 
allows read through into intron 1 which contains a stop codon at its start, producing a 
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mutant exon 1 fragment on translation. Furthermore, multiple cell models have 
demonstrated rapid onset of cell toxicity and cell death on expression of mHTT exon 1 
(Ho et al, 2001; Miller et al, 2010; Sahoo et al, 2016). 
 
1.3.2.2 HD-iPSC derived models 
 
The discovery that human fibroblasts could be reprogrammed into pluripotent stem 
cells through the expression of four specific transcription factors (Oct3/4, Sox2, c-Myc, 
and Klf4) has led to a revolution in cell biology (Takahashi & Yamanaka, 2006). 
Induced pluripotent stem cells (iPSCs) have been generated from HD patient 
fibroblasts (Park et al, 2008), and subsequently differentiated into neurons, including 
MSNs (Arber et al, 2015; Delli Carri et al, 2013). Such models perhaps most closely 
reflect the disease state. Stem cells and iPSC-derived neurons have been shown to 
demonstrate enhanced lysosomal activity (Camnasio et al, 2012). Aggregate formation 
also occurs, but only on the addition of a stressor (Jeon et al, 2012). More recently HD 
iPSCs have been shown to have impaired neurogenesis compared to control cells 
(Conforti et al, 2018). 
 
One issue with iPSC research is the genetic heterogeneity that occurs between patient 
derived cell lines, making it difficult to draw comparisons between them (although very 
recently, a genetic allelic series of isogenic human embryonic stem cell (hESC) lines 
with graded increases in CAG repeat length has been engineered (Ruzo et al, 2018)). 
Neuronal differentiation protocols for iPSCs are also currently rather long and complex 
(Delli Carri et al, 2013), making this cell type less suited to high throughput studies; 
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although with improvements in iPSC culture techniques, and better high content 
screening platforms, this is likely to change in the near future.  
 
 
1.4 HTT protein aggregation, trafficking and clearance 
 
1.4.1 Mutant HTT aggregation and its role in disease pathogenesis 
 
Many neurodegenerative diseases have protein aggregates as a cardinal feature, for 
example amyloid inclusions derived from amyloid precursor protein (APP) in 
Alzheimer’s disease, and alpha synuclein in Parkinson’s disease. In HD, mHTT positive 
inclusions are found in the nuclei and neurites of patient derived brain tissue (DiFiglia 
et al, 1997). Inclusion frequency and rate of formation are polyglutamine length 
dependent, and inclusion size increases with disease duration (Hughes & Jones, 
2014). At the structural level, pathological polyQ expansion in exon 1 triggers the 
formation of antiparallel-β-rich and detergent resistant filamentous aggregates, similar 
to amyloid fibrils (Hoffner & Djian, 2014). Mutant HTT fragments are able to fold into 
different conformations under different conditions such as their phosphorylation state 
(Caron et al, 2014) or surrounding temperature (Nekooki-Machida et al, 2009).  
 
The definitive role of these inclusions (whether toxic or protective) has not yet been 
established. Toxicity is suggested by experiments showing that the reduction of 
aggregate formation in mice correlated with improvements in phenotype (Labbadia et 
al, 2011; Labbadia et al, 2012). Inclusions are thought to sequester and decrease 
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levels of essential cellular proteins such as transcription factors (Schaffar et al, 2004), 
chaperones (Park et al, 2013) and nuclear-cytoplasmic transport machinery (Woerner 
et al, 2016), and mHTT aggregates can also physically obstruct subcellular transport 
due to their large size (Li et al, 2003). However, in human HD brains, the distribution of 
aggregates does not correspond to sites of known pathology (Gutekunst et al, 1999), 
and MSNs which are the most vulnerable cell type in HD have no or few aggregates 
(Kuemmerle et al, 1999). A transgenic mouse model expressing an N-terminal mHTT 
fragment with exon 1 and 2 develops many inclusions but does not display any 
neuronal dysfunction (Slow et al, 2005). Longitudinal survival studies of primary 
neurons expressing fluorescently tagged mHTT exon 1 showed that the formation of 
inclusions in particular neurons correlated with neuronal survival (Arrasate et al, 2004).  
 
The location of aggregates may be important; R6 mouse lines with >200 CAG repeats 
show mHTT localised to the cytoplasm and have a much milder phenotype with later 
disease onset than R6 lines with <200 CAG repeats (Dragatsis et al, 2009; Morton et 
al, 2009). This contrasts with the findings of Woerner et al who showed that 
cytoplasmic rather than nuclear accumulation of fibrillar amyloid aggregates in 
HEK293T cells led to increased toxicity (Woerner et al, 2016). It may be possible that 
distinct structural forms of HTT aggregates may be of differing importance in terms of 
their relative contribution to cell toxicity (Caron et al, 2014; Nekooki-Machida et al, 
2009). Another recent study that reconciles these differing views of IB toxicity shows 
that the formation of HTT IBs triggers a state of cellular quiescence and redirects cells 
from fast apoptosis to a slower cell death by necrosis, as a result of co-aggregation 
with other proteins (Ramdzan et al, 2017). 
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1.4.2 Cellular mechanisms for protein clearance: the UPS and autophagy 
 
There are two major pathways for the degradation of proteins in eukaryotic cells. The 
ubiquitin-proteasome system (UPS) clears the majority (80-90%), mostly comprising 
soluble and short-lived or damaged proteins. Autophagy primarily removes long-lived 
or aggregated proteins, and damaged organelles. Both pathways are critical for the 
maintenance of cellular homeostasis, and their activities are tightly regulated 
(Lilienbaum, 2013). 
 
Degradation of a protein via the UPS involves two successive steps; firstly conjugation 
of a minimum of four K48-linked ubiquitin (Ub) monomers to the substrate followed by 
degradation of the tagged protein by the downstream 26S proteasome complex 
(Glickman & Ciechanover, 2002). This consists of a 20S proteolytic particle and one or 
two 19S regulatory particles. The cylindrical 20S proteasome is a hollow four-ring 
structure that contains in each of its central β-rings three types of active sites, which 
are chymotrypsin-like, trypsin-like, and caspase-like in specificity.  Its outer α-rings 
contain a gated channel for substrate entry. The 19S regulatory particle performs many 
functions, including binding and disassembly of the Ub chain, ATP hydrolysis, and the 
unfolding and translocation of the substrate into the 20S core (Kim & Goldberg, 2017).  
 
Autophagy is a conserved pathway that delivers cytoplasmic contents to the lysosome 
for degradation, by means of double-membraned vesicles called autophagosomes. The 
first step is the formation of a double-membraned, cup-shaped autophagosome 
precursor (the phagophore), that engulfs substrates as its edges extend. After the 
phagophore edges close to form a vesicle, the completed autophagosomes traffic 
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along microtubules to enable autophagosome-lysosome fusion, which leads to the 
degradation of its contents by lysosomal hydrolases (Menzies et al, 2017).  
 
1.4.2.1 The UPS and autophagy in HD 
 
Impairment of the UPS has long been considered an attractive hypothesis for neuronal 
dysfunction in HD. Inclusion bodies in HD mouse models and patient brains are rich in 
ubiquitin and proteasome components, suggesting that the UPS may be affected. 
However, studies into UPS function in HD have yielded conflicting results. 
Accumulation of polyubiquitin chains and increased levels of monoubiquitinylated 
histone H2A have been reported in HD mouse tissues (Bett et al, 2009a). Assays of 
proteasome activity showed normal or increased activity in brain extracts of an HD 
mouse model (Díaz-Hernández et al, 2003), however, human post-mortem HD brains 
have shown diminished core proteasome activity (Seo et al, 2004). In support of a 
general blockade of UPS-dependent protein degradation, it has been shown that the 
presence of a mutant polyQ tract can hinder a protein's proteasomal degradation 
(Holmberg et al, 2004), and it has also been reported that eukaryotic proteasomes are 
unable to degrade polyglutamine tracts (Venkatraman et al, 2004). However, Pratt et al 
have demonstrated that polyglutamine tracts are degraded efficiently by eukaryotic 
proteasomes (Pratt & Rechsteiner, 2008), and this was supported by the finding that 
mHtt exon 1 was completely digested by mammalian proteasomes (Juenemann et al, 
2013).  
 
These conflicting results raise the possibility that mutant polyQ tracts may exert 
different effects on the UPS depending on expression levels, subcellular localisation 
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and cell-type. Since the UPS is a highly ATP-dependent system (Schrader et al, 2009), 
defective mitochondria transport that is known to occur in HD neurons (Reddy & 
Shirendeb, 2012) may lead to ATP deficiency in neurites and nerve terminals, thus 
impeding the local degradation of mHtt by the proteasome in these subcellular regions 
(Zhao et al, 2016). Upregulation of the UPS is an attractive therapeutic avenue in HD, 
and the overexpression of ube3a, an ubiquitin E3 ligase, can activate the UPS and 
decrease mHtt aggregates in the brains of HD knock-in mice (Bhat et al, 2014). 
 
A role for autophagy in the clearance of mHTT aggregates is indicated by studies 
showing that upregulation of autophagy leads to a reduction of mHTT aggregates (Qin 
et al, 2003; Sasazawa et al, 2015). On the other hand, mHtt compromises autophagy 
by perturbing cargo recognition and autophagosome motility (Martinez-Vicente et al, 
2010; Wong & Holzbaur, 2014). Using an optical pulse-chase method, Tsvetkov et al 
have shown that abnormally expanded polyQ peptides are specifically recognised and 
targeted for degradation, in a process particularly dependent on autophagy. Faster 
clearance of mutant polypeptides correlated with longer neuronal survival, and speed 
of clearance varied between neuronal subtypes which may help explain the selective 
MSN vulnerability observed in HD (Tsvetkov et al, 2013).   
 
1.4.3 Trafficking of HTT and mHTT 
 
Much can be inferred about the trafficking of HTT from its myriad functions; its role in 
neuronal vesicle trafficking and axonal transport, mitochondrial trafficking, control of 
synaptic activity, and transcriptional regulation. It is likely that HTT shuttles between 
different cellular compartments to facilitate these processes. An understanding of how 
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the trafficking of mutant HTT differs from that of the wild type protein may lend insights 
into which mechanisms are most important in triggering the neurodegeneration seen in 
HD. 
 
Initial studies into the subcellular location of HTT found differences between mutant 
and wild type forms (Gourfinkel-An et al, 1997), though results were often conflicting. 
Various cell culture models found huntingtin in the cytoplasm but not in the nucleus 
(Persichetti et al, 1995; Trottier et al, 1995). N-terminal fragments of mutant huntingtin 
formed aggregates in the cytoplasm and the nucleus, but full-length huntingtin with 
either normal or expanded repeats was localised to the cytoplasm (Cooper et al, 1998). 
Further immunofluorescence studies found that full-length wild type Htt could be 
detected in the nucleus of multiple mammalian cell lines (De Rooij et al, 1996; 
Dorsman et al, 1999), but that in HD autopsy brain, neuronal intra-nuclear inclusions 
could only be detected by N-terminal antibodies (Dorsman et al, 1999). Subcellular 
fractionation studies confirmed the presence of huntingtin in the nucleus of human skin 
fibroblasts (De Rooij et al, 1996).  These early studies may have been hampered by 
the lack of well characterised antibodies and by working in non-human and/or non-
neuronal cells.  
 
More recent studies have shown that the trafficking of HTT is dependent on the cell 
context. Under normal conditions, the huntingtin N-terminal is thought to be a 
membrane binding domain that can reversibly target to the endoplasmic reticulum (ER) 
and vesicles. On ER stress, huntingtin dissociates and enters the nucleus(Atwal et al, 
2007). Nuclear huntingtin also increases at certain points during the cell cycle (Martín-
Aparicio et al, 2002), and localises to the mitotic spindle during cell division (Godin et 
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al, 2010). Within the nucleus, huntingtin has been localised to chromatin (Benn et al, 
2008). Stress dependent phosphorylation at Ser13 and Ser16 targets full-length HTT to 
chromatin-dependent sub-regions of the nucleus, the mitotic spindle and cleavage 
furrow during cell division (Atwal et al, 2011). Huntingtin has also been shown to 
transport to the nuclear compartment during the meiotic stage of spermatogenesis (Im 
et al, 2014).  
 
In response to reactive oxygen species (ROS) stress the N17 domain undergoes 
structural change, resulting in HTT dissociation from the ER membrane, increased N17 
phosphorylation, and nuclear targeting (DiGiovanni et al, 2016). Using novel 
chromobodies, HTT was shown to localise to sites of DNA damage, where it acts as a 
scaffold for proteins of the DNA damage response pathway, and this process is 
deficient in HD patient fibroblasts (Maiuri et al, 2017). HTT also localises to early 
endosomes and forms cytosolic puncta, termed huntingtin stress bodies (HSBs) as part 
of a rapid cell stress response, and this is associated with the arrest of endosomal 
trafficking which conserves ATP use. Mutant HTT displays defective recovery from this 
stress response (Nath et al, 2015).   
 
As HD progresses, shuttling of HTT in and out of the nucleus may become disrupted, 
leading to its accumulation in the nucleus. HTT is known to contain a nuclear 
localisation signal (NLS) near its N-terminus, between aa 174-207 (Desmond et al, 
2012). This may explain the rapid pathology in the R6/2 mouse, which expresses 
amino acids 1-81 of Htt and does not contain the NLS. This small fragment may be 
able to pass unrestricted into the nucleus by diffusion through the nuclear pore 
complex (NPC), whereas larger proteins require an NLS to enter using a facilitated 
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diffusion mechanism. With CAG repeat lengths >200 in the R6/2 mouse, nuclear 
localisation is inhibited due to the larger fragment size, and lack of the NLS. This may 
account for the amelioration in toxicity that is seen. Huntingtin also contains two 
nuclear export signals (NES), one at its C-terminus (Xia et al, 2003) and one within the 
N17 domain (Maiuri et al, 2013).  
 
 
1.5 Aims of this project 
 
The first goal of my PhD work was to create a HTT allelic series human neuronal cell 
model of Huntington’s disease, in which the effects of increasing CAG-repeat length 
could be assessed against a fixed genetic background. Three different approaches 
were used: 
 
1. Knock-in of different CAG repeat lengths (50Q, 80Q and 125Q) into the endogenous 
HTT gene locus of a human NSC line using recombinant adeno-associated virus 
(AAV). This would create a truly isogenic cell series in which the mHTT is expressed at 
physiological levels; however ultimately this approach was not successful.  
 
2. Optimisation and validation of a transgenic human NSC allelic series that 
overexpresses HTT exon 1 with 29, 71 and 129 CAG repeats. NSCs were 
differentiated into immature neurons for further experiments. 
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3. Generation of an iPSC panel from siblings who have JHD and carry mutations with 
56, 67 and 73 CAG repeats respectively, and their unaffected mother. iPSCs were 
differentiated into MSNs using established protocols.  
 
The second part of my PhD work aimed to use the models generated to: 
 
1. Investigate the effect of HTT exon 1 with increasing CAG repeat lengths on cell 
differentiation and morphology, cell viability and response to cell stress. 
 
2. Study the effect of increasing CAG repeat length on HTT aggregation, and response 
to UPS and autophagy inhibitors. 
 
3. Assess the ability of a novel proteasomal activator to clear mHTT from exon 1 
overexpressing NSCs. 
 
4. Study the differences in the trafficking of huntingtin protein in MSNs derived from 
related control and JHD iPSCs. 
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2 Materials and Methods 
 
Sigma-Aldrich laboratory chemicals, Gibco cell culture reagents, Nunc cell culture 
plasticware and Invitrogen molecular biology reagents were used throughout unless 
stated otherwise. 
 
2.1 Cell culture  
 
2.1.1 Neural stem cell culture  
 
The ReNcellVM neural stem cell (NSC) line was obtained from ReNeuron. The line was 
originally derived from ten-week gestation foetal midbrain, in accordance with national 
ethical and legal guidelines, and immortalised by transduction with the v-myc oncogene 
(Donato et al, 2007; Pollock et al, 2006). The STROC05 human NSC line was also 
provided by ReNeuron. The cells were originally isolated from twelve-week gestation 
whole ganglionic eminence and transfected with a retroviral vector encoding the 
conditional immortalization gene cmyc-ERTAM (El-Akabawy et al, 2011).  
 
Both NSC lines were grown as a monolayer on laminin coated plasticware in NSC 
medium (appendix A.1.1). To maintain STROC05 proliferation in the stem cell state, 4-
hydroxy-tamoxifen (4-OHT) at 0.1 nM was added to the NSC medium. For routine 
culture, cells were seeded at a density of 1.2x104 cells/cm2. Flasks were pre-coated 
with 10 µg/ml mouse laminin-1 [Culturex PathClear; Trevigen] in cold Dulbecco’s 
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Modified Eagle's Medium (DMEM): Nutrient Mixture F-12 (F12), incubated at 37°C for a 
minimum of 2 hrs, and washed with warm DMEM:F12 just prior to use.  
 
NSCs required media change every 3-4 days and were passaged at 80-90% 
confluence. To passage, cells were washed with Hank’s Balanced Salt Solution 
(HBSS), and trypsinised using Trypzean-EDTA [Lonza] that was added in sufficient 
volume to coat the surface of the flask and incubated at 37°C, 5% CO2 for 5 min. The 
equivalent volume of defined trypsin inhibitor (DTI) was added to the flask, and the 
cells were triturated and transferred to a Falcon tube for centrifugation at 300 xg for 5 
mins at room temperature. The resulting cell pellet was re-suspended in warm NSC 
media, and the cells counted with a haemocytometer prior to re-seeding into laminin 
coated plasticware. 
 
2.1.2 Freezing and storage of neural stem cells  
 
Both ReNcellVM and STROC05 cells were frozen in cryovials of at least 1 million cells, 
in 1 ml of NSC media containing 10% dimethyl sulfoxide (DMSO). The vials were 
placed into a Mr. FrostyTM Freezing Container [Nalgene] and into the freezer at -80°C 
for at least 2 hrs, and then transferred to liquid nitrogen for long-term storage.  
 
2.1.3 Differentiation of neural stem cell lines  
 
On reaching 90% confluence, ReNcellVM NSCs were media changed into 
differentiation medium (appendix A.1.2) supplemented with 2 ng/ml glial cell-derived 
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neurotrophic factor (GDNF) [Peprotech] and 0.5 mM dibutyryl cyclic adenosine 
monophosphate (cAMP) [Calbiochem]. Differentiating cell cultures were media 
changed every 3-4 days. After two weeks, the differentiation medium was no longer 
supplemented with GDNF or cAMP, and a lower L-glutamine concentration of 0.5 mM 
was used. ReNcellVM neurons have been maintained in this long-term differentiation 
media for over six weeks, with media changes every 3-4 days.  
 
STROC05 NSCs were differentiated on reaching 80-90% confluence; the differentiation 
medium was supplemented with 1 µM purmorphamine [Calbiochem]. Cells were media 
changed every 3-4 days until seven days post-differentiation, the media was switched 
to Neurobasal medium supplemented with 1 x B27 supplement [Invitrogen], 2mM L-
glutamine, 10ng/ml bFGF and 1 µM purmorphamine. At fourteen days post start of 
differentiation Neurobasal medium supplemented with 1x B27 supplement, 2 mM L-
glutamine and 1µM purmorphamine was used to media change the cells. Cells were 
analysed at 21 days post-differentiation. This protocol is adapted from El-Akabawy et al 
2011 (El-Akabawy et al, 2011).  
 
2.1.4 Antibiotic kill curves  
 
NSCs were seeded at the usual cell density into laminin coated 6-well plates. 
Puromycin was added to the culture medium after 24 hrs to achieve a range of final 
concentrations between 0-150 ng/ml. The cells were observed and percentage 
confluence of the wells recorded at the same time every day for one week. The 
minimum concentration of antibiotic needed to kill wild-type cells over 3-4 days was 
determined.  
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2.1.5 Human embryonic kidney cells (HEK-293T) culture  
 
Human embryonic kidney (HEK) cells were obtained from ReNeuron. Cells were 
seeded at 8 x 104 cells/cm2 and grown as a monolayer on untreated plasticware in HEK 
culture medium (appendix A.1.3). Cells were passaged at 80-90% confluency. Spent 
culture medium was aspirated and discarded. An appropriate volume of warmed 
TrypZean-EDTA [Lonza] sufficient to cover the surface area of the flask was added, 
and the flask incubated for 5 mins at 37°C; 5%CO2. An equal volume of warmed 
HEK293 medium was added, followed by gentle trituration. The cell suspension was 
transferred to a Falcon tube and centrifuged at 300 xg for 5 mins at room temperature. 
The cell pellet was resuspended in media, cells counted using a haemocytometer (or a 
1:10 split ratio), and reseeded. 
 
2.1.6 HCT116 human colon adenocarcinoma cell line culture  
 
HCT116 cells were obtained from ReNeuron. Cells were seeded at a density of 5 x 104 
cells/cm2 and grown as a monolayer on untreated plasticware in HCT116 medium 
(appendix A.1.4). Post seeding, flasks were placed in the incubator at 37°C; 5%CO2 
and media changed every 2-3 days. Cells were passaged at 80-90 % confluency, as 
described above for HEK cells, but using HCT116 medium in lieu of HEK medium. 
Following resuspension of the cell pellet, cells were counted using a haemocytometer 
(or a split ratio of 1:10-1:20), and reseeded. 
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2.1.7 Mycoplasma testing  
 
All cell lines were tested for the presence of mycoplasma immediately post thawing, 
and also routinely during passage to ensure no contamination. Spent media was tested 
using the LookOut Mycoplasma PCR Detection Kit [Sigma]. 
 
 
2.2 Induced pluripotent stem cells (iPSCs)  
 
Fibroblasts were derived from skin biopsies taken from three siblings who have juvenile 
HD and carry HTT mutations with 56, 67 and 73 CAG repeats respectively, and their 
mother who is an unaffected control. 
 
2.2.1 Consent and ethics  
 
All skin biopsies were performed in accordance with the Declaration of Helsinki and 
approved by the University College London (UCL)/UCL Hospitals Joint Research 
Ethics Committee (LREC 03/N008, amendment 16). The subjects were recruited 
through the Huntington’s disease clinic at the National Hospital for Neurology and 
Neurosurgery, London. All subjects provided informed written consent.  
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2.2.2 Skin biopsy procedure  
 
Two adjacent 3 mm punch biopsies were taken from each subject’s forearm using a 
sterile 3 mm biopsy punch blade [Medline]. 0.5 ml 1% lignocaine with 1/10000 
adrenaline was used as local anaesthetic and injected subcutaneously using a 25G 
needle 5 mins prior to the procedure. The full thickness skin specimen was placed 
directly into a sterile container with fibroblast medium. Pressure was applied using 
gauze to the biopsy site for 10 mins and the wound closed using steristrips. A sterile 
dressing was then applied; no sutures were required. A follow up telephone call was 
made to the subject 24 hrs later to ensure that no complications had developed. In all 
cases the skin sample arrived in the laboratory within 2 hrs, and was kept at room 
temperature during transport. 
 
2.2.3 Fibroblast culture  
 
Each skin sample was cut into squares of 0.5-1 mm2 and placed epidermis side up into 
one well of a 6-well plate containing two drops of warm fibroblast medium (appendix 
A.1.5) with 2.5 ml/L amphotericin B [Sigma], which was added for the first two weeks of 
culture. A sterile coverslip was placed over the pieces of tissue to help them adhere to 
the plate, and then a further 2 ml warmed medium was added to the well, making sure 
not to dislodge the coverslip. The plate was placed undisturbed in the incubator at 
37°C; 5%CO2 for two days, taking care not to jolt the incubator at all. After this time the 
plate was checked for infection. 
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One week after plating the biopsy, the media was changed; at this point epithelial cells 
were seen surrounding the skin piece and fibroblasts emerging beyond them. 
Henceforth, cells were media changed every 3-4 days. After two weeks the cells were 
passaged. The spent media was removed and the cells washed with 2 ml PBS, 
ensuring that it reached under the coverslip. One millilitre of 0.05% Trypsin-EDTA 
[Gibco] was added for 5 mins at 37°C and, after checking that the fibroblasts had 
dissociated (epithelial cells do not transfer), an equal volume of fibroblast medium was 
added. The cells were triturated and transferred to a 15 ml Falcon tube, taking care not 
to transfer any pieces of skin. The cells were centrifuged at 300 xg for 5 min. The cell 
pellet was resuspended in 1ml of medium, and cells counted using a haemocytometer. 
The cells were then reseeded into uncoated flasks at a density of 1x104 cells/cm2 with 
an appropriate volume of medium (without amphotericin B).  
 
Fibroblasts were expanded and frozen down at passage 3, 4 and 5. Half a million cells 
were frozen per cryovial [Corning] in 1ml of fibroblast medium containing 30% 
additional FBS and 10% DMSO. Vials were stored in liquid nitrogen.  
 
2.2.4 Induced pluripotent stem cell (iPSC) generation  
 
Vials of frozen fibroblasts were sent to Professor Ali Brivanlou at the Laboratory of 
Stem Cell Biology at Rockefeller University. The cells were used to generate iPSCs by 
Sendai virus reprogramming using the CytoTune-iPS 2.0 Sendai reprogramming kit. 
These were verified by the expression of pluripotency markers, differentiation into all 
germ layers using a self-organisation assay, karyotyping, Sanger sequencing to 
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confirm the CAG repeat length and confirmation of the absence of exogenous Sendai 
virus. Three different clones of iPSCs were generated from each subject.  
 
2.2.5 Induced pluripotent stem cell (iPSC) culture 
 
This protocol was adapted from Shi et al 2012 (Shi et al, 2012). iPSCs were cultured 
on Geltrex coated 6-well plates in Essential 8 medium containing Essential 8 
supplement (10ml 50X supplement was added to 500ml Essential 8 medium to make 
Essential 8 medium+ (E8+)). To coat the plates, 1 ml 1:100 Geltrex:cold sterile 
DMEM:F12 was used per well of a 6-well plate, and plates were incubated at 37°C for 
a minimum of 1 hr prior to use. One vial of frozen iPSCs was thawed into one well of a 
6-well plate. The vial was removed from liquid nitrogen and immersed in a water bath 
at 37°C (without submerging the cap). Once thawed, cells were immediately 
transferred into a sterile 15ml falcon tube and 10mls of E8+ at room temperature was 
added drop-wise. The cells were centrifuged at 200 xg for 5 mins. The supernatant was 
discarded and the cell pellet resuspended in 2 ml of E8+ by gentle pipetting. Following 
removal of the Geltrex solution from the pre-coated Geltrex well, this iPSC cell 
suspension was added drop-wise to the well, and cells dispersed across the well 
surface with gentle side to side motion. The plate was then placed in the incubator at 
37°C; 5% CO2 and full media changes carried out daily with E8+ until cells reached 
85% confluency.  
 
iPSCs were passaged when reaching 80-85% confluency, or when individual colony 
size became too large or too dense, or on the appearance of morphologically different 
cells that were starting to differentiate. Generally a split ratio of 1:6 was used. For cells 
Chapter 2 
 
78 
 
undergoing passage, spent medium was aspirated and cells rinsed in 2 ml D-PBS. One 
millilitre of 0.5 mM EDTA in D-PBS was added and cells incubated at 37°C for 3-4 
mins. When iPSCs appeared to separate and become phase bright, the EDTA was 
aspirated. Two millilitres of E8+ was added to the cells and titurated gently, and the cell 
suspension was then made up to the appropriate volume with further E8+. The 
suspension was then added drop-wise to a pre-coated Geltrex plate (removing the 
Geltrex solution just prior to plating), with a final volume of 1.5 ml per well. The plate 
was returned to the incubator with daily media changes thereafter. Generally iPSCs 
needed to be passaged every 4-5 days.  
 
For freezing and storage of iPSCs, the procedure was carried out as for iPSC passage 
described but following aspiration of EDTA, 1 ml of ice cold E8+ with 10% DMSO was 
added per well to titurate the cells. The suspension was transferred to a cryovial and 
placed in a Mr FrostyTM Freezing Container [Nalgene] at -80°C, with transfer to liquid 
nitrogen the next day for long term storage.  
 
2.2.6 Medium spiny neuron (MSN) differentiation  
 
On reaching 80% confluence with appropriate colony sizes and cell morphology, iPSCs 
were passaged from one well of a 6-well plate into six wells of a 12-well plate. iPSCs 
were maintained in this format until reaching 80-90% confluency, after which MSN 
differentiation was commenced. Spent media was removed and iPSCs washed with D-
PBS. Two millilitres per well of room temperature N2B27 differentiation medium 
(appendix A.1.6) supplemented with SMAD inhibitors: 100 nM LDN (1:5000), 10 µM 
SB431542 (1:1000) and 200 nM dorsomorphin (1:5000) was added. Cultures were 
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maintained in this medium until passage 1, with half volume media changes on 
alternate days. 
 
An initial passage was carried out at dd9 (though this could be delayed to dd12 for less 
developed cultures), at a ratio of 2:3 onto fibronectin coated 12-well plates. Fresh 
plates were coated with 0.5 ml per well of 25 µg/ml fibronectin solution in D-PBS (1:40), 
incubated at 37°C for at least 1 hr and washed with D-PBS prior to use. One hr prior to 
passaging, spent media was removed from the cells and replaced with 1.5 ml N2B27 
differentiation medium (appendix A.1.6) supplemented with 25 ng/ml (1:4000) activin A 
and 10 µM ROCK inhibitor (1:1000) and incubated at 37°C. After 1 hr, this 
“conditioned” media was removed into a falcon tube and the cells were washed with D-
PBS. 0.5 ml 0.02% EDTA was added for 1 minute at 37°C. The EDTA was aspirated 
and the conditioned media was added to the cells at a volume of 1 ml per well. The well 
surface was then scratched with the tip of a 10 ml serological pipette held upright to 
generate large clusters of cells, as shown in scratch pattern 1 (figure 2.1). The cells 
were collected into a sample tube and made up to an appropriate volume to achieve a 
2:3 split ratio, using the remainder of the conditioned media plus fresh N2B27 with 
activin A and ROCK inhibitor as above. After removing PBS from the fibronectin coated 
plates, the cell suspension was distributed drop-wise into the new 12-well plate at a 
volume of 1.5 ml per well.  The day following this passage, 1 ml medium was replaced 
with 1.5 ml fresh N2B27 medium containing activin A but no ROCK inhibitor. Half 
volume media changes were carried out on alternate days, thereby gradually diluting 
out the ROCK inhibitor. 
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Figure 2.1: Scratch patterns used in passage 1 and passage 2 respectively 
during MSN differentiation.  
 
A second passage was carried out between dd19-dd22, at the neural progenitor cell 
stage. Cultures were observed to be multi-layered with occasional rosette formation. 
Cells were passaged at a ratio of between 1:1 and 1:4 onto poly-D- lysine/laminin 
coated plates; commonly cells were plated into 6-well plates or 10 cm dishes at this 
stage. To coat, 1 ml per well of a 6-well plate of 0.01% poly-D-lysine in dH2O was 
added and the plate incubated at 37°C for at least 2 hrs. Plates were then washed with 
sterile dH2O and 1 ml of 20 µg/ml laminin diluted in cold DMEM-F12 was added and 
further incubated at 37°C for at least 1 hr. Spent media was aspirated from the cells 
undergoing passage, and the cells washed in D-PBS. 0.5 ml 0.02% EDTA was added 
directly to the cells and incubated for 1-2 mins at 37°C. EDTA was aspirated and 1ml of 
N2B27 medium with activin A was added to each well. The well surface was scratched 
with the tip of a P1000 pipette, to generate small clusters of cells, as shown in scratch 
pattern 2 (figure 2.1). The cell clusters were collected into a falcon tube and 
resuspended by tituration with a 5 ml stripette. The cell suspension was made up to an 
appropriate volume with further N2B27 medium with activin A, and reseeded at a 
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volume of 2 ml per well of a 6-well plate, or 10 ml in a 10 cm dish.  Half volume media 
changes were carried out with N2B27 medium with activin A on alternate days. 
 
At dd26 a half volume media change with N2B27 media with vitamin A (see appendix 
A.1.6) supplemented with activin A (25 ng/ml), 20 ng/ml BDNF and 20 ng/ml GDNF 
was carried out. Thereafter cultures were maintained in N2B27 media with vitamin A 
with added activin A, 10 ng/ml BDNF and 10 ng/ml GDNF, changing half the volume of 
media on alternate days.  This was continued up to and including at least dd35. As 
reported by Arber et al (Arber et al, 2015), by dd35 80% of cells are neuronal (NeuN+), 
of which 80% display CTIP2 staining and 40-60% are DARPP32 positive. Neurons 
have been cultured up to 150 days (personal communication).  
 
 
2.3 Molecular biology 
 
2.3.1 RNA extraction  
 
Spent media was removed from a confluent T25 flask and the cells washed with HBSS. 
TRIzol 2.5 ml was added (1 ml per cm2) and the cells lysed directly in the flask by 
trituration. One ml of the suspension was transferred to an Eppendorf tube and 
incubated for 5 mins at room temperature. 0.2 ml chloroform was added, and the tube 
shaken for 15 sec, followed by further incubation for 2-3 mins at room temperature. The 
sample was centrifuged at 12,000 xg for 15 mins at 4°C. The colourless, upper 
aqueous phase of this sample containing the RNA was removed and placed into a new 
tube. 0.5 ml of 100% isopropanol was added and incubated for 10 mins at room 
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temperature. The sample was centrifuged at 12,000 xg for 10 mins at 4°C. The 
supernatant was removed and the RNA pellet was washed: 1ml of 75% ethanol was 
added, the sample vortexed and centrifuged at 7500 xg for 5 mins at 4°C. The wash 
was discarded and the pellet air dried for 5-10 min. The pellet was resuspended in 50 
µl of RNase-free water, incubated at 55°C for 15 mins and then stored at -70°C. Prior 
to storage, the concentration of RNA was determined using a NanoDrop 
microspectrophotometer.  
 
2.3.2 cDNA synthesis 
 
cDNA was generated from RNA using SuperScript II Reverse Transcriptase. One µl 
random primers (50-250 ng), 1 µl 10 mM dNTP mix and 1 ng – 5 µg of extracted RNA 
were added to a nuclease free microcentrifuge tube and made up to 12 µl with 
RNase/DNase-free water. The mixture was heated to 65°C for 5 min, quick-chilled on 
ice and briefly centrifuged. Four microlitres 5X First Strand Buffer and 2 µl 0.1M 
dithiothreitol (DTT) was added, the contents mixed gently and incubated for 2 mins at 
room temperature. One microlitre of SuperScript II RT was added and mixed by 
pipetting. The reaction mixture was incubated as follows: 10 mins at 25°C, 50 mins at 
42°C, and 15 mins at 70°C. 
 
2.3.3 PCR for huntingtin gene  
 
Using primers against the HTT sequence, (to amplify bp 153-449 and bp 9171-9361) 
polymerase chain reaction (PCR) was undertaken on cDNA using REDTaq DNA 
Polymerase kit [Sigma]. 25 µl of REDTaq ReadyMix, 2.5 µl of forward primer (0.5 µM), 
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2.5 µl of reverse primer (0.5 µM), 1 µl of template cDNA was added to a reaction tube 
and made up to 50 µl using water. PCR cycling conditions were: 94°C for 1 min, 55°C 
for 1 min, 72°C for 2 mins for 35 cycles. The reaction was visualised on a 1% agarose 
gel (1 g agarose, 100 ml 1x Tris/Borate/EDTA (TBE) buffer and 10 µl ethidium 
bromide).  
 
2.3.4 DNA purification  
 
DNA was purified using Gene Elute Blood Genomic DNA Kit [Sigma]. This was 
undertaken prior to mycoplasma testing of spent media, and on PCR reactions on DNA 
bands extracted from agarose gel. 
 
 
2.4 Western blotting 
 
2.4.1 Protein extraction 
 
Cell pellets for western blotting and HTT quantification were prepared: a confluent cell 
culture flask was washed with HBSS, trypsinised and an equal volume of DTI added 
after 5 min. The resulting cell suspension was transferred to a 15ml Falcon tube and 
centrifuged at 300 xg for 5 min. The cell pellet was resuspended in 1 ml of phosphate-
buffered saline (PBS) with 1x protease inhibitor (PI) cocktail [Roche], centrifuged again, 
the supernatant discarded and the pellet snap frozen and stored at -80°C.  
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Cell pellets were thawed on ice and resuspended in 100 µl lysis buffer (appendix A.3) 
with 1/1000 benzonase 250 U\µl [Novartis]. The protein concentration of each sample 
was measured using the Bradford assay [Bio-Rad]. In a 96-well plate reader, 200 µl of 
x1 Bio-Rad reagent was added to 10 µl of a 20-fold dilution (in PBS) sample, and also 
to a series of protein standards of known concentration between 0-500 µg/ml, and the 
plate read using Tecan, X-Fluor 4. A standard curve was plotted and the 
concentrations of samples calculated against this.  
 
2.4.2 Western blotting procedure 
 
Lysates were diluted to 1 mg/ml using lysis buffer. When blotting for HTT protein a 
methanol precipitation step was included. One hundred microlitres of each sample 
(containing 100 µg of protein) was added to 900 µl of ice cold methanol in a 1.5ml 
Eppendorf tube and incubated at -20°C for at least 30 mins (the methanol precipitation 
step is used to remove lipids, unfolded proteins and Triton X). The samples were then 
centrifuged for 10 mins at 4°C at 18,000 xg. The methanol was then poured off and the 
resulting pellet air-dried for 20 min.  
 
100 µl of 1x sample buffer (appendix A.3) was added to each dried sample pellet, 
incubated on a shaking heater at 95°C, 800 rpm for 10 min, and checked to ensure the 
pellet had dissolved. Twenty microlitres per sample and 10 µl LI-COR Chameleon 
molecular weight marker was loaded onto a Novex 12% Tris-Glycine gel (or when 
blotting for HTT a gradient 12-20% Tris-Glycine gel) which was first clamped into the 
Invitrogen Novex Mini-Cell Gel tank and filled with running buffer (appendix A.3). The 
tank was connected to a power pack and the gel was run at 90 V until the samples 
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lined up at the edge of the gel stack (after approximately 10 min) and then increased to 
150 V to run for at least 1 hr or longer. 
 
The gel was then carefully removed from the gel running apparatus and covered with 
nitrocellulose membrane for protein transfer, then layered into the transfer apparatus 
with sponges and Whatmann filter paper soaked in 1x transfer buffer (appendix A.3). 
The transfer apparatus was then clamped into the tank and filled up with transfer 
buffer. The transfer stack was connected to the power pack and run at 35 V for 2 hrs, 
or at 15 V overnight. The membrane was then removed from the transfer apparatus 
and washed in 1x PBS on a gentle shake to remove any buffer.  
 
The membrane was blocked in 8 ml Odyssey Blocking Buffer (LI-COR Biosciences) for 
1 hr at room temperature in a staining tray placed on a shaking platform. Primary 
antibody was added directly to the blocking buffer and incubated at 4°C overnight (with 
continual shaking). Primary antibody was washed off with 0.1% PBS Tween-20 
(PBST), using five 10 ml washes over 30 min, with shaking throughout. Secondary 
antibodies were added to the membrane in 8 ml blocking buffer, and incubated for 1 hr 
at room temperature in the dark with gentle shaking. Unbound secondary antibody was 
removed with three washes in 0.1% PBST over 20 min, with shaking throughout. The 
primary and secondary antibodies used are listed in appendix table A.1. 
 
The membrane was visualised directly using the LI-COR Odyssey image system. 
Image resolution was set at 169 µM, and images obtained in the 700 nM and 800 nM 
channels, both set at intensity 5.0 as a starting point.  
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2.5 Immunoassays for HTT quantification 
 
Cell pellets of each available ReNcellVM line were sent to Evotec for quantification of 
total and mutant HTT levels using the ELISA-based Meso Scale Discovery 
electrochemiluminescence platform (Macdonald et al, 2014). The 2B7/4C9 antibody 
pair was used to detect total HTT and 2B7/MW1 antibody pair was used to detect 
mutant HTT. For studies of HTT trafficking described in chapter 6, whole cell pellets 
and cell fractions of 129Q and 29Q HTT exon 1 ReNcellVM lines and three clones of 
control and 73Q MSN were again sent to Evotec, but on this occasion total and mHTT 
levels were measured using the ultra-sensitive Erenna Singulex human HTT protein 
detection assay (Wild et al, 2015). 
 
 
2.6 Transduction with recombinant adeno-associated virus 
(rAAV) vectors  
 
2.6.1 Generating recombinant adeno-associated virus (rAAV)  
 
rAAV vectors were created in conjunction with Horizon Discovery. Three vectors 
carrying exon 1 of the HTT gene with 50, 80 and 125 CAG repeats respectively were 
made. The vectors also contained a puromycin resistance gene, flanked by LoxP sites, 
and right and left homology arms containing HTT intronic sequence. The overall vector 
size was around 7 kb. 
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Plasmid vectors (pVector), as well as plasmids encoding viral replication and coat 
proteins (pDJ) and helper proteins (pHelper) [Agilent technologies] were used to carry 
out lipofectamine transfection of HEK-293T cells, thus generating adeno-associated 
virus containing our HTT exon 1 cassette. 
 
On reaching 70-80% confluency, the spent media was removed from a T75 flask of 
HEK-293 cells and replaced with 9 ml fresh media. The transfection mix was prepared; 
per T75 flask 18.75 µg of pVector, 18.75 µg of pDJ and pHelper (combination supplied 
by Horizon), and 37.5 µl of PLUS reagent [Invitrogen] were added to 1ml of HEK cell 
medium without serum and incubated at room temperature for 5 min. Fifty six 
microlitres of lipofectamine [Invitrogen] was then added to this, and further incubated 
for 30 mins at room temperature. The transfection mixture was then added to the T75 
flask (already containing 9 ml medium), and rocked gently to distribute evenly. The 
flask was then incubated at 37°C; 5% CO2 for 18-24 hrs, inspected for 
toxicity/cytopathic effects and then returned to the incubator for a further 48 hrs. 
Overall, ten T75 flasks of HEK-293T cells were transfected per vector. 
 
72 hrs post transfection, the culture medium was collected into 50 ml Falcon tubes and 
centrifuged at 1000 xg for 5 min. The clarified supernatant was stored in a fresh 50 ml 
tube, and the remaining cell pellet kept. Three millilitres of PBS was added to wash 
each T75 flask, and transferred to a 50 ml falcon tube and centrifuged at 1000 xg for 5 
min. The PBS was then discarded, and the remaining small cell pellet kept. Two 
millilitres of 1x trypsin-EDTA was added to each flask, incubated for 5 mins at 37°C, 
5% CO2. Dissociated cells were resuspended in 2 ml HEK-293T cell medium, and the 
cell suspension transferred to a 50 ml Falcon tube and centrifuged at 1000 xg for 5 
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mins. The supernatant was discarded and the cell pellet kept. The three cell pellets 
were resuspended in 10 ml of HEK cell medium, and the suspension centrifuged at 
1000 xg for 5 mins. The supernatant was discarded. The resulting cell pellet and the 
clarified supernatant were stored at -80°C. 
 
2.6.2 AAV purification  
 
The clarified supernatant (crude lysate) and cell pellet were removed from the -80°C 
freezer and warmed for 30 mins in the water bath at 37°C. The cell pellet was 
resuspended in 3 ml lysis buffer (0.15M NaCl, 50 mM Tris-HCl pH 8.5), and the tube 
placed into a dry ice ethanol bath for 10 mins to snap freeze the contents. The cell 
suspension was then thawed again in a 37°C waterbath and vortexed to aid disruption 
of the cells. This freeze-thaw cycle was repeated a further two times. The treated cell 
suspension and thawed crude lysate were then combined and distributed between 50 
ml Falcon tubes and centrifuged at 2900 rpm for 30 min. 
 
The supernatant was collected into a T75 flask, 1 µl benzonase nuclease (384 U/µl) 
[Sigma] added for every 10 ml, and incubated at 37°C for 30 min. The addition of 
benzonase nuclease removes any contaminating DNA in the supernatant. The 
benzonase treated virus supernatant was then purified using the AAV purification 
VIRAKITTM [Virapur] which uses a membrane based filtration method and a series of 
filtration, washing and elution steps. The eluted virus was distributed into sterile 1.5 ml 
tubes in 0.5 ml aliquots, and stored at -80°C. 
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2.6.3 AAV copy number quantification  
 
Purified rAAV2 was quantified by quantitative real-time PCR (qPCR). Ten units 
amplification grade DNase1 and 5 µl of 10x DNase1 buffer was added to 5 µl of 
purified virus and the volume made up to 50 µl with molecular grade water. This was 
incubated at 37°C for 30 mins and then at 95°C for 2 min. Treatment with DNase1 is to 
eliminate and residual contaminating DNA. To each 50 µl sample, 1 µl proteinase K 
(20mg/ml) [Roche], 75 µl proteinase K buffer 2 x (1% SDS, 200 µM NaCl) and 24 µl of 
molecular grade water was added and the sample incubated at 56°C for 1 hr and then 
at 95°C for 5 mins at 95°C. Treatment with proteinase K was used to release the 
encapsidated viral genome. 
 
The sample was diluted to 10% in dH20. A series of five-fold dilutions of a pAAV 
plasmid containing the puromycin resistance gene of known concentration was 
prepared as shown in Table 2.1. The calculation of the number of copies of 
puromycinR/ml in 1 µg of double stranded pAAV is based on the following formula: 
(2 x 6.02 x 1023) / (610 x 7000 x 106) = 2.821 x 1011 where: 
 
2 = number of copies of puromycinR gene per double stranded pAAV 
6.02 x 1023 = number of molecules (copies) per mole of substance 
610 = average molecular weight (MW) in (g/mole) of 1 nucleotide base pair 
7000 = average number of base pairs in one pAAV  
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Standard  µg/ml Copies puromycinR/ml 
1 1.000 e0 2.821 e11 
2 2.000 e-1 5.642 e10 
3 4.000 e-2 1.128 e10 
4 8.000 e-3 2.257 e9 
5 1.600 e-3 4.514 e8 
6 3.200 e-4 9.027 e7 
7 6.400 e-5 1.805 e7 
8 1.2800 e-5 3.611 e6 
9 2.560 e-6 7.222 e5 
10 5.120 e-7 1.444 e5 
11 1.024 e-7 2.889 e4 
12 2.048 e-8 5.777 e3 
 
Table 2.1: Standards used in calculation of AAV quantification. For derivation see 
text. 
 
To quantify the concentration of rAAV2 qPCR reactions were set up in triplicate, with 
each of the standards, the virus and a negative control. For each reaction a master mix 
was assembled with 0.225 µl of 100 µM forward primer 
(CACGCGCCACACCGTCGACCC). 0.225 µl of 100 µM reverse primer 
(GGGAACCGCTGAACTCGGCCA), 11.05 µl PCR grade water and 12.5 µl of SYBR 
Green master mix [Applied Biosystems]. 24 µl of master mix and 1 µl of sample were 
added to each well.  
 
Reactions were set up in a MicroAmp fast optical 96-well reaction plate, and sealed 
with MicroAmp optical adhesive film [Applied Biosystems]. The plates were centrifuged 
Chapter 2 
 
91 
 
for 10 sec and 300 xg and were run on a 7500 Fast real-time PCR machine [Appied 
Biosystems] using 7500 software. The PCR cycling conditions were as follows: 95°C 
for 3 mins followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
 
The amplification plots were analysed to determine the Ct (threshold cycle value) for 
each standard and a standard curve was plotted of initial copies of puromycinR/ml vs 
Ct. This was used to determine the rAAV2 titre in genome copies (GC)/ml; the Ct of the 
sample was used to determine corresponding value of copies of puromycinR/ml, and 
this was multiplied by the overall dilution factor of the sample, including during sample 
preparation (i.e. a factor of 300). 
 
2.6.4 Transduction of cells 
 
ReNcellVM NSCs were seeded in NSC media at the usual density into a T25 flask, and 
placed in the incubator at 37°C; 5% CO2.  After 24 hrs cells were media changed and 
AAV virus added to achieve a multiplicity of infection (MOI) of 100 000. On adding 
virus, the cells were returned to the incubator for 72 hrs. Confluent cells were then 
passaged into a T75 flask, with fresh NSC media (without virus) and grown for 24 hrs, 
before adding puromycin at a concentration of 75 ng/ml. Simultaneously, 75 ng/ml 
puromycin in NSC media was added to a control flask of ReNcell VM NSCs, to ensure 
lethality at this dose. The infected cells were expanded and grown under antibiotic 
selection for two weeks, following which stocks of each line were frozen down. 
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2.6.5 Screening cells for integration  
 
ReNcellVM NSCs were screened for positive integration of the vector into the native 
HTT exon 1 locus. After antibiotic selection, as described, cells were seeded into 96-
well plates at a density of 10 cells per well and grown in the incubator at 37°C; 5% CO2 
for 10-14 days. Generally 2-4 plates were seeded per vector, per round of screening. 
Once the wells had reached confluence, the plates were passaged into new 96-well 
plates, whilst taking samples for lysis and subsequent screening PCR.  
 
In order to harvest gDNA from pools of cells (each cell “pool” derives from one well of 
the 96-well plate), 20 µl lysis buffer comprising DirectPCR lysis buffer [Viagen] with 1% 
proteinase K of >800U/ml [Roche] was added to each well of a 96-well PCR plate 
[Thermo]. Lysis plates were prepared just prior to passaging the cells. 
 
Confluent 96-well screening plates were prepared as follows: spent media was 
removed and cells washed with 100 µl HBSS per well. Trypzean 25 µl was added per 
well and incubated for 5 mins at 37°C. The wells were triturated and 5 µl of cell 
suspension was transferred into the pre-prepared lysis plate. The same volume of DTI 
was then added to the remaining cells in Trypzean, and 25 µl of this suspension was 
transferred into a new laminin coated 96-well plate containing 100 µl NSC media per 
well. It was imperative that the orientation of the 96-well plates remained the same 
between the cell culture plates and the lysis plates, so that any positive pools could be 
identified and expanded. The lysis plates were sealed with optical adhesive cover and 
placed on the PCR Tetrad machine with conditions as follows: 55°C for 15 mins and 
then 85°C for 45 mins. The lysis plates were stored at 4°C until PCR.  
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2.6.5.1 PCR screening strategy 
 
All primers were designed using Primer 3 software, and the position relative to the 
vector and specificity to intended binding sites checked with BLAST nucleotide.  RH 
For 2 (ccctggaaaagctgatgaag) and RH Rev 2 (gcaaatgcaggttctgtcaa) were selected for 
screening as an internal positive control band is generated from the wild type allele, 
thus confirming that the PCR reaction has worked. In theory, a correctly targeted vector 
gives rise to three different products, as shown in figure 3.9. Using RH2 primers, the 
size in base pairs of the expected products following positive homologous 
recombination is shown in table 3.2 (chapter 3). 
 
PCR reaction master mix was assembled using the GoTaq DNA Polymerase kit from 
Promega. For 100 reactions master mix was made up as follows: 
400 µl x5 Green GoTaq Reaction Buffer (supplied) 
50 µl dNTPs [Promega] 
120 µl MgCl2 (supplied) 
120 µl DMSO 
20 µl GoTaq enzyme (supplied) 
1060 µl PCR grade H20 
15 µl forward primer (100 µM) [Sigma, custom] 
15 µl reverse primer (100 µM) [Sigma, custom] 
 
18 µl of master mix and 2 µl of sample (lysed cell pools) were added per reaction into a 
96-well PCR plate, again ensuring that orientation of the lysis plate and PCR plate 
matched. A touchdown PCR protocol was used with the parameters shown in table 2.2. 
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PCR products were visualised using gel electrophoresis on a 1% agarose gel 
(Tris/Borate/EDTA (TBE) buffer with 1% agarose, heated to boiling point, cooled and 
1/10,000 SYBR Safe [Thermo] added) in an extra-large gel tank to allow simultaneous 
processing of 96 samples. End wells were loaded with Hyperladder 1kb [Bioline]. 
 
Step Number of cycles Temperature °C Incubation time (sec) 
1 1 94 180 
2 3 94 15 
  64 30 
  70 240 
3 3 94 15 
  61 30 
  70 240 
4 3 94 15 
  58 30 
  70 240 
5 35 94 15 
  57 30 
  70 240 
6 1 70 300 
7  4 Hold 
 
Table 2.2: Touchdown PCR protocol for use with screening primers 
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2.6.5.2 Other screening primers 
 
As described in the results, we also used other screening primers to isolate positively 
integrated pools (table 2.3).  
 
Primer Set Forward (For) Reverse (Rev) 
RH2 Nest gggtcttcccttgtcctctc 
 
aaatctcggctcctccaagt 
 
RH2 Sp* Nest aagctgatgaaggtcgacataa 
 
tcccaacacacataggcaaa 
 
A atagcagctttgctccttcg 
 
aaatgccatctgggacacat 
 
B atagcagctttgctccttcg 
 
gcaaatgcaggttctgtcaa 
 
C gtcaccgagctgcaagaact 
 
aaatgccatctgggacacat 
 
LH2 gggtgcactcccataaagaa ccctggtttctc gcaaataa 
PGK/Puromycin atagcagctttgctccttcg agttcttgcagctcggtgac 
 
Table 2.3: Alternative screening primers used. 
 
 
2.7 Immunofluorescence imaging 
 
2.7.1 Immunofluorescence studies 
 
Cells were seeded onto laminin coated baked glass coverslips contained in a 4-well 
dish, at an appropriate density for optimal cell growth, and differentiation was 
commenced. At various time-points cells were fixed using 100 µl of 4% 
paraformaldehyde (PFA) per well for 20 mins at room temperature, and stored in 100 µl 
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PBS with 0.2 % sodium azide at 4°C. To permeabilise the cells, the PBS with 0.2 % 
sodium azide was removed and 100 µl of 0.2 % Triton X-100 added for 15 mins at 
room temperature. This was then removed and the cells blocked with 100 µl per well of 
10% goat serum and 1 % BSA in PBS for 1 hr at room temperature. (When using the 
sheep anti-S830 antibody, donkey serum was used to block instead of goat serum).  
 
Primary antibodies were added in 100 µl PBS at concentrations shown in appendix 
table A.2, and incubated overnight at 4°C. The wells were then washed gently five 
times in 100 µl PBS and secondary antibodies (appendix table A.2) added at a dilution 
of 1/1000. The coverslips were incubated for 1 hr in the dark at room temperature. 
Following this, two further PBS washes were carried out and Hoescht [Sigma] 1/10,000 
in PBS was added for 5 mins at room temperature. The coverslips were washed 3 
more times in PBS and then left in 100 µl PBS, at 4°C in the dark, until imaging. 
Coverslips were mounted onto slides [Superfrost Thermo] with Dako fluorescent 
mounting medium with DAPI [Agilent] and visualised using a Zeiss 710 confocal 
microscope. 
 
2.7.2 High content imaging 
 
96-well ClearView plates [Perkin Elmer] were seeded with HTT exon 1 overexpressing 
ReNcellVM cells as well as GFP only and wild-type cells, at a density of 25,000 
cells/well. The cells were differentiated from the next day using the protocols previously 
described. Plates were fixed at various time-points, permeabilised and stained with 
antibodies as described in section 2.7.1.  
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Image capture for high content screening was initially carried out using the Perkin 
Elmer Opera LX automated confocal microscope, which has a UV channel plus three 
laser lines exciting at 488, 560 and 640 nm. Cell nuclei stained with Hoescht were 
detected by the UV channel, and the 488 channel detected the GFP expressed by the 
ReNcellVM HTT exon 1 cell model, thus allowing visualization of cell boundaries. The 
remaining two channels were used to detect antibodies as shown in appendix table 
A.2. Following the installation of the newer Opera Phenix machine, training was 
undertaken to operate this system and subsequent image capture for analysis of 
neuronal phenotypes in ReNcellVM HTT exon 1 lines. 
 
2.7.2.1 Image analysis 
 
Images captured on the Opera LX microscope, namely those of the time course of 
inclusion body formation in the ReNcellVM HTT exon 1 lines, were analysed in 
conjunction with Dr. Janos Kriston-Vizi at the UCL Laboratory of Cell and Molecular 
Biology, using Image J and R. Subsequent image analysis of images from the Opera 
Phenix were analysed by Dr. Rhia Ghosh using Columbus software; this software 
allows the construction of a modular pipeline to analyse multiple cell parameters such 
as nuclear morphology, staining patterns and intensity across thousands of images in 
an objective manner. Results were exported to Microsoft Excel and reformatted for 
analysis using GraphPad Prism.  
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2.7.3 Super-resolution imaging 
 
This was undertaken in conjunction with Dr. Ed Smith from the laboratory of Professor 
Gillian Bates (UCL). Super resolution fluorescent images were captured using a Nikon 
Eclipse Ni-E N-SIM Super Resolution system and Andor Ixon camera. Images were 
saved as ND2 files and processed using NIS Elements AR software with n-SIM 
module. Final images were exported as TIFF files images. Acquisition was performed 
in a 3D SIM mode using the 100× 1.49 NA total internal reflection fluorescence 
objective lens with 28 z steps per stack at a step interval of 0.1 µm. 
 
 
2.8 Cytotoxicity assays 
 
2.8.1 Lactate dehydrogenase (LDH) assay 
 
The LDH assay was carried out using the Promega 96® non-radioactive cytotoxicity 
assay. ReNcellVM cells were cultured in standard 96-well plates, in 200 µl of media per 
well. A row of “positive control” wells were treated with 22 µl of 10% Triton-X to achieve 
a final concentration of 1% Triton-X in media for total cell lysis (to give the maximal 
LDH concentration equivalent to 100% cell death) over 1 hr at 37°C. Fifty microlitres of 
media was then removed per well and placed into a 96-well microplate [Greiner], to be 
used for the LDH assay. A row of wells containing media only was also included to 
calculate the background absorbance. Fifty microlitres of CytoTox 96® Reagent was 
then added to each test well; the plates were covered with foil to protect them from 
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light, and incubated for 30 mins at room temperature. Fifty microlitres of Stop Solution 
was then added to each well. Any large bubbles were popped using a syringe needle, 
and absorbance was recorded at 490 nm using the Tecan Sunrise plate reader. After 
subtracting the background absorbance of the media only wells from all the wells, 
percentage cell death was calculated in the test wells as a proportion of the total cell 
death in the positive control wells. 
 
Variability between cell numbers was seen to occur in some cases due to delamination 
from the laminin coated culture plates, and was thought to have an effect on the results 
of the LDH assay. To account for this, the above protocol was modified to carry out 
whole plate lysis and calculate a percentage cell death in each well tested. Fifty 
microlitres of media was removed per well of the cell culture plate and placed into a 96-
well microplate. Ten percent Triton-X was then added to all the wells at a volume of 
16.7 µl (creating a final volume of 166.7 µl per well) to trigger 100% cell lysis over 1 hr 
at 37°C. Fifty microlitres of this “lysed” media was then transferred into a separate 96-
well assay plate, and a row of media-only wells was also included. Fifty microlitres of 
CytoTox 96® Reagent was then added to each test well of both the assay plates (both 
pre- and post-lysis test wells), and the protocol carried out as described above. To 
calculate the percentage cell death in each well, following subtraction of background 
the absorbance of the pre-lysis test wells was multiplied by the dilution factor due to 
addition of 10% Triton-X (in this case 150/167) and divided by the value of the 
absorbance in the post-lysis test wells.  
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2.8.2 MTT assay 
 
The MTT (3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay was 
carried out using the MTT based In Vitro Toxicology Assay Kit [Sigma]. Cell cultures in 
96-well plate format were removed from the incubator and placed in the laminar flow 
hood. MTT was reconstituted in media to a concentration of 5 mg/ml. This was added 
to the cells in an amount equal to 10% of the culture medium volume. The cells were 
returned to the incubator for 4 hrs. Following this time, cultures were removed from the 
incubator and a volume of DMSO equal to the original culture medium volume was 
added to each well to dissolve the resulting formazan crystals. The culture plate was 
then placed in the Tecan Sunrise absorbance microplate reader and background 
absorbance measured at 690 nm, and subtracted from absorbance at 570 nm. 
 
2.8.3 Alamar Blue assay 
 
The alamar blue assay was carried out using the alamarBlue® Cell Viability Assay 
Protocol from ThermoFisher. Cell cultures in 96-well plate format were removed from 
the incubator and placed in the laminar flow hood.  AlamarBlue® cell viability reagent 
(10X) was added directly to the cell culture medium at 1/10th of the total volume. Cells 
were then returned to the incubator for 4 hrs. The absorbance of the plate was 
measured using the Tecan Sunrise absorbance microplate reader at 570 nm using 600 
nm as a reference wavelength, using a blank of media only. The percentage difference 
in reduction of resazurin between control (wild-type ReNcellVM cells) and test wells 
(HTT exon 1 ReNcellVM cells) was calculated as follows: 
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Percentage difference =  (O2 x A1) – (O1 x A2) 
    -----------------------------        x 100 
(O2 x P1) – (O1 x P2) 
 
 
 
Where:  
 
O1 = molar extinction coefficient (E) of oxidised alamarBlue at 570 nm (in this case 
E=80586) 
O2= E of oxidised alamarBlue at 600 nm (in this case E=117216) 
A1 = absorbance of test well at 570 nm  
A2 = absorbance of test well at 600 nm 
P1 = absorbance of control well at 570 nm  
P2 = absorbance of positive growth control well at 600 nm 
 
 
2.8.4 Imaging markers of cytotoxicity 
 
Imaging methods to ascertain cytotoxicity in the HTT exon 1 ReNcellVM lines were 
complicated by the expression of GFP in these cells, which therefore precluded the use 
of any green fluorescent cytotoxicity markers designed for the detection in the 488 
channel.  
 
2.8.4.1 Propidium iodide (P.I.) staining 
 
1 mg/ml of P.I. [Invitrogen] was diluted 1:3000 in 2x SSC (0.3 M NaCl, 0.03 M sodium 
citrate, pH 7.0) to make a final working concentration of 500 nM. Cells on coverslips 
were fixed and permeabilised as described in section 2.8.1. Three hundred microlitres 
of 500 nM P.I. per coverslip was added for 5 mins, and then washed off in SSC. 
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Hoescht staining was then carried out, followed by mounting of the slides and 
visualisation using confocal microscopy, as described in section 2.7.1.  
 
2.8.4.2 Mitotracker Red labelling 
 
MitoTracker® Red CMXRos was purchased from Invitrogen. The product was 
dissolved in DMSO to make a stock solution of 1 mM. This was further diluted in media 
to achieve final working concentrations of 100 nM and 500 nM that were added to the 
ReNcellVM cells being tested. The cells were then incubated for 30 mins, after which 
the media containing MitoTracker Red was removed, and cells washed in warm PBS. 
The cells were imaged after fixation, permeabilisation and further staining (Hoescht) 
was carried out, as described in section 2.7.1. A concentration of 100 nM was found to 
be the optimal concentration of MitoTracker Red for labelling the ReNcellVM lines.  
 
2.8.4.3 Activated Caspase 3 antibody staining 
 
Antibody to activated caspase 3 (rabbit polyclonal) was purchased from Abcam 
(ab13847). This was tested for immunocytochemistry on GFP only ReNcellVM cells 
treated with 1 µM staurosporin (STS) at various dilutions, as described in section 2.7.1. 
An optimal dilution of 1/100 was ascertained, and this was used to stain a 96-well plate 
of the differentiated HTT exon 1 ReNcellVM panel which was then imaged on the 
Opera Phenix, with image analysis carried out using Columbus (section 2.7.2). 
 
 
Chapter 2 
 
103 
 
2.9 Subcellular fractionation 
 
This was carried out using the Subcellular Protein Fractionation Kit for Cultured Cells 
(Thermo; cat no 78840), making minor adaptations to the standard protocol for 
optimisation in the ReNcellVM and iPSC lines. Stepwise separation of cytoplasmic, 
membrane, nuclear soluble, chromatin-bound and cytoskeletal protein extracts from 
differentiated cells was carried out using a series of sequential buffers. Following 
differentiation, neuronal cell pellets of ReNcellVM cells were prepared as described in 
section 2.5.1. iPSC-derived MSNs pellets were formed by removal of spent media 
followed by the addition of an appropriate volume of Accutase for 5 mins; the cells were 
gently removed using a 10 ml stripette and centrifuged in a falcon tube at 500 xg for 5 
mins followed by a PBS wash. Each cell pellet was divided into two, with one being 
snap frozen as a whole cell pellet, and the other for subcellular fractionation.  
 
The subcellular fractionation protocol was carried out on ice. Starting with a packed cell 
volume of 50 µl for each cell pellet, 200 µl of ice-cold Cytoplasmic Extraction Buffer 
(CEB) with 1:100 protease inhibitors (Thermo Scientific Halt Protease Inhibitor 
Cocktail) was added to the dry cell pellet and incubated at 4°C for 10 mins with gentle 
mixing. This reagent causes selective cell membrane permeablisation, releasing 
soluble cytoplasmic contents. The tube was centrifuged at 500 ×g for 5 mins and the 
supernatant (cytoplasmic extract) was immediately transferred to a clean pre-chilled 
tube on ice. Two hundred microlitres of ice-cold Membrane Extraction Buffer (MEB) 
containing protease inhibitors was added to the pellet and the tube vortexed for 5 s on 
the highest setting, followed by incubation at 4°C for 10 mins with gentle mixing. This 
reagent dissolves plasma, mitochondria and ER/Golgi membranes but does not 
solubilise nuclear membranes. The tube was then centrifuged at 3000 ×g for 5 mins 
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and the supernatant (membrane extract) transferred to a clean pre-chilled tube on ice. 
Two hundred microlitres of ice-cold Nuclear Extraction Buffer (NEB) containing 
protease inhibitors was added to the pellet and vortexed for 15 s. The solution was 
incubated at 4°C for 30 mins with gentle mixing, followed by centrifugation at 5000 ×g 
for 5 mins. This reagent yields the soluble nuclear extract from previously intact nuclei. 
The supernatant (soluble nuclear extract) was transferred to a clean pre-chilled tube on 
ice.  
 
A second nuclear extraction was performed to release chromatin-bound nuclear 
proteins. Chromatin-bound extraction buffer (CEB) was prepared by adding protease 
inhibitors, 10 µL of 100 mM CaCl2 and 6 µL of micrococcal nuclease (600 units) to 200 
µL of room temperature NEB. This was added to the pellet and vortexed 15 s. 
Benzonase 1 µL was added and the solution incubated in a 37°C water bath for 30 
mins. After incubation, the sample was again vortexed on the highest setting for 15 s 
and centrifuged at 18,000 ×g for 5 mins. The supernatant (chromatin-bound nuclear 
extract) was transferred to a clean pre-chilled tube on ice. One hundred microlitres of 
room temperature Pellet Extraction Buffer (PEB) containing protease inhibitors was 
added to the pellet and the tube vortexed for 15 s followed by incubation at room 
temperature for 10 mins. This final reagent isolates cytoskeletal proteins. The sample 
was centrifuged at 16,000 ×g for 5 mins. The supernatant (the cytoskeletal extract) was 
transferred to a new tube. All fractions were transferred from ice to storage at -80°C for 
HTT quantification at a later date. 
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2.10 Statistical analysis 
 
All graphs were created and statistical analysis carried out using GraphPad Prism 6 
(GraphPad). To analyse the effect of HTT exon 1 overexpression on neuronal 
differentiation in ReNcellVM cells, images were analysed on Columbus and data on 
multiple parameters was exported to Microsoft Excel. This was reformatted into tables 
suitable for GraphPad. One-way ANOVA with Bonferroni’s correction was used to 
analyse the effect of increasing CAG repeat length on β3-tubulin, GFAP and nestin 
expression, as well as nuclear metrics. For cytotoxicity experiments in these lines, two-
way ANOVA with Bonferroni’s correction was used to analyse the time course of LDH 
release, with one-way ANOVA to determine the effect of HTT exon 1 overexpression 
on the reduction of alamar blue and on activated caspase-3 staining in these cells.  The 
dose-response curves for H2O2, MG132 and lactacystin in the HTT exon 1 ReNcellVM 
lines were analysed using two-way ANOVA with Bonferroni’s correction. The impact of 
chronic application of toxins over time was also analysed using this method.  
 
The time course of nuclear inclusion formation in the HTT exon 1 ReNcellVM cells was 
analysed using two-way ANOVA with Bonferroni’s correction to determine the effect of 
increasing CAG repeat length and increasing time on the percentage of cells containing 
nuclear IBs. The total nuclear count across all lines at dd7 and dd14 was also analysed 
in this way. Two-way ANOVA with Bonferroni’s correction was also used to analyse the 
effect of increasing CAG repeat length and increasing time on the number of IBs 
formed per IB-containing cell. The number of peri-nuclear inclusions and the intensity 
of cytoplasmic HTT exon 1 staining over time were also assessed using two-way 
ANOVA with Bonferroni’s correction. The effect of IB formation on nuclear size was 
Chapter 2 
 
106 
 
assessed using one-way ANOVA with Bonferroni’s correction within each line. Two-
tailed unpaired t-test was used to assess the impact of IB formation on the expression 
of B3-tubulin. The effect of MG132 and bafilomycin on HTT staining levels across the 
HTT exon 1 ReNcellVM panel was analysed using two-way ANOVA with Bonferroni’s 
correction, and this was also used to analyse the effect of PTI compounds on HTT 
exon 1 clearance in these cells.  
 
For the study of HTT trafficking described in chapter 6, the distribution of total HTT 
levels in control and 73Q MSNs and MSN cell fractions were compared using two-way 
ANOVA. Two-tailed unpaired t-test was used to analyse differences between total HTT 
levels in 29Q and 129Q HTT exon 1 ReNcellVM whole cell pellets, and to compare the 
percentage of nuclear HTT (as a proportion of total cell HTT) between these two lines. 
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3 Generating a HTT allelic series neuronal cell 
model of Huntington’s disease  
 
 
3.1 Background 
 
The importance of the length of the CAG repeat expansion mutation in the HTT gene is 
clinically evident. It determines whether patients will get adult onset HD (40+ CAG 
repeats), juvenile onset HD (>55 CAG repeats), or a reduced penetrance form of HD 
(36-40 CAG repeats). Patients who inherit 35 or less CAG repeats will remain free of 
the disease, though CAG repeat lengths from 27-35 may expand in future generations 
to cause HD. In addition CAG repeat length is the most important factor that 
determines age of onset of HD on a population level (Langbehn et al, 2010). The effect 
of increasing CAG repeat length in an otherwise constant model system in order to 
create an “allelic series” may lend insight into how this factor drives HD pathogenesis, 
and may also provide a useful tool for the testing of pre-clinical compounds in the 
search for disease modifying treatments. 
 
The ideal cell model must reflect the disease state as closely as possible. In the case 
of HD, this means using cells which are human derived (HD is an exclusively human 
disease) and neuronal (to reflect the primary site of HD pathology). In addition cell 
models should be renewable, and thus easily shared by the research community, and 
have robust differentiation protocols. The ReNcellVM neural stem cell (NSC) line, 
derived from ten-week gestation foetal midbrain, and the STROC05 human NSC line, 
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originally isolated from twelve-week gestation whole ganglionic eminence, were 
thought to fulfil these requirements, and it was decided to use these as a basis for a 
novel cell model of HD.  Inserting increasing CAG repeat lengths into the endogenous 
HTT locus of these lines would form an isogenic allelic series, in which full length HTT 
and mHTT would be expressed at physiological levels. The only difference between the 
lines in the series would be the length of the polyglutamine tract in the HTT protein, 
thus eliminating any genetic heterogeneity that could affect results.  
 
Prior to the development of CRISPR/Cas9 technology that has recently revolutionised 
genome editing, viral transduction with adeno-associated virus (AAV) was considered 
to be one of the most efficient methods of gene targeting in mammalian cells (Vasileva 
& Jessberger, 2005). Homologous recombination rates varying from 1 in 10,000 up to 1 
in 100 have been achieved in human cells using this method, compared to less than 1 
in 1,000,000 with other transfection methods. AAV has been proven to infect a wide 
range of human cells and to introduce many types of genetic modifications including 
insertions as well as deletions and point mutations. Other advantages of AAV include 
its single stranded genome, which allows efficient delivery to the nucleus, relatively 
easy construction using PCR-based methods and non-pathogenicity (Khan et al, 2011). 
Indeed recombinant AAV (rAAV) remains a key tool in the delivery of potential genetic 
therapies, including for HD (Miniarikova et al, 2018). It was therefore decided to utilise 
this technology to develop an isogenic allelic series human neuronal model of HD.  
 
One potential concern over the use of full length HTT cellular models is the timescale 
taken for disease associated phenotypes to develop. HD is generally an adult onset 
disease and even in juvenile HD cases it is extremely rare to have onset of symptoms 
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in early childhood. One method of simulating the effect of aging in neuronal cultures is 
to subject the cells to various cellular stressors. Alternatively, transgenic cell models 
expressing N-terminal fragments are known to give rise to disease phenotypes in a 
matter of days, or sometimes hours, depending on the cell line transduced and levels 
of overexpression. This is particularly useful for high-throughput therapeutics 
screening. A HTT exon 1 overexpression human neuronal model of HD was therefore 
optimised and characterised, to study the impact of increasing HTT exon 1 CAG 
repeat-length on neuronal phenotypes. 
 
Recent developments in iPSC technology, both in terms of their generation and 
differentiation into specific neuronal subtypes of interest, have made them increasingly 
attractive for modelling HD due to their close physiological representation of the 
disease state. MSNs, which are the earliest neurons to degenerate in HD, can be 
generated following a 36 day differentiation protocol that yields 20-50% of DARPP32 
positive cells. This protocol mirrors the developmental changes seen in neurogenesis, 
and uses activin A to induce lateral ganglionic eminence (LGE) characteristics in neural 
progenitors derived from pluripotent stem cells (Arber et al, 2015). The genetic 
backgrounds of iPSCs donors are known to have an effect on transcription and 
differentiation of the resulting cell lines (Kyttälä et al, 2016). Therefore direct 
comparisons between different HD-iPSC lines can be difficult. Consequently, a panel of 
iPSCs was generated from a family of HD-affected siblings (who have a relatively 
similar genetic background) and their mother as a control, with three clones from each 
line.  
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3.2 Aims  
 
1. To characterise and assess suitability of a human neural stem (NSC) cell line to be 
used for the generation of a new cell model of HD. 
 
2. To create an isogenic HTT allelic series in this NSC line using rAAV to knock in 
increasing CAG repeat lengths into the endogenous HTT locus.  
 
3. To optimise and characterise a transgenic HTT exon 1 overexpressing allelic series 
cell model in this same NSC line.  
 
4. To generate a panel of HD iPSCs with increasing CAG repeat lengths from HD 
affected siblings, and their unaffected mother as a genetically related control. 
 
 
3.3 Methods 
 
For characterisation of the ReNcellVM and STROC05 lines, NSCs were cultured and 
differentiated as described (section 2.1.1 and 2.1.3). In order to confirm endogenous 
HTT transcription in these lines, RNA extraction, cDNA generation, and PCR (section 
2.3) was carried out. HTT protein expression was confirmed by Western blotting 
(section 2.4). Antibiotic kill curves were generated for each line (section 2.1.4). 
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Immunofluorescence studies of the STROC05 line were carried out as described 
(section 2.7.1).  
 
In order to create the Horizon knock-in allelic series, recombinant AAV (rAAV) carrying 
the HTT 50, 80 and 125 CAG repeat vectors was first generated (section 2.6.1). After 
purification (section 2.6.2) and quantification using qPCR (section 2.6.3), the virus was 
used to transduce the ReNcellVM line (section 2.6.4), and cells were then screened for 
positive homologous recombination as described (section 2.6.5). The HTT exon 1 
overexpression lines were thawed (section 2.1) and expanded. HTT exon 1 expression 
was confirmed on Western blotting (section 2.4) and further quantification carried out 
by Evotec using the MSD assay (section 2.5). For generation of the iPSC panel, ethics 
and consent were obtained (section 2.2.1) and then punch biopsies of the skin carried 
out (section 2.2.2). Fibroblast cultures were developed from these (section 2.2.3) and 
frozen vials sent to Professor Ali Brivanlou at the Rockefeller centre for iPSC 
generation (section 2.2.4). iPSCs were differentiated into MSNs as detailed in section 
2.2.6. 
 
 
3.4 Contributions 
 
The work described in this chapter was carried out with collaborators in the following 
areas:  
Horizon Discovery Ltd., who provided the vectors and plasmids used in the generation 
of rAAV. 
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Professor Gill Bates who gifted the ReNcellVM lines with GFP and HTT exon 1 
inserted. 
Evotec Ltd who carried out the HTT MSD assay.  
Professor Ali Brivanlou who generated iPSC lines from our patient-derived fibroblasts. 
All other work was carried out by Dr. Rhia Ghosh.  
 
 
3.5 Results  
  
3.5.1 Characterisation of the ReNcellVM and STROC05 neural stem cell 
lines  
 
In order to ensure that the neural stem cell lines were suitable for generation of HD cell 
models, it was necessary to ensure that they were expressing native HTT. Previous 
sequencing of HTT in both lines had confirmed that they carry two wild-type alleles with 
19/21 CAG repeats in the ReNcellVM line and 20/22 repeats in the STROC05 line.  
 
3.5.1.1 Characterisation of ReNcellVM neural stem cell line 
 
RNA was extracted from ReNcellVM NSCs and cDNA synthesis using reverse 
transcriptase was carried out as described. PCR was performed out using two sets of 
primers against HTT, with results as shown in figure 3.1. This confirmed that the 
ReNcell line was transcribing the wild type HTT gene.  
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Figure 3.1: PCR on ReNcellVM cDNA template. Samples are shown in lanes 1, 3 
and 5 with negative control water in lanes 2, 4, and 6. Lanes 1 and 2 show results 
using HTT 9171/9361 primers, lanes 3 and 4 show results using HTT 153/449 primers, 
and lanes 5 and 6 show results using GAPDH primers as a positive control for the PCR 
reaction.  
 
 
Western blotting of protein extracted from a cell pellet of ReNcellVM NSCs was carried 
out using the MAB2166 antibody against HTT directed against (amino acids 181-810). 
This revealed that the ReNcellVM line was expressing HTT protein (figure 3.3). 
 
ReNcellVM NSCs were differentiated on coverslips for two weeks and tested by our 
collaborator Dr. Stephanie Schorge for electrophysiological activity. Despite previous 
work that had demonstrated electrical activity (Donato et al, 2007), the neurons were 
not found to generate action potentials, suggesting that these cells are still relatively 
immature in terms of neuronal development.  
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Finally, antibiotic kill curves calculated by Dr. Andre demonstrated that a concentration 
of 75 ng/ml of puromycin was sufficient to kill wild-type ReNcellVM NSCs – therefore 
this concentration was used when infecting the cells with the AAV vectors (see below). 
 
3.5.1.2 Characterisation of STROC05 neural stem cell line 
 
RNA extraction and cDNA synthesis was also carried out in STROC05 NSCs, and PCR 
performed using 2 sets of primers against HTT, with results as shown in figure 3.2. This 
confirmed that the STROC05 line was transcribing the wild type HTT gene.  
 
 
Figure 3.2: PCR on STROC05 cDNA template. Samples are shown in lanes 1, 3 and 
5 with negative control water in lanes 2, 4, and 6. Lanes 1 and 2 show results using 
HTT 9171/9361 primers, lanes 3 and 4 show results using HTT 153/449 primers, and 
lanes 5 and 6 show results using GAPDH primers as a positive control for the PCR 
reaction.  
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Western blotting of protein extracted from a cell pellet of STROCO5 NSCs with 
MAB2166 antibody revealed that the STROC05 line was also expressing HTT protein 
(figure 3.3). 
 
Figure 3.3: Western blot of protein extracted from STROC05 and ReNcellVM 
NSCs. Probing with the anti-HTT MAB2166 antibody confirms the expression of HTT 
protein in both STROCO5 and ReNcellVM NSC lines.  
 
 
STROC05 cells were differentiated on coverslips for 3 weeks as per our standard 
protocol, and tested for electrophysiological activity. The differentiated neurons did not 
generate action potentials. 
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Antibiotic kill curves for puromycin were determined and the data is shown in figure 3.4. 
From this a concentration of 50 ng/ml was determined to be the minimum required to 
kill wild-type STROC05 cells over 3-4 days.  
 
 
Figure 3.4: Puromycin kill curve in STROC05 NSCs.  Cells were exposed to a range 
of puromycin concentrations from 0-150 ng/ml, and percentage confluence of the 
culture was recorded daily. 50 ng/ml is shown to be the lowest concentration of 
puromycin that kills STROCO5 NSCs over 4 days. 
 
 
Effect of activin A on STROC05 cell differentiation 
 
GABAergic MSNs are the principal projection neurons of the striatum and are defined 
by their expression of the dopamine- and cAMP-regulated phosphoprotein (DARPP-
32). These cells specifically degenerate in early HD. Previous studies have shown that 
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STROC05 cells differentiate into neurons of which a small proportion are DARPP-32 
positive, and this proportion increases on the addition of the Hedgehog agonist 
purmorphamine (El-Akabawy et al, 2011). Therefore, this was used as the standard 
differentiation protocol in this study.   
 
The effect of adding activin A at 25 ng/ml throughout the standard 3-week 
differentiation protocol, both instead of and as well as purmorphamine, was tested. 
Activin A is a multifunctional TGFβ family protein that has been shown to induce 
forebrain neurogenesis in a neuronal subtype-restricted manner, and increases striatal 
neuron differentiation in human pluripotent stem cells (Arber et al, 2015). Primary 
antibodies against DARPP-32 and FOXP1 (a marker of striatal neuron precursors, 
normally expressed in the lateral ganglionic eminence) were used to detect MSNs. As 
can be seen from figure 3.5, STROC05 NSCs yield very few medium spiny neurons on 
differentiation (as reflected by DARPP-32 and FOXP1 staining), and the addition of 
activin A made little difference. This may be because the STROC05 cells are derived at 
too late a gestational stage for activin A to influence striatal development. 
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Figure 3.5: Immunofluorescence of dd21 STROC05 cells reveals very few striatal 
neurons following the standard differentiation protocol (left images), the addition of 
activin to the standard protocol (middle images) and the replacement of 
purmorphamine with activin in the protocol (right images). The addition of activin A to 
the STROC05 differentiation protocol does not increase the MSN yield in this line. 
Neuronal marker MAP2 – green; striatal markers DARPP-32 (top panel) and FOXP1 
(bottom panel) – red; nuclei (Hoescht) - blue.  
 
 
Generally, the STROC05 cells were found to be more slow-growing than the 
ReNcellVM. They did not tolerate repeated passaging as well, and later work found 
them to be very sensitive to the effects of AAV infection – critical for creation of the 
knock-in allelic series.  For these reasons, in combination with the very low MSN yield 
on differentiation, future neural stem cell work and cell modelling efforts were 
concentrated on the ReNcellVM line.  
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3.5.2 Generation of an AAV-mediated knock-in HTT exon 1 allelic series 
in the ReNcellVM neural stem cell line 
 
The overall aim was to create an isogenic HTT allelic series in the ReNcellVM line, by 
using AAV to knock-in different CAG repeat lengths (50Q, 80Q and 125Q) at the 
endogenous HTT exon 1 locus. Full length HTT and mHTT would be expressed at 
physiological levels and direct comparisons between cell lines could be made. An 
overview of the processes used to generate this line is shown in figure 3.6. 
 
3.5.2.1 Recombinant AAV production and ReNcellVM infection with rAAV 
 
HTT exon 1 vectors with 50, 80 and 125 CAG repeats were created by Horizon 
Discovery, as per figure 3.7. Vectors contained the puromycin resistance gene to allow 
for selection of cells that had taken up the vector successfully. LoxP sites flanked the 
resistance gene, for its later removal by the addition of Cre recombinase in successfully 
integrated cells. Right and left homology arms containing HTT intronic sequence were 
included to target the vector for homologous recombination. The overall vector size 
was 7 kb.  
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Figure 3.6: Overview of recombinant adeno-associated virus generation and 
subsequent transduction of the ReNcellVM line. 
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Figure 3.7: Panel of rAAV vectors with three different CAG repeat lengths. Vectors 
containing 50, 80 or 125 CAG repeats were generated, each containing a puromycin 
resistance gene (yellow box) flanked by LoxP sites (black triangle). This was flanked on 
each side by maximal length left and right homology arms to target the vector correctly 
for homologous recombination.  
 
 
Plasmid vectors were packaged into HEK 293T cells using lipofectamine transfection, 
along with plasmids encoding viral replication and coat proteins, and helper proteins. 
The resulting rAAV generated was purified, quantified and used to infect ReNcellVM 
NSCs. An example amplification plot for qPCR for the quantification of rAAV80Q is 
shown in figure 3.8. Viral titres were calculated for each construct, as shown in table 
3.1. 
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Figure 3.8: Top: Amplification plot for qPCR of AAV80. Curves in grey correspond 
to the standards (loaded in triplicate). The blue curve is a 1:15 dilution of the sample, 
the green curve is 1:30 dilution. CT values were determined at the threshold shown. 
Bottom: Standard curve generated from CT values of the standards (plotted in red). 
The dark blue points correspond to the samples, at the respective dilutions. On 
calculating the final viral titre, this dilution factor and the dilution used throughout the 
RT-PCR setup was multiplied by the quantity generated from the standard curve. 
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Virus construct 
Genome Copies /ml (also equivalent 
to MOI) 
rAAV50 7.85 x 1011 
rAAV80 9.7 x 1011 
rAAV125 5.56 x 1011 
 
Table 3.1: Viral titres of all three constructs. 
 
Following infection and two weeks of antibiotic selection with puromycin, vials of 
selected ReNcellVM NSCs of at least 1x106cells were frozen down and stored in liquid 
nitrogen.  
 
3.5.2.2 Screening ReNcellVM NSCs for homologous recombination of rAAV 
HTT exon 1 vectors 
 
A PCR-based screening strategy was employed. Primers were designed that would 
distinguish a positively integrated vector, and also generate an internal positive control 
band from the wild type allele, thus confirming that the PCR reaction had worked. The 
DNA sequence of the forward primer site in the left homology arm was also included in 
the vector just after the puromycin resistance gene, forming a second “nested” forward 
primer site. In theory, a cell with a correctly targeted vector gives rise to three different 
products, as shown in figure 3.9. The screening primer was referred to “RH2”. 
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Figure 3.9: Top panel - design of screening primers “RH2”. The DNA sequence of 
the forward primer site in the left homology arm is also present immediately following 
the puromycin resistance gene, forming a second “nested” forward primer site. The 
RH2 forward primer would therefore amplify from both these sites, paired with the RH2 
reverse primer, giving rise to two PCR products of different lengths from a correctly 
targeted allele. Bottom panel - PCR bands generated from off target and correctly 
targeted integration of vector. In the case of a correctly targeted cell, two PCR bands 
are generated from the positively integrated allele and one further PCR band from the 
wild type allele, as shown.  
 
 
Using RH2 primers, the size in base pairs of the expected products following positive 
homologous recombination is shown in table 3.2. 
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 Targeted allele Wild-type allele Nested allele 
AAV 50 3351 1960 1652 
AAV 80 3441 1960 1652 
AAV 125 3576 1960 1652 
 
Table 3.2: Expected size of DNA bands generated from PCR with RH2 primers. 
 
Due to the large size of the full-length targeted allele and the need for PCR 
amplification over a long CAG repeat in order to form this product, it was not 
necessarily expected to see this product following PCR reactions. The presence of the 
nested allele in addition to a wild-type allele would indicate successful “on-target” 
recombination. 
 
Cells were seeded at a density of ten cells per well into 96-well plates and grown until 
confluent. Our screening strategy was to identify a well containing a positively 
integrated cell (or colony), and to then carry out single cell dilution from this “positive 
pool” in order to isolate a positively integrated clone. A density of 100 cells per well was 
also attempted for screening of pools, however no positive pools were identified using 
this approach. This was thought to be due to the PCR screen not being able to amplify 
any potential “nested allele” in the presence of a much higher ratio of wild type alleles 
(around 1:200 assuming one positive integration per well), due to competition for the 
same primers. Single cell dilution into 96 well plates and PCR screening of subsequent 
colonies was also attempted. However, due to the low homologous recombination rate, 
this approach did not yield any positive hits and so a seeding density of ten cells per 
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well was employed. It was however confirmed that the ReNcellVM lines were able to 
tolerate single cell dilution.  
 
Cells from each well of a 96-well plate seeded at 10 cells per well were lysed and 
screened using PCR as described. Overall, the following numbers of corresponding 
pools that were screened in this way are shown in table 3.3. This suggests a very low 
rate of homologous recombination of the rAAV vector in our ReNcellVM line. 
 
 
Cell line Number of pools screened 
Putative positive pools 
identified 
ReNcellVM 50Q 780 0 
ReNcellVM 80Q 734 3 
ReNcellVM 125Q 679 0 
 
Table 3.3: Total screened number of pools derived from seeding density of 10 cells per 
well. 
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Identification and verification of a ReNcellVM pool containing a correctly 
integrated rAAV vector 
 
An example of a PCR reaction identifying our first positive pool (P1) following a screen 
of ReNcellVM 80Q is shown in figure 3.10. 
 
 
Figure 3.10: Identification of ReNcellVM NSC pool containing a correctly 
integrated rAAV 80Q vector. PCR reaction with RH2 primers showing amplification of 
a wild-type band and “nested” allele underneath it.  
 
 
The PCR product was also run out further on the gel in order to more accurately size 
the lower product (figure 3.11). 
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Figure 3.11: Further testing of ReNcellVM NSC pool containing a potentially 
correctly integrated rAAV 80Q vector. Duplicate PCR reactions with RH2 primers on 
lysed gDNA from P1 cells was carried out and the PCR products were run out further 
on the agarose gel in order to more accurately size the lower band. The nested allele is 
confirmed to be between 1600-1700bp in size (Expected size=1652). 
 
Due to the small size difference between the wild type and nested allele, the PCR 
product was run for 3 hrs to achieve sufficient separation for sizing. This led to leaching 
of SYBRSafe from the agarose gel, causing difficulties in visualisation, but the problem 
was overcome by placing the gel in a 1/10,000 SYBR-bath for 30 min with agitation 
before imaging. The lower band was of the expected size corresponding to the nested 
allele.  
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The positive pool of cells was expanded, and vials were frozen down and stored in 
liquid nitrogen. Further experiments were undertaken to verify this potential positive 
pool. It was not possible to directly sequence the pool as it contained mixed clones. 
Therefore the lower band was extracted from the agarose gel and purified. Sixty µl of 
purified DNA was obtained, at a concentration of 2.7 ng/ml, but ultimately this was not 
sufficient for successful sequencing.  
 
A “nested PCR” strategy was therefore employed to confirm the identity of the lower 
band of PCR product. Primers were designed as shown in figure 3.12, and used to test 
the extracted, purified DNA from the lower gel band. 
 
Figure 3.12: Design of “nested PCR” primers. Primers RH2 Nest and RH2 Sp* Nest 
designed to confirm identity of the extracted lower band from PCR of the potential 
ReNcellVM 80Q NSC pool.  
 
 
The RH2 Nest primers would amplify from both the integrated vector and also the wild 
type band (which may be contaminating the purified sample due to its proximity to the 
lower band on the gel). The RH2 Sp* Nest primer set would only amplify from an 
integrated vector and not the wild type band due to the forward primer being sited in 
the LoxP site. Results of PCR using these primer sets are shown in figure 3.13. 
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Figure 3.13: “Nested PCR” confirms that the ReNcellVM pool P1 does contain the 
correctly integrated 80Q rAAV vector. PCR on DNA from extracted lower band on 
agarose gel (lanes 1 + 4), wild type ReNcell whole genomic DNA (lanes 2 + 5) and 
water (lanes 3+6). Lanes 1-3 were amplified using RH2 Nest primers and lanes 4-6 
using RH2 Sp* Nest primers. The amplification of PCR product in lanes 1 and 4 
confirms that the DNA from the extracted band contained the 80Q rAAV vector. The 
band in lane 2 is to be expected as RH2 Nest primers can amplify from the wild-type 
HTT allele. 
 
 
This suggests that this particular cell pool (P1) did contain a positively 
integrated clone.  
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Identification of further ReNcellVM pools containing a correctly integrated rAAV 
vector 
 
Two further potentially positive ReNcellVM 80Q pools (P2 and P3) were identified as 
shown in figure 3.14. On running these products out further on the gel (figure 3.15), P2 
was sized correctly for the nested allele but P3 was not. However, on performing gel 
extraction and DNA purification of the P2 lower band, followed by nested PCR 
reactions as described above (figure 3.16), this was also proven to be a false positive. 
 
Figure 3.14: Identification of further potential ReNcellVM NSC pools containing a 
correctly integrated rAAV 80Q vector. Two further ReNcellVM 80Q pools, 
designated P2 and P3, gave a possible “nested” band on PCR (red arrows). 
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Figure 3.15: Further testing of P2 and P3 ReNcellVM NSC pools. Duplicate PCR 
reactions with RH2 primers on lysed gDNA from P2 and P3 cells was carried out and 
the PCR products were run out further on the agarose gel in order to more accurately 
size the lower band. P2 is on left, and is sized correctly (between 1600 and 1700bp) for 
the expected product (red arrow). However, P3 on the right is too small (green arrow). 
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Figure 3.16: “Nested PCR” shows that the ReNcellVM pool P2 does not contain 
the correctly integrated 80Q rAAV vector. PCR on P2 DNA from extracted lower 
band on agarose gel (lanes 1 + 4), wild type ReNcell whole genomic DNA (lanes 2 + 5) 
and water (lanes 3+6). Lanes 1-3 were amplified using RH2 Nest primers and lanes 4-
6 using RH2 Sp* Nest primers. The amplification of PCR product in lanes 1 and 2 is 
likely to be amplification from a wild-type HTT allele, given the lack of any PCR product 
in lane 4.  
 
 
3.5.2.3 Isolating a single positively integrated clone within a positive 
ReNcellVM pool  
 
Having isolated one positive pool (P1) of ReNcellVM 80Q cells, the plan was to isolate 
at least one clone with the positively integrated AAV-80Q construct. The clonal line 
would then be treated with Cre recombinase in order to remove the PGK/Puromycin 
cassette which is flanked by LoxP sites within the vector. This would leave only the 
expanded HTT exon 1 in its native gene locus.  
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Initially the screening PCR with RH2 primers was repeated on DNA from lysed P1 
cells. On confirming that this pool still contained the integrated AAV-80Q vector, 5 x 96-
well plates were seeded at 1 cell per well (single cell dilution) to make clonal 
populations. The positive pool was expanded and vials were frozen down. Overall, over 
a 2 week period 52 clones were identified, genomic DNA was isolated and PCR 
screened with RH2 primers. Unfortunately, none of these clones contained the 
positively integrated vector. 
 
On thawing frozen vials of P1 cells for further single cell cloning, the pools were 
retested to ensure that they still contained the positively integrated vector. 
Unfortunately, it was found that this was not always the case. Most of the thawed vials 
of banked P1 cells were negative for the positively integrated vector; the few that 
displayed a nested allele when tested immediately post thaw, then tested negative by 
the subsequent passage. This would suggest that any positively integrated cells within 
the pool have a survival disadvantage on freeze-thawing and/or repeated passaging.  
 
3.5.2.4 Alternative screening strategies to identify and isolate ReNcellVM NSCs 
containing correctly integrated rAAV vectors 
 
Bulk pools of ReNcellVM 80Q NSCs that had been frozen down post antibiotic 
selection were tested using PCR with primers designed to amplify only in the presence 
of a homologous recombined construct. These were designed such that the forward 
primer was sited in sequence specific to the vector (i.e. the LOXP site, PGK promoter 
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or puromycin resistance gene) and the reverse primer was outside the right homology 
arm. These primers are designed to be used directly on lysed gDNA from the ReNcells. 
Unfortunately there is no internal positive control band generated, as there is with our 
RH2 screening primers – for this reason these primer sets were not used in our initial 
screening approach. However, as there are no competing DNA products (nothing is 
amplified from the wild type allele), the PCR reaction would have sufficient power to 
detect even a very small proportion of homologous recombined cells.  
 
 
Figure 3.17: PCR of DNA from bulk pool ReNcell 80Q lysate with 10 different 
screening primer sets. In lanes 1-9 primers were designed as described above. Lane 
10 primers were entirely within the PGK/Puromycin segment, which would detect the 
presence of the 80Q vector anywhere in the genome. PCR bands of the expected size 
are seen in lane 1, 2 and 7, suggesting this pool did contain the correctly integrated 
rAAV 80Q vector.  
 
Three of the nine primer sets that were designed to detect homologous recombination 
directly from lysed cells amplified products of the expected size (figure 3.17), 
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confirming that the original bulk pool did contain the positively integrated product. 
These three primer sets were designated A, B and C.   
 
Using the same primer sets (A, B and C) bulk pools of ReNcellVM 125Q were thawed 
and tested, and also showed that the positively recombined vector was present (figure 
3.18). 
 
 
Figure 3.18: PCR of DNA from bulk pool ReNcell 125Q lysate. DNA was tested with 
primer set A, B and C (lanes 1-3 respectively), LH2 primers (lane 4) RH2 primers (lane 
5) and PGK/Puromycin primers (lane 6). The amplified band in lane 3 suggests 
correctly integrated rAAV 125Q vector in this pool of ReNcellVM NSCs.  
 
However, other vials of cells that were frozen down at the same time and from the 
same batch did not amplify anything using these primers, just as was observed for P1 
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cells. On seeding the positive bulk pool ReNcellVM 125Q at 1000 cells per well into a 
96 well plate, and screening the subsequent lysates, no positive pools were identified. 
These two findings again raise the possibility of a selective disadvantage for positively 
integrated cells on thawing, or a slower rate of proliferation compared to non-integrated 
cells such that the percentage of positively integrated cells decreases exponentially 
with each passage.  
 
3.5.2.5 HCT116 cell line infection with rAAV and subsequent screening for 
homologous recombination of rAAV HTT exon 1 vectors 
 
It was also considered that the homologous recombination rate in the ReNcellVM line 
may be very low due to intrinsic properties of the neural stem cells. HCT116 cells are a 
robust and commonly used human colonic cancer cell line that has previously been to 
be generally amenable to AAV infection and site directed genetic manipulation (Khan et 
al, 2011). HCT116 cells were therefore infected with rAAV 125Q at 100,000 viral 
particles/cell for 72 hrs, and the infected cells were expanded. After 24 hrs puromycin 
(0.35 µg/ml) was added to the NSC medium, and the cells remained under antibiotic 
selection for two weeks. Post selection, vials of cells were frozen down.  
 
Lysate from bulk pools of infected, selected HCT116 125Q cells was tested using PCR 
with various screening primers as shown in figure 3.19.  
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Figure 3.19: PCR of DNA from bulk pool HCT116-125Q lysate. DNA was tested with 
primer set A, B and C (lanes 1-3), LH2 primers (lane 4) RH2 primers (lane 5) and 
PGK/Puromycin primers (lane 6). Amplification of bands in lanes 1 and 3 suggest 
correct integration of the rAAV 125Q vector in these cells.  
 
 
This confirmed positive integration of AAV125 in the HCT116 cells, and the infected, 
selected cells were therefore seeded at 1000 cells per well into 20 wells of a 96-well 
plate and once confluent, gDNA lysate was tested using primer set A, B and C. The 
results using primer set C showed the clearest amplification and the results are shown 
in figure 3.20. 
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Figure 3.20: PCR of DNA from 1000 cell per well pools of HCT116-125Q cells. Of 
the 20 wells tested with primer set C, 3 were found to be positive i.e. to contain cells 
with the homologous recombined vector. 
 
 
Cell pools from these three wells were then expanded, frozen down and stored, and at 
the same time, one cell pool was reseeded at 100 cells per well into 20 wells of a 96 
well plate, and re-screened with primer set A and C when confluent. A PGK/Puromycin 
primer set was also used as a positive control for the PCR reaction and to confirm the 
presence of the rAAV vector anywhere in the cells. From this, one positive pool was 
identified and designated HCT-P1 (figure 3.21).   
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Figure 3.21: PCR of DNA from 100 cell per well pools of HCT116-125Q cells. 10 
separate pools were tested. For each pool, primer sets A, C and PGK/Puromycin were 
used (loaded left to right for each sample). 1 positive pool (marked by yellow stars) was 
identified. 
 
HCT-P1 cells were plated out directly at 10 cells per well into 48 wells of a new 96W 
plate (i.e. with no further passages between), but on PCR testing the subsequent 
lysates from these wells using primer set A, B and C, no positive pools were identified. 
Therefore although with the HCT116 line three positive pools were identified from 
twenty wells seeded at 1000 cells per well, suggesting a higher recombination rate than 
the ReNcellVM line, ultimately the problem of loss of positive signal over subsequent 
passages, freeze/thawing and expanding from low cell seeding density (which places 
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extra stress on the cells) precluded the successful isolation of a single homologously 
recombined HCT116 clone.   
 
 
3.5.3 Generation and characterisation of an allelic series HTT exon 1 
overexpression model in the ReNcellVM neural stem cell line 
 
3.5.3.1 Generation of HTT exon 1 overexpressing ReNcellVM cells 
 
This line was gifted to us by Professor Gillian Bates (King’s College London). Briefly, 
ReNcellVM NSCs underwent lentivirus transduction with vectors containing HTT exon 
1 with 29, 71 and 129 CAG repeats respectively, each linked with an internal ribosome 
entry site (IRES) to the gene encoding green fluorescent protein (GFP) (figure 3.22). 
 
 
Figure 3.22: Plasmid vector used to create the HTT exon 1 overexpression line. 
Reproduced from Sirinathsingh: “Generation of human stem cell models of 
Huntington’s disease”. 
 
 
The vectors were created by Dr. Sirinathsingh using molecular cloning methods. The 
A2UCOE promoter reduces the chance of post-integration transgene silencing by 
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conferring a dominant chromatin opening function that is a more transcriptionally active 
structure. The internal ribosome entry site (IRES) sequence allows translation initiation 
in the middle of an mRNA, allowing for the independent translation of HTT exon 1 and 
GFP. The woodchuck post-transcriptional regulatory element (WPRE) is commonly 
inserted into lentiviral contructs to increase mRNA transport out of the nucleus, hence 
increasing viral titre (Sirinathsingh, 2009). To create a negative control line, ReNcellVM 
NSCs were transduced with a GFP-only expressing vector.  
 
It is worth noting that each HTT exon 1 vector terminates the polyglutamine CAG tract 
with a further CAA-CAG. Therefore on translation a protein with 31, 73 and 131Q is 
formed from 29, 71 and 129 CAG respectively. However for the sake of clarity, 
throughout the rest of this thesis, they will be referred to as 29, 71 and 129Q or CAG 
interchangeably depending on whether the protein (Q) or gene (CAG) is being 
discussed.  
 
For each line, the cells were sorted by fluorescence activated cell sorting (FACS) on 
the basis of GFP expression. Four populations of low to high expressing cells were 
pooled for each line, and these were labelled POP7 (lowest expression level), POP4 
(low middle expression level), POP5 (high middle expression level), and POP6 (highest 
expression level). Vials of cells were received that had been transduced with GFP-only 
and HTT exon 1 29Q, 71Q and 129Q constructs, of different POP numbers.  
 
These vials were thawed, mycoplasma tested, expanded over 2-3 passages and 
pellets prepared for Western blotting and HTT quantification using the ELISA-based 
MSD electrochemiluminescence assay. The aim was to find a panel of cell lines with 
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similar expression levels of HTT exon 1 in order to ascertain the effect of increasing 
CAG repeat length on cellular phenotypes and the behaviour of the HTT exon 1 protein 
itself. 
 
3.5.3.2 Quantification of HTT exon 1 expression in ReNcellVM lines 
 
Western blotting with 4C9 and S830 antibody identified at least one ReNcellVM line 
expressing each of the constructs. Both these antibodies are HTT specific. 4C9 is a 
monoclonal antibody raised against the human specific proline-rich region (amino acid 
65–84). S830 also binds to the N-terminal of HTT (amino acids 1-90) but has a higher 
affinity for expanded polyglutamine lengths. As can be seen from figure 3.23, of the 
cells that were tested only one HTT exon 1 129Q expressing line was identified. HTT 
exon 1 29Q and 71Q lines with a matched or similar level of expression were therefore 
sought.  
 
The membrane was stripped and re-probed with GFP and β-actin antibody, and the 
results were analysed using densitometry to calculate the intensity of the bands, as 
shown in figure 3.24. The GFP:β-actin ratio was determined to give an indication of the 
levels of GFP expression in the cell, and the percentage of GFP expression relative to 
the 129Q POP 7 line was calculated. Due to the design of the transgene construct, with 
the GFP gene linked via an IRES construct to HTT exon 1, the levels of GFP 
expression are assumed to be proportional to the level of HTT exon 1 expression.  
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Figure 3.23: Western blot of HTT exon 1 overexpressing and GFP only ReNcellVM 
NSCs. Of the 129Q lines, only 129Q POP7 is expressing the mutant 129Q exon 1 – 
the remaining 4 129Q lines are not (indeed, they seem to be expressing a 29Q exon 1 
product). Green – S830 antibody, Red – 4C9 antibody.  
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Figure 3.24: Top panel: Western blot of GFP and β-actin in HTT exon 1 
overexpressing ReNcellVM lines. Green – GFP, Red - β-actin. Bottom panel: 
Quantification of blot using densitometry of bands to determine GFP expression 
relative to the 129Q POP 7 line (the only 129Q expressing line). A matched expressing 
HTT exon 1 29Q/71Q/129Q panel is highlighted in green, and a matched highly 
expressing HTT exon 1 29Q/71Q pair of lines are highlighted in blue. 
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Using this method some variability of GFP expression level was found, even between 
lines of the same POP. However, a pair of HTT exon 1 29Q and 71Q highly-expressing 
lines were identified. An allelic series of ReNcellVM HTT exon 1 29Q, 71Q and 129Q 
POP 7 cells with lower, and relatively well matched expression levels of HTT exon 1 
was also identified. 
 
To ensure that the stripping process did not have an effect on the GFP analysis, the 
same gel samples were run again, and the membrane probed directly with GFP and β-
actin antibody. On this occasion the band intensity was calculated directly using the 
Licor Odyssey software. Direct probing of the membrane revealed even greater 
variability of relative GFP expression levels across constructs of the same POP level, 
and across the whole range of lines generally, however this analysis also confirmed the 
well matched high-expressing ReNcellVM HTT exon 1  29Q/71Q pair of cell lines and 
the lower expressing, matched panel of HTT exon 1  29Q/71Q/129Q POP7 cells to be 
taken forward for further experiments.  
 
Western blotting using 4C9 and S830 antibodies was also performed on the same 
panel of cells following two weeks of differentiation, to ensure that this did not affect 
expression of the transgene (figure 3.25). This confirmed that transduced ReNcellVM 
neurons were still expressing the construct. 
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Figure 3.25: Western blot confirms expression of HTT exon 1 in ReNcellVM 
neurons after differentiation. Red – 4C9, Green – S830.  
 
In order to confirm and further quantify the expression of HTT exon 1 in these cells, 
whole cell pellets from thirteen cell lines (including wild-type ReNcellVM) were 
analysed by Evotec using the ELISA-based MSD assay. For each cell line, pellets of 
neural stem cells and differentiated cells (day 14) were sent. Total HTT levels were 
measured using the 2B7/4C9 antibody pair, and mutant HTT using the 2B7/MW1 
antibody pair. Overall, the MSD assays confirmed that all the ReNcellVM HTT exon 1  
lines were definitively expressing the HTT exon 1 construct. The expression levels of 
HTT exon 1 in the 29Q and 71Q lines were ranked POP7<POP4<POP5<POP6 as 
expected. Both the 29Q and 71Q lines displayed higher total/expanded HTT 
expression levels in differentiated neurons than in NSC state, however in the 129Q line 
there was no difference. As expected, there was no expression of expanded HTT in the 
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wild-type and GFP only control lines. It is worth noting that the MW1 mutant HTT 
antibody displays polyQ length dependency, and therefore the results of the mutant 
HTT assay cannot be used to make comparisons between cell lines. The 4C9 antibody 
binds to the polyproline region of HTT and is not affected by polyQ length. Levels of 
total HTT were therefore compared across all the cell lines, and with endogenous HTT 
expression in wild-type and GFP only lines. This data is shown in figure 3.26.  
 
A panel of cell lines with relatively low, well-matched HTT exon 1 expression 
levels and a highly expressing 71Q line (71Q-H) was then taken forward for 
further experiments (table 3.4).  
 
 
Table 3.4: The level of HTT relative to endogenous HTT (which is the only HTT 
present in the GFP only line). 
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Figure 3.26: Quantification of total HTT levels in ReNcellVM HTT exon 1 lines. 
Top graph: Total HTT levels measured by 2B7/4C9 MSD assay in NSC and dd14 
cells. Bottom graph: Total HTT levels in panel of HTT exon 1 lines with closest 
matching expression levels, and the high expressing 71Q comparator (71Q-H). (n=3, 
technical replicates) 
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3.5.3.3 Characterisation of HTT exon 1 ReNcellVM lines 
 
The full panel of HTT exon 1 cells was differentiated for two weeks and culture 
composition was analysed. Immunofluorescence of 14-day differentiated cells 
demonstrated the expression of B3-tubulin, GFAP and nestin (see figure 3.27). The 
formation of inclusion bodies (IBs) that bound to S830 anti-HTT antibody was noted. 
There was no evidence of expression of other cell type markers - MAP2, Olig1, HuD, or 
neurofilament (NF200), nor did the cells express glutamate receptors (Western blotting 
for GluR2 and VGlut1 was negative). 
 
 
Figure 3.27: Immunocytochemistry of 71Q-H line at day 14 of differentiation. Cells 
are shown to have expression of B3-tubulin, GFAP and nestin. Blue – Hoescht (nuclei), 
Green – GFP, White – S830 HTT antibody, Red – cell marker as shown. 
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These findings were confirmed on Western blotting (figure 3.28).  
 
 
Figure 3.28: Western blotting at day 14 of wild-type, 29Q and 71Q-H lines 
confirms that B3-tubulin, GFAP and nestin are expressed in these cells. There is 
no expression of MAP2, HuD, Olig1 or neurofilament (NF200). 
 
The lack of glutamate receptor expression likely contributed to the lack of 
electrophysiological activity in this cell line, and indicates that they are not true mature 
neurons. In addition, there appears to be an overlap in staining pattern of B3-tubulin, 
GFAP and nestin (each of which was imaged in separate experiments). B3-tubulin is a 
microtubule protein predominantly expressed in neurons, and is a standard neuronal 
marker used in immunohistochemistry. The pattern of B3-tubulin staining in the HTT 
exon 1 ReNcellVM cells displays a neuronal morphology, however the persistence of 
abundant nestin (an intermediate filament protein and neuroectodermal stem cell 
marker) indicates that the neuronal culture is still very immature.  
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More surprising is the pattern of GFAP staining observed, which appears to be axonal 
and overlapping with B3-tubulin staining. GFAP is an intermediate filament protein 
expressed predominantly in glial cells, including astrocytes, and would not be expected 
to overlap with the distribution of B3-tubulin. A small amount of GFAP staining is known 
to occur in immature neurons, however in this case the extent of overlap raises the 
possibility that the HTT exon 1 ReNcellVM cells are not differentiating into true 
neuronal cells but rather forming neuron/astrocyte hybrid cells or “asterons”, as have 
been previously described (Laywell et al, 2005). These findings must be kept in mind, 
though for this thesis the ReNcellVM cells are referred to as “neurons” due to the 
strong presence of B3-tubulin and their characteristic neuronal morphology.  
 
The effect of increasing CAG length on differentiation and culture composition was 
further assessed at a later date (see chapter 4), and an in-depth analysis of HTT 
inclusion formation was also carried out (see chapter 5).  
 
3.5.4 HTT allelic series iPSC model of Huntington’s disease 
 
Neurons derived from HD-iPSCs are likely the most genetically precise model of 
Huntington’s disease. Through utilisation of established differentiation protocols, HD-
iPSC derived MSNs (the most vulnerable neuronal subtype in HD) can be studied. In 
creating a panel of iPSCs from an HD family who carry different CAG repeat length 
mutations, and their unaffected biological mother, it was hoped that some of the issues 
raised by genetic heterogeneity, when comparing different HD-iPSC lines, would be 
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ameliorated. The relatively similar genetic background of the lines will allow us to better 
assess the effect of increasing CAG repeat length on cellular phenotypes. 
 
3.5.4.1 Generation of iPSC lines 
 
This family was known to the Tabrizi group through the Huntington’s Disease clinic at 
the National Hospital for Neurology and Neurosurgery. Three siblings aged 26, 22 and 
20 years old at the time of biopsy had inherited the HD gene mutation from their father 
(since deceased). All three transmitted mutations underwent expansion (anticipation) 
such that the siblings were all diagnosed with Juvenile HD at the ages of 14, 17 and 12 
respectively, although in all cases symptoms had preceded the diagnosis by many 
years. Genetic testing has confirmed that their HD gene mutations contain 67, 56 and 
73 CAG repeats respectively. Their mother was aged 46 at the time of biopsy, and is 
the genetically related control.  
 
Punch biopsies of the skin were carried out as described. There were no immediate or 
late complications. Explant cultures were set up as described, with all four samples. 
Fibroblasts were successfully isolated, expanded and frozen down in vials from 
passage 3-5 as summarized in table 3.5.  
 
 
 
 
Chapter 3 
 
154 
 
Line CAG-repeat 
length 
Passage Date frozen No of vials No of 
cells per 
vial 
QS-01-FB 56 P3 
P4 
20.7.14 
25.7.14 
13 
10 
513 500 
560 000 
QS-02-FB Control P3 
P4 
P5 
20.7.14 
25.7.14 
28.7.14 
3 
7 
2 
516 000 
506 000 
500 000 
QS-03-FB 73 P3 
P4 
P3* 
20.7.14 
25.7.14 
31.7.14 
7 
15 
2 
546 000 
559 000 
500 000 
QS-04-FB 67 P3 
P4 
25.7.14 
28.7.14 
7 
3 
500 000 
500 000 
Table 3.5: Summary fibroblast lines frozen and stored in liquid nitrogen.  
 
 
Vials of frozen cells were sent to Professor Ali Brivanlou and his team at the 
Rockefeller Centre, and the fibroblasts were reprogrammed into iPSCs via Sendai 
reprogramming. Vials of iPSCs (at least three clones per subject) were sent back to us. 
Verification of the iPSCs included confirmation of expression of pluripotency markers, 
karyotyping, Sanger sequencing to confirm the HTT polyQ repeat-length, confirmation 
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of the absence of exogenous Sendai virus and mycoplasma testing. The ability to 
differentiate into all germ layers was also confirmed by longer-running teratoma 
assays.  
 
3.5.4.2 Differentiation of iPSCs into MSNs 
 
Following a differentiation protocol of at least 36 days, adapted from the laboratory of 
Meng Li (Arber et al, 2015), MSNs were obtained for all three clones of the 73Q line 
(designated 73Q clone 1, 73Q clone 2 and 73Q clone 3) and the control lines 
(designated 20Q clone 1, 20Q clone 2 and 20Q clone 3). This protocol is known to 
generate up to 50% MSNs in culture (defined by positive DARPP32 staining). Figure 
3.29 shows bright field images of all these lines following the MSN differentiation 
protocol, and figures 6.5 and 6.6 (chapter 6) show immunocytochemistry confirming the 
presence of DARPP-32 positive cells with characteristic MSN morphology. 
Experiments were carried out using the control 20Q and the longest CAG repeat 73Q 
lines to increase chances of demonstrating a pathogenic effect. Three clones were 
used in parallel in order to mitigate the effects of clonal variability that is known to occur 
in iPSCs and provide biological replicates.  
 
Chapter 3 
 
156 
 
 
Figure 3.29: Differentiation of three control (20Q) and three mutant (73Q) iPSC 
lines. Bright field images of three clones of control and 73Q MSNs, from top to bottom. 
Images taken between days 38-49 of differentiation.  
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3.6 Discussion 
 
The ReNcellVM line is a well validated NSC line that has been shown to differentiate 
into neurons, astrocytes and oligodendrocytes (Donato et al, 2007). The line has 
previously been used to study aspects of disease pathogenesis in Parkinson’s disease 
(Gandhi et al, 2009); its robust growth, straightforward differentiation protocol and 
amenability to viral transduction also make it a useful line for the development of an HD 
model. The STROC05 NSC line has previously been shown to produce 7% DARPP-32 
positive cells on differentiation (El-Akabawy et al, 2011) and therefore was an 
appealing choice of cell line as MSNs are the most affected cells in HD. However, its 
slow growth and poor tolerance of viral transduction led to a shift in focus of cell 
modelling efforts onto the ReNcellVM line.  
 
The attempt to create an isogenic HTT allelic series in the ReNcellVM line using rAAV 
vectors to knock in increasing CAG repeat lengths into the endogenous HTT locus was 
not successful. There are a number of potential reasons to account for this. Firstly, the 
rate of homologous recombination (HR) in the ReNcellVM line was much lower than 
expected, based on observations in other cell types (Khan et al, 2011; Khan et al, 
2010). It was considered that this may be due to neural stem cell specific factors, and 
attempts were made to create the allelic series in the HCT116 colorectal cancer line, 
which has previously been successfully engineered using AAV transfection (Khan et al, 
2011); however low rates of recombination were again encountered. AAV is limited by 
the size of vector it can incorporate; the vector size of 7kb is at the upper limit. It is 
possible that the length of the desired insertion sequence was too long relative to the 
length of the homology arms to successfully guide HR of the full construct. 
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A different issue was that in both ReNcellVM and HCT116 lines, pools of cells that 
were identified on screening as containing the positively integrated vector lost their 
positive signal over subsequent passages and freeze/thaw. This may be due to 
selective advantage of wild-type cells (without mHTT knock-in), both in the speed of 
cell division/doubling time, and in the tolerance of cell stress (in this case the 
freeze/thaw process). Indeed there is evidence that mHTT affects mitotic spindle 
formation (Godin et al, 2010) and cells expressing mHTT are known to be more 
sensitive to stress (Zhang et al, 2010). 
 
Genome editing may also be achieved using engineered nucleases composed of 
sequence-specific DNA-binding domains fused to a non-specific DNA cleavage 
module. These include zinc finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs). More recently this field has been revolutionised by the 
discovery of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 
(CRISPR-associated system 9) nuclease, which is a prokaryotic immune system 
conferring acquired immunity to phages (Horvath & Barrangou, 2010). The system has 
been manipulated to perform targeted genome editing in mammalian cells; using a 
specific 20 bp single-guide RNA (gRNA), complexed mutant Cas9 is guided to the 
target region, which is followed by a 5’-NGG protospacer adjacent motif (PAM). Mutant 
Cas9 produces a single strand DNA break upstream of the PAM, which lends itself to 
repair via homologous recombination (Yang et al, 2014). This method has since been 
used to introduce CAG repeats into HEK-293 cells and HD-iPSCs (An et al, 2014), and 
more recently CRISPR/Cas9 has also been used to create an isogenic HTT allelic 
series in human ESCs (Ruzo et al, 2018).  
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The aim of optimisation and characterisation of a neural stem cell HTT exon 1 
overexpression model of HD was achieved. An allelic series containing HTT exon 1 
with 29Q, 71Q and 129Q repeats with relatively matched expression levels has been 
generated in ReNcellVM NSCs. The panel can be differentiated into B3-tubulin positive 
cells, and the pathogenic lines develop HTT inclusion bodies, a pathognomic hallmark 
of HD. HD is a disease of adult onset, and so one consideration when designing cell 
models is the timescale over which mutant phenotypes would develop. HTT exon 1 
animal models such as the R6/2 mouse rapidly develop an aggressive phenotype 
which is amenable to study (Mangiarini et al, 1996). Similarly, HTT exon 1 cell models 
of rat striatal progenitors (Colby et al, 2006) and human neuroblastoma (Ho et al, 2001) 
show early aggregate formation. Human HD-iPSC derived neuronal models do not 
show spontaneous aggregate formation (Consortium, 2012), however neurons derived 
from human embryonic stem cells (hESCs) expressing the mHTT exon 1 transgene 
(Q73 and Q145) display EM48 positive aggregates after several months (Lu & 
Palacino, 2013).  
 
Multiple lines of evidence highlight the importance of HTT exon 1 in the pathogenesis 
of HD. Post-mortem studies of human brain tissue demonstrate that nuclear and 
cytosolic inclusions are composed primarily of N-terminal fragments (DiFiglia et al, 
1997). The smallest N-terminal fragment detected by western blotting using a panel of 
HTT antibodies in a full length mouse model of HD was exactly equivalent to an exon 1 
product (Landles et al, 2010). A mechanism for generation of mutant HTT exon 1 has 
been demonstrated in mouse models expressing full length mutant Htt (mouse) and 
HTT (human), and also in patient derived fibroblasts and post-mortem human brain 
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tissue (Neueder et al, 2017); abnormal splicing in the presence of an expanded CAG 
repeat allows read through into intron 1 which contains a stop codon at its start, 
producing a mutant exon 1 fragment on translation (Sathasivam et al, 2013). A study in 
transgenic Drosophila engineered to express one of seven naturally occurring N-
terminal HTT fragments against a constant genetic background, revealed that the exon 
1 peptide is particularly toxic in terms of survival and degeneration of photoreceptor 
neurons (Barbaro et al, 2015). This HTT exon 1 overexpressing ReNcellVM model is 
therefore a useful tool to study pathogenic mechanisms in HD, particularly in a high-
throughput format.  
 
The generation of disease relevant cell models has been revolutionised since the 
discovery by Yamanaka and colleagues (Takahashi et al, 2007) that human fibroblasts 
can be re-programmed into self-renewing pluripotent stem cells through the expression 
of 4 key factors (Oct3/4, Sox2, Klf4, and c-Myc). iPSCs derived from patients are the 
most genetically precise disease model, and as such, provide an exciting platform from 
which to discover or validate disease mechanisms and test therapeutics. There are 
now many methods to generate iPSCs. Retroviral vectors encoding reprogramming 
genes require integration into the host genome for expression; DNA based vectors 
such as plasmid vectors, adenovirus and AAV remain as episomes and do not require 
integration, however they do sometimes still incorporate into host chromosomes and 
can potentially disrupt other important genes. iPSCs from this HD family were 
generated using a modified, non-transmissable form of Sendai virus (SeV), which are 
always non-integrating and remain in the cytoplasm (Fusaki et al, 2009).  
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HD-iPSCs have been generated (Park et al, 2008) that show no apparent differences 
from wild-type cells, but on neuronal differentiation, differences in protein expression, 
differentiation efficiency and neurite length (Chae et al, 2012), as well as in lysosomal 
function (Camnasio et al, 2012) can be observed. Even at early stages of 
differentiation, increased caspase 3/7 activity is seen, suggesting that mHTT containing 
cells are more susceptible to stress (Zhang et al, 2010). Restoration of the CAG repeat 
to wild type length was shown by the Ellerby group to prevent cell death, increase 
BDNF transcription, recue mitochondrial dysfunction and normalise elevated caspase 
3/7 activity in HD-iPSC lines (An et al, 2012). Recently, HD-iPSC lines have been 
shown to display neurodevelopmental abnormalities on differentiation, from the 
acquisition of neuroectodermal fate (early) to striatal and cortical identity (late) (Conforti 
et al, 2018).  
 
In general terms research using iPSC cells has, been limited by the genetic 
heterogeneity between patient derived cell lines, which makes direct comparisons 
between lines of different CAG repeat lengths difficult. The impact of donor cell type, 
age of donor and method of iPSC reprogramming can also all have an effect on iPSC 
behaviour (Cahan & Daley, 2013). It is hoped that by generating iPSC lines using 
fibroblasts from the same genetically related family by means of the same 
reprogramming method will, this background noise will be diminished. Another 
limitation has been the development of robust neuronal differentiation protocols (Hu et 
al, 2010). However, recently Professor Meng Li’s group has shown yields of around 20-
50% MSNs on differentiation of ESCs and iPSCs and the neurons have been shown to 
have electrophysiological activity (Arber et al, 2015). One remaining issue is the degree 
to which iPSC clones (derived from the same donor) vary from each other, and the 
number of clones required for experimental validity. Subtle inter-clone variations have 
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been observed in the HD-family iPSC lines in terms of speed of cell proliferation and 
ease of neuronal differentiation. This may be due to differences that arise during the 
reprogramming process and may relate to persistence of epigenetic modifications on 
iPSC derivation.  
 
 
3.7 Summary 
 
Two HD cell models have been generated and validated and form the basis for the 
work described in this thesis. The first is a neural stem cell (ReNcellVM) HTT exon 1 
allelic series with relatively matched expression levels of 29Q, 71Q and 129Q (and a 
GFP only control). This will be used to study the impact of HTT exon 1 on neuronal 
phenotypes and the effect of increasing polyglutamine length on the HTT protein itself. 
The second is a panel of iPSCs derived from a genetically related HD family who have 
Juvenile HD, and their mother (as control). These will be differentiated into MSNs in 
order to study differences between the trafficking of wild-type and mutant HTT.  
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4 Effect of increasing HTT exon 1 CAG repeat 
length on neuronal phenotypes 
 
4.1 Background 
 
Following the successful generation of a HTT exon 1 allelic series in the ReNcellVM 
human neural stem cell line as described in chapter 3, this model was taken forwards 
for further experiments to determine the effect of increasing HTT exon 1 CAG repeat 
length on neuronal viability and response to cell stress. HTT CAG repeat length 
determines HD disease status, age of onset and the rate of disease progression; 
therefore determining CAG repeat length dependent neuronal phenotypes is key to 
understanding how this factor impacts on HD pathogenesis.  
 
HTT exon 1 and other N-terminal fragments have been shown to exert toxicity in a 
variety of cellular model systems, as shown in table 4.1. Pathological effects of mHTT 
exon 1 expression can sometimes be observed within 24 hours and in most cases by a 
few days. Increased cell death has been recorded both at baseline and in response to 
toxin exposure. Many such models are however in non-human and/or non-neuronal 
cells, and therefore may not reflect the disease state. The effect of an allelic series HTT 
exon 1 (29Q, 71Q and 129Q) overexpression on neuronal differentiation and cell 
viability in the human ReNcellVM NSC line was therefore studied.  
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Model Construct Toxicity 
HEK-293 
 
N2a mouse 
neuroblastoma 
N63 and N171 
each with 18Q or 
82Q 
48 hrs post transfection, increased 
vulnerability to treatment with STS 
500 nM for 4hrs in both 82Q lines, 
as determined by PI staining. 
More prominent in shorter 
fragment (Cooper et al, 1998). 
HEK-293 Transient 
transfection with 
N-terminal 
fragments of 
various lengths, 
each with 15Q or 
128Q  
Increased cell death (MTT assay) 
in 128Q lines, particularly in 
shorter fragments, following 
treatment with Tamoxifen 35 µM 
(Hackam et al, 1998). 
SK-N-SH human 
neuroblastoma  
 
COS-7 monkey 
kidney 
HTT exon 1 with 
21Q and 71Q 
Higher cell death as determined 
by nuclear fragmentation in 71Q 
than 21Q (Ho et al, 2001). 
PC12 rat 
phaeochromocytoma  
Inducible N63 with 
23Q or 148Q 
On differentiation 148Q line had 
50% cell death at 6 days 
compared to no rise above 
baseline cell death with 23Q 
(trypan blue exclusion assay) 
(Igarashi et al, 2003). 
Rat embryo derived 
striatal neurons 
Inducible N548 
26Q and 165Q 
Decreased viability (MTS assay) in 
165Q line compared to 26Q on 24 
hours exposure to MG132 (0-
200UM), 3NP and QA (Seo et al, 
2007). 
N2a mouse 
neuroblastoma  
N-terminal with 
20Q and 150Q. 
Increased PI staining, decreased 
neurite outgrowth. 
Increased activated caspase 3 on 
WB at baseline and in response to 
Camptothecin (Ye et al, 2008). 
Rat striatal neurons Htt exon 1 with 
17Q, 47Q, 72Q, 
97Q and GFP. 
PolyQ dependent nuclear 
fragmentation, neurite dystrophy 
and cell death (assessed by loss 
of reporter fluorescent protein) 
(Miller et al, 2010). 
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Model Construct Toxicity 
HC2S2 rat 
neuroprogenitor line 
(4 day differentiation 
protocol) 
eGFP tagged htt 
exon 1 with 28Q 
or 74Q 
Increased nuclear 
fragmentation/shrinking in 74Q 
line after 6 days, increasing up to 
10 days. 
Increased neuritic degeneration in 
74Q line after 4 days. 
Increased neuronal sensitivity to 
H2O2 at all doses 50-200 µM 
(nuclear morphology assay) (Dong 
et al, 2011). 
hESC-derived 
neurons (2 month 
differentiation 
protocol) 
HTT exon 1 23Q, 
73Q and 145Q 
(15-20 fold 
overexpression) 
CAG-dependent cell death under 
“basal” medium conditions seen 
within 24 hrs, increased over 5 
days. Live/dead imaging assays 
(Lu & Palacino, 2013). 
PC12 rat 
phaeochromocytoma 
line 
eGFP tagged HTT 
exon 1 with 25Q 
or 97Q 
For 97Q line only: 
Inclusion formation within 24 hrs 
Increased cell death (LDH assay) 
after 24 hrs 
Nuclear DNA damage within 6 hrs  
Caspase 3 activation by 24 hrs 
Decreased oxygen consumption 
rate by 24 hrs 
(Sahoo et al, 2016) 
 
Table 4.1: HTT exon 1 and N-terminal fragment models of Huntington’s disease 
with summary of the resultant cytotoxicity findings. 
 
The presence of mHTT is known to cause increased sensitivity to a variety of cell 
stressors. Redox homeostasis is required for normal neuronal functioning, and 
oxidative stress is said to occur when oxidants overwhelm the antioxidant capacity of 
the cell. Oxidative stress in known to cause DNA damage and transcriptional 
dysregulation, and has been implicated as a primary event in HD pathogenesis (Kumar 
& Ratan, 2016). Striatum and cortex from HD brains at post-mortem have shown 
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increased levels of oxidative damage (Browne et al, 1999). Higher levels of oxidative 
biomarkers in the blood of HD patients compared to healthy controls have also been 
found (Chen et al, 2007). However it is not clear if these findings are caused by mHTT 
directly or are a manifestation of dying neurons or decreased turnover of oxidative 
biomarkers. Hydrogen peroxide (H2O2) can be used to generate oxidative stress when 
applied to cells in culture, and has been shown to induce increased levels of DNA 
damage in HD compared to control-iPSC-derived neurons (Chiu et al, 2015). The 
ability of H2O2 to induce cell death in the HTT exon 1 allelic series was therefore 
investigated. 
 
Excitotoxicity is caused by excessive excitatory glutamatergic signalling and leads to 
disruption of intracellular calcium levels, mitochondrial energy failure and cell death. In 
HD, alterations in glutamatergic signalling occur through changes in glutamate release 
(Joshi et al, 2009), over activity of glutamate receptors (Benn et al, 2007), decreased 
levels of glutamate transporters and therefore reduced glutamate uptake (Huang et al, 
2010). The resulting rise in extracellular glutamate then leads to increased signalling 
through glutamate receptors including AMPA and NMDA-R. The injection of the NMDA-
R agonist quinolinic acid (QA) into rodent striatum has long been known to result in an 
HD-like phenotype (Beal et al, 1986). Hence the response of the HTT exon 1 lines to 
the application of glutamic acid was studied, expecting that the pathogenic lines would 
be more vulnerable to excitotoxic cell death. 
 
Protein homeostasis is important for neuronal survival and involves the timely 
clearance of damaged or misfolded proteins from the cytoplasm. Disruption of this 
process occurs in HD, as evidenced by the accumulation of mHTT aggregates and 
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ubiquitinylated proteins in HD mouse models and patient brains. Mammalian 
proteasomes have been shown to completely digest mHTT exon 1 (Juenemann et al, 
2013),  and autophagy is also involved in  the degradation of expanded polyQ peptides 
(Tsvetkov et al, 2013).  Conversely, both the UPS and autophagy are thought to be 
adversely affected by the presence of mHTT (Seo et al, 2004; Wong & Holzbaur, 
2014). The effect of both proteasomal and autophagy inhibitors might therefore be 
expected to enhance toxicity in the HTT exon 1 cell lines, and this was tested as 
described below.  
 
 
4.2 Aims 
 
To establish the effect of HTT exon 1 with increasing CAG repeat lengths on: 
1. Neuronal differentiation and culture composition. 
2. Neuronal viability. 
3. The response of neurons to pathological stressors (oxidative stress, excitotoxic 
stress and disruption of protein homeostasis using UPS and autophagy inhibitors). 
 
 
 
4.3 Methods 
 
HTT exon 1 ReNcellVM NSCs were cultured and differentiated as described in section 
2.1.1 and 2.1.3. To determine the effect of HTT exon 1 on neuronal differentiation cells 
were grown in a 96 well plate format for 2 weeks, and then fixed and stained using 
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antibodies to cell markers (section 2.7.1). High content imaging on the Opera Phenix 
was then carried out (section 2.7.2) with image analysis using the Columbus software 
(section 2.7.2.1). Subsequently graphs were produced and statistical analysis carried 
out using Prism software (section 2.10). 
 
For the assessment of cell viability, biochemical assays (LDH, MTT and Alamar Blue) 
were performed as described in sections 2.8.1, 2.8.2 and 2.8.3 respectively. Imaging 
markers of cytotoxicity were also investigated; propidium iodide, mitotracker red and 
anti-activated caspase 3 antibody were all tested as described in section 2.8.4. The 
response of HTT exon 1 cells to various pathological stressors (H2O2, glutamate, 
MG132, lactacystin, epoxomicin and bafilomycin) was then tested; all toxins were 
purchased from Sigma and reconstituted when needed as per instructions. Viability 
was then assessed using the LDH assay as previously described.   
 
 
 
4.4 Contributions 
 
The work described in this chapter was carried out by Dr. Rhia Ghosh. 
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4.5 Results 
 
4.5.1 Effect of HTT exon 1 overexpression on neuronal differentiation in 
the ReNcellVM line 
 
High content imaging using the Opera Phenix followed by image analysis using 
Columbus software was carried out at day 14 of differentiation to assess the effect of 
CAG repeat length on neuronal differentiation and nuclear metrics. For each stain, 
eight wells were imaged per line, each with eighteen fields of view. The image analysis 
software comprises a modular “building-block” system, and an appropriate analysis 
pipeline can be constructed by the user depending on the pattern of staining to be 
analysed. In the case of cell markers for B3-tubulin, GFAP and nestin, a “mask” was 
generated based on cell segmentation of neurons, and cells were deemed to be 
positive for a marker if intensity of staining reached a certain threshold. The software 
then applied this threshold across all images to generate the number of positive cells 
per well. Total cell number per well was generated using a simple automated nuclear 
count, and a percentage of positive cells was calculated. Therefore results of eighteen 
fields of view were averaged to give the overall result per well, and each well is a 
technical replicate. 
 
96-97% of cells expressed the neuronal marker B3-tubulin, with the exception of the 
129Q line which had a slightly lower proportion at 94% (figure 4.1). This may indicate 
that the most highly pathogenic HTT exon 1 fragment is having an adverse effect on 
neuronal differentiation.  
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Figure 4.1: B3-tubulin staining is slightly lower in the ReNcellVM HTT exon 1 
129Q line. Full ReNcellVM HTT exon 1 panel at dd14 stained with B3-tubulin antibody 
shows all lines differentiate into a high proportion of B3-tubulin cells with neuronal 
morphology. However the 129Q line has slightly lower percentage of cells that express 
B3-tubulin – 94%, whereas this is 96-97% across the other lines. (One-way ANOVA 
with Bonferroni’s correction, n=8 (technical replicates)).  
Images: Red – B3-tubulin, Blue – Hoescht (nuclei).  
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Figure 4.2: GFAP staining uniform across the ReNcellVM HTT exon 1 panel. Full 
ReNcellVM HTT exon 1 panel at dd14 stained with GFAP (red) shows all lines express 
GFAP (97% of cells are GFAP positive), and there are no differences between the 
lines. (One-way ANOVA with Bonferroni’s correction, n=8 (technical replicates)).  
Images: Red – GFAP, Blue – Hoescht (nuclei).  
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Figure 4.3: Nestin staining across the ReNcellVM HTT exon 1 panel at dd14 shows 
that 92-96% of cells express nestin. Differences between lines are not thought to be 
biologically significant.  (One-way ANOVA with Bonferroni’s correction, n=8 (technical 
replicates).  
Images: Red – Nestin, Blue – Hoescht (nuclei). 
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GFAP expression was similar at 97% across all lines (figure 4.2), and persistent nestin 
staining was seen in 92-96% of all cells (variation between lines was not thought to be 
biologically significant) (figure 4.3).  
 
As discussed in detail in section 3.5.3.3, the staining pattern of B3-tubulin, GFAP and 
nestin share a high degree of overlap, indicating that these neurons are highly 
immature, or that neuron/astrocyte hybrid cells have been formed. An alternative 
possibility is that the pattern of GFAP staining observed is artefact; to assess this 
further a negative control cell line known to have no GFAP expression would have 
been useful, to stain alongside the HTT exon 1 ReNellVM cells (the secondary only 
control was the same as for B3-tubulin (figure 4.1), with the same solution of secondary 
antibodies being used).   
 
Nuclear metrics including nuclear size (area), intensity and roundness were also 
analysed from all three previous experiments, based on the Hoescht staining of the 
nuclei (figure 4.4). There were no significant differences between the lines, although 
the 129Q line did show a trend towards increased size. This may be due to intranuclear 
inclusion body formation occurring in a greater number of cells in this line (see chapter 
5), leading to a small increase in mean average nuclear size. 
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Figure 4.4: Analysis of nuclear metrics across the ReNcellVM HTT exon 1 panel 
at dd14 shows no significant differences between the lines in terms of nuclear area, 
intensity or roundness. A trend towards increased nuclear size in the 129Q line is 
observed, but this falls short of statistical significance. (One-way ANOVA with 
Bonferroni’s correction, n=24 (technical replicates) 
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4.5.1.1 Problems with long term cell culture of the ReNcellVM HTT exon 1 lines 
 
One issue that was noted on differentiation of the HTT exon 1 cell lines (including 
control and pathogenic lines) was the appearance of gaps in the cell monolayer that 
increased over time. This led to a “honeycombed” appearance of the cell cultures, 
which would render them unsuitable for high content imaging. It was hypothesised that 
this may be due to cells no longer adhering to the laminin coating after a certain period 
of time. Therefore, the cells were reseeded after seven days of growth onto freshly 
coated plates. However many cells did not continue differentiating normally once 
reseeded. Matrigel and Geltrex were used in lieu of laminin to coat the plasticware, but 
this also did not make any difference. 
 
The density at which the cells were seeded was also considered to be playing a role. 
Therefore, cells were seeded at a density of 1000, 5000, 10,000 and 25,000 per well of 
a 96-well plate, and appearance compared after two weeks. From this it was 
determined that a seeding density of 10,000 cells per well reduced the frequency with 
which “honeycombing” occurred, compared to higher seeding densities. Seeding 
densities of less than 10,000 per well produced overly sparse cultures that were 
unsuitable for imaging.  Gentle media changes exchanging half the media volume also 
helped.  
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4.5.2 Effect of HTT exon 1 overexpression on cell viability in the  
ReNcellVM line 
 
From routine observations on cell culture, there was no overt cell death visible in these 
lines, including in the 129Q line and the highly expressing 71Q line. Cells were 
confirmed to be expressing exon 1 by checking for GFP expression using the 
microscope green light filter. A variety of biochemical methods were then used to 
ascertain any subtle differences in cell viability between the lines.  
 
4.5.2.1 Lactate dehydrogenase (LDH) assay in HTT exon 1 overexpressing 
ReNcellVM lines 
 
Lactate dehydrogenase (LDH) is a stable cytosolic enzyme that is released upon cell 
lysis into the surrounding medium, and has a half-life of 9 hours. Released LDH in 
culture supernatants is measured with a 30-minute coupled enzymatic assay, which 
results in the conversion of a tetrazolium salt (iodonitrotetrazolium violet (INT)) into a 
red formazan product. The amount of colour formed is proportional to the number of 
lysed cells, and wavelength absorbance data collected using a standard 96-well plate 
reader. 6x96 well plates were seeded with the HTT exon 1 cell panel (GFP only, 29Q, 
71Q, 129Q and 71Q high expressor (71Q-H)) as well as wild type ReNcellVM NSCs, at 
a density of 25,000 cells per well, with differentiation commenced after 24 hours. One 
plate was used for LDH assay at day 0, 7, 14, 28 and 42 of differentiation and the 
remaining plate was tested following a delayed media change at day 42. 8 wells were 
tested per condition, which are technical replicates.  
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Due to the random and variable “honeycombing” effect mentioned in section 4.5.1.1, 
there was potentially a variation in cell numbers between wells (despite initially seeding 
NSCs at the same density). Variable cell numbers would affect the results of the LDH 
assay, as wells containing greater numbers of cells would release more LDH for the 
same percentage cell death. To account for this variability, following the removal of 50 
µl of media/supernatant for LDH assay, 16.7 µl of 10% TritonX was added to the 
remaining media in each well for 1hour at 37 degrees, in order to cause complete lysis 
of the remaining cells. LDH assay was then also carried out on these wells. Percentage 
cell death could then be calculated for each well, by comparing LDH assay results pre- 
and post- lysis. Results of the LDH time course are shown in figure 4.5. There were no 
significant differences between the lines.  
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Figure 4.5: Time course of LDH assay in HTT exon 1 and wild-type ReNcellVM 
cells up to 6 weeks of differentiation. Plates were analysed at dd0, 7, 14, 21, 28 and 
42 with removal of supernatant for measurement of LDH. This was followed by lysing 
all remaining cells in each well and recording the levels of LDH at 100% cell death. The 
percentage cell death per well was then calculated for each well. There are no 
significant differences in cell death between lines (Two-way ANOVA with Bonferroni’s 
correction, n=8 per timepoint). 
 
 
LDH assay was consistently carried out 24 hours after media changing the cells with 
200 µl of fresh ReNcellVM media. At day 42 of differentiation, a delayed LDH assay 
was also carried out 120 hours after a media change to ensure sufficient accumulation 
of LDH in the supernatant. However this made no difference to the results.  
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4.5.2.2 MTT assay in HTT exon 1 overexpressing ReNcellVM lines 
 
MTT (3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assays were 
carried out on 96 well plates of the HTT exon 1 panel, seeded as described for the LDH 
assay. Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring, 
yielding purple formazan crystals which are insoluble in aqueous solutions. The 
crystals were dissolved in DMSO and the absorbance of the resulting purple solution 
was spectrophotometrically measured at a wavelength of 570 nm, with background 
absorbance at 690 nm subtracted. Results of MTT assay carried out at day 0, 7, 14 
and 28 of differentiation are shown in figure 4.6, with 8 wells or technical replicates per 
condition; they confirm that there are no consistent differences in cell viability, as 
reflected by mitochondrial activity, between the HTT exon 1 lines. In this assay it was 
not possible to account for variation in cell number caused by the “honeycomb” effect 
described previously – this may account for the greater variability seen in the results. 
 
Chapter 4 
 
180 
 
MTT timecourse
Day of differentiation
Ab
s
 5
70
-6
90
nm
0 7 14 28
0.0
0.5
1.0
1.5
2.0
2.5
WT
GFP
29Q
71Q
129Q
71Q-H
 
Figure 4.6: MTT assay in HTT exon 1 and wild-type ReNcellVM up to 4 weeks of 
differentiation. Cells were tested at dd0, 7, 14 and 28, but no consistent pattern of 
differences between cell lines was found. (n=8 per timepoint). 
 
 
4.5.2.3 Alamar Blue assay in HTT exon 1 overexpressing ReNcellVM lines 
 
The Alamar blue assay measures the reducing conditions within cells, as an indicator 
of cell viability. The active ingredient is resazurin, a non-toxic, cell permeable 
compound that is blue in color and virtually non-fluorescent. Upon entering cells, 
resazurin is reduced to resorufin, a compound that is red in color and highly 
fluorescent. Viable cells continuously convert resazurin to resorufin, increasing the 
overall fluorescence and color of the surrounding media. Absorbance was measured 
on a spectrophotometer at 570 nm, using 600 nm as a reference wavelength.  
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The assay was carried out on wild-type ReNcellVM, 29Q and the high expressing 71Q 
lines at day 14 of differentiation. The percentage of reduction in the HTT exon 1 lines 
were calculated relative to the wild-type cells as described. No significant differences 
were found in either the 29Q or the 71Q-H line, as compared to control (figure 4.7). 
 
 
Figure 4.7: Alamar blue assay in HTT exon 1 and wild-type ReNcellVM cells at 2 
weeks of differentiation. Percentage reduction of Alamar blue by dd14 29Q and 71Q-
H HTT exon 1 ReNcellVM cells compared to wild-type dd14 ReNcellVM cells is shown. 
One-way ANOVA confirms no significant differences between control and either 29Q or 
71Q-H lines (n=16 per condition, technical replicates).  
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4.5.2.4 Imaging markers of cytotoxicity in HTT exon 1 overexpressing 
ReNcellVM lines 
 
In order to complement the above biochemical methods, an imaging method to 
ascertain cytotoxicity was sought. This was complicated by the expression of GFP in 
the HTT exon 1 lines, which therefore precluded the use of any green fluorescent 
cytotoxicity markers designed for the detection in the 488 channel.  
 
Propidium iodide (PI) is a commonly used dye used to visualise dead cells. In late 
apoptotic and necrotic cells, the integrity of the plasma and nuclear membranes 
decreases, allowing PI to pass through the membranes, intercalate into nucleic acids 
and display red fluorescence. However when applied to GFP only cells that had been 
treated with 1 µM staurosporine (STS) to induce apoptosis, it did not stain the cells 
(figure 4.8). As can be seen, Hoescht staining did confirm the presence of pyknotic 
nuclei and apoptotic bodies, therefore P.I. staining was unsuccessful.  
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Figure 4.8: Propidium iodide (P.I.) staining in dd14 GFP only ReNcellVM cells 
treated with 1 µM STS was not successful.  
Blue- Hoescht, Red – P.I., Green - GFP.  
 
Mitotracker Red dye was also tested. This dye successfully stained mitochondria in the 
cells. Addition of 100 nM staurosporine changed the pattern of staining observed, with 
mitochondria adopting a more rounded and less tubular appearance, but there were no 
overt differences between control and pathogenic lines (figure 4.9). The pattern of 
staining observed did not to lend itself to automated image processing on Columbus 
and so alternative imaging markers of cytotoxicity were sought. 
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Figure 4.9: Example of staining with Mitotracker Red dye in dd14 control (wild-type) 
ReNcellVM cells +/- staurosporine (STS), and HTT exon 1 29Q and 71Q-H ReNcellVM  
lines. Mitochondria adopt a more rounded and less tubular appearance in response to 
STS treatment, but there are no overt differences seen between wild-type, 29Q and 
71Q-H lines.  
Red – mitotracker Red dye, Blue – Hoescht (nuclei).  
 
 
The antibody to activated caspase-3 was also tested (using a secondary antibody that 
fluoresced at 568 nm), as a marker of early apoptosis, with results as shown in figure 
4.10. It can be seen that a bright signal is obtained for apoptotic cells (which have 
apoptotic bodies clearly visible with Hoescht staining).  
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Figure 4.10: Anti-activated caspase 3 staining in dd14 GFP only ReNcellVM cells 
with STS treatment and control. On treatment with STS, some nuclei undergo 
apoptosis, as can be seen by the formation of apoptotic bodies visible with Hoescht 
staining. Apoptotic cells also are brightly staining with the anti-activated caspase 3 
antibody, confirming the utility of this antibody as an imaging marker for early toxicity in 
high content imaging studies.  
Red: anti-activated caspase 3, Green- GFP, Blue – Hoescht (nuclei).  
 
 
This antibody was therefore used as an imaging marker for early toxicity in high content 
imaging studies, to look for differences across the HTT exon 1 lines at baseline after 14 
days of differentiation. The overall intensity of anti-activated caspase 3 staining per well 
was divided by the total nuclear count (to account for the variability in cell number 
between wells). This showed small but significantly higher levels of anti-activated 
caspase 3 staining in the 71Q-H line compared to the control GFP line, however there 
was no difference between this and the other lines in the matched panel (figure 4.11).  
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Figure 4.11: Intensity of anti-activated caspase 3 staining in ReNcellVM HTT exon 
1 lines analysed by high content imaging at dd14 shows significantly higher 
activated caspase 3 staining in the 71Q-H line compared to the control GFP line (One-
way ANOVA with Bonferroni’s correction, **=P≤0.01, n=8 per condition, technical 
replicates). 
 
 
 
4.5.2.5 Effect of HTT exon 1 overexpression on the response of ReNcellVM 
neurons to acute cell stress 
 
The impact of HTT exon 1 expression on vulnerability to acute cell stress for 24 hours 
was then investigated, using a variety of cell stressors. 29Q and 71Q-H cells were 
seeded at 20,000 cells/well and differentiated for two weeks in 96 well plates and then 
treated with various cell stressors at a range of doses. LDH assay was then carried out 
after 24 hours, with percentage cell death calculated compared to a positive control of 
10% Triton-X which lysed all cells. For each cell line, six wells (technical replicates) 
were tested per dose.   
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4.5.2.6 Hydrogen peroxide (H2O2) application in HTT exon 1 overexpressing 
ReNcellVM cells 
 
Oxidative stress has previously been implicated in HD pathogenesis. Previous studies 
have shown that a dose of 300 µM is sufficient to cause toxicity in HD-iPSCs 
(Consortium, 2012), and 100 µM in SH-SY5Y cells (Nirmaladevi et al, 2014). Therefore 
the following doses were tested 0, 10, 50, 100, 200, 500 and 1000 µM, with results as 
shown in figure 4.12. The cells displayed sensitivity to H2O2 in a dose range as 
expected, but there were no differences between the 71Q-H and 29Q control line over 
the dynamic range.  
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Figure 4.12: Hydrogen peroxide dose response curve in dd14 HTT exon 1 29Q 
and 71Q-H ReNcellVM cells. LDH assay was used to calculate cell death as a 
percentage of total cell lysis induced in positive control wells by 10% Triton-X. No 
significant differences are seen between the two lines in response to hydrogen 
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peroxide from 0-500 µM – cell death at 1000 µM is above 100% and therefore spurious 
(Two way ANOVA with Bonferroni’s correction, n=6 per dose). 
 
 
4.5.2.7 Glutamate application in HTT exon 1 overexpressing ReNcellVM cells 
 
Excitotoxicity has been implicated as a pathogenic mechanism in HD. Therefore the 
effect of glutamate on the HTT exon 1 cells was tested. A literature search revealed 
that doses of 30 µM or 125 µM had an effect on neuronal cells and so a range from 0-
1000 µM was tested. Initial attempts were not successful as the hydrochloric acid used 
to reconstitute the L-glutamic acid inactivated the LDH assay. Therefore after 24 hours 
of exposure to glutamate, full media change was carried out and the LDH assay 
performed after a further 24 hours. It was expected that this would still exert a 
measureable effect on the cells, as previous published protocols have replaced 
neurons in regular media after glutamate exposure for 24 hours prior to performing the 
cytotoxicity assay. The results are shown in figure 4.13.  
 
This flat response to very high doses of glutamate was not expected. Subsequent 
Western blotting for VGlut1 transporter and GluR2 (an AMPA subunit) receptors 
revealed that the HTT exon 1 lines were not expressing these glutamate receptors by 
day 14 of differentiation. Therefore these particular cells are not vulnerable to the 
effects of glutamate induced excitotoxicity; this may be due to the immaturity of the 
neuronal culture at day 14.  
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Figure 4.13: Glutamate dose response curve in dd14 HTT exon 1 29Q and 71Q-H 
ReNcellVM cells shows no response in either cell line to the application of even high 
doses of glutamate. LDH assay was used to calculate cell death as a percentage of 
total cell lysis induced in positive control wells by 10% Triton-X. (n=6 per dose). 
 
 
4.5.2.8 MG132 application in HTT exon 1 overexpressing ReNcellVM cells 
 
MG132 is a commonly used, reversible proteasomal inhibitor. The UPS is known to be 
affected in HD and so by applying MG132 as a pathological stressor it would be 
expected to find increased cell toxicity in the pathogenic HTT exon 1 lines. Previous 
studies have shown that 24 hours of MG132 exposure at doses ranging from 0-200 µM 
induces cell death in mHTT expressing rat striatal neurons (Seo et al, 2007), and doses 
of 5 µM induce aggregate formation in HD-iPSCs (Jeon et al, 2012). Therefore a dose 
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range of 0-500 µM was tested in the 71Q-H and 29Q lines, with results shown in figure 
4.14. 
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Figure 4.14: MG132 dose response curve in dd14 HTT exon 1 29Q and 71Q-H 
ReNcellVM cells. LDH assay was used to calculate cell death as a percentage of total 
cell lysis induced in positive control wells by 10% Triton-X. No significant differences 
are seen between the two lines in response to MG132 (Two-way ANOVA with 
Bonferroni’s correction). The level of cell death in both lines is much lower than 
expected, even at high doses of MG132 (n=6 per dose). 
 
 
There was no difference in response to MG132 between the control and pathogenic 
lines. The relatively small effect of MG132 on cell death was also surprising. Therefore 
the experiment was repeated using whole plate lysis using 10% Triton X to calculate 
the percentage cell death per well (figure 4.15).  
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Figure 4.15: MG132 dose response curve in dd14 HTT exon 1 29Q and 71Q-H 
ReNcellVM cells calculated using alternative method; LDH assay was carried out 
followed by whole plate lysis with 10% Triton-X and repeat LDH assay, to calculate 
percentage cell death in each well. Significantly higher cell death in the pathogenic 
71Q-H line compared to the control 29Q line is seen at 200 µM MG132 (Two-way 
ANOVA with Bonferroni correction, p<0.05). However this effect is small and overall the 
percentage of cell death is still lower than expected (n=6 per dose). 
 
 
Using this method, there was significantly higher cell death in the pathogenic 71Q-H 
lines compared to the 29Q control at the highest dose of MG132 tested. It should be 
noted however that this effect was slight, and overall the percentage of cell death was 
still lower than expected. In order to ensure that the batch of MG132 used was not at 
fault, the experiment was repeated using pre-reconstituted MG132 that was from 
another company and on cells that had been differentiated for 4 weeks. However as 
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can be seen from figure 4.16, this again showed no difference between control and 
pathogenic lines and confirmed low levels of cell death even at high doses. 
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Figure 4.16: MG132 dose response curve in dd14 HTT exon 1 29Q and 129Q 
ReNcellVM cells. A new batch of pre-reconstituted MG132 was applied at appropriate 
concentrations. LDH assay was used to calculate cell death as a percentage of total 
cell lysis induced in positive control wells by 10% Triton-X. Again, no significant 
differences in cell death are seen between the two lines (Two-way ANOVA with 
Bonferroni’s correction, n=6 per dose) and the level of cell death in both lines remains 
low.  
 
4.5.2.9 Lactacystin application in HTT exon 1 overexpressing ReNcellVM cells 
 
Lactacystin is an irreversible proteasomal inhibitor. Previous studies have shown doses 
between 10-50 µM induce cell death in PC12 cells (Fornai et al, 2003). A dose 
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response curve ranging from 0-200 µM was tested in the 71Q-H and 29Q lines, with 
results shown in figure 4.17. Lactacystin did not induce cell death in the cell lines 
tested, even at high doses. 
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Figure 4.17: Lactacystin dose response curve in dd14 HTT exon 1 29Q and 71Q-H 
ReNcellVM cells. LDH assay was used to calculate cell death as a percentage of total 
cell lysis induced in positive control wells by 10% Triton-X. No significant differences 
are seen between the two lines in response to lactacystin (Two-way ANOVA with 
Bonferroni’s correction, n=6 per dose). Cell death is not induced by lactacystin in either 
the control or mutant lines. 
 
 
Repeat testing of MG132 and lactacystin was carried out on HTT exon 1 29Q, 71Q and 
71Q-H ReNcellVM cells at very high doses, and compared to high dose hydrogen 
Chapter 4 
 
194 
 
peroxide, and no treatment. This confirmed lower than expected cell death in these 
lines in response to proteasomal inhibition, as seen in figure 4.18. 
 
Co
ntr
ol
 50
0 µ
M
2O2H
 10
00
 µM
2O2H
La
c 2
00
 µM
La
c 5
00
 µM
La
c 1
00
0 µ
M
MG
13
2 2
00
UM
MG
13
2 5
00
UM
0
20
40
60
80
100
29Q ReNcellVM
71Q ReNcellVM
71Q-H ReNcellVM
%
 c
el
l d
ea
th
 c
.f.
 T
rit
on
 X
 
Figure 4.18: Cell death induced by high doses of H2O2, lactacystin and MG132 in 
dd14 HTT exon 1 29Q, 71Q and 71Q-H ReNcellVM cells. LDH assay again confirms 
minimal cell death in response to treatment with high doses of proteasomal inhibitors 
lactacystin (Lac) and MG132.  However high doses of H2O2 do induce cell death as 
expected. (n=4 per dose). 
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4.5.2.10 Epoxomicin application in HTT exon 1 overexpressing ReNcellVM    
cells 
 
Epoxomicin is another irreversible proteasomal inhibitor that was tested in the 29Q and 
129Q lines, but with similar lack of effect (figure 4.19). 
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Figure 4.19: Epoxomicin dose response curve in dd14 HTT exon 1 29Q and 129Q 
ReNcellVM cells. LDH assay was used to calculate cell death as a percentage of total 
cell lysis induced in positive control wells by 10% Triton-X. Cell death is not induced by 
epoxomicin either the control or mutant line. (n=6 per dose). 
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4.5.2.11 MVB003 confirms UPS system inhibition in HTT exon 1 
overexpressing ReNcellVM cells 
 
In order to ascertain that proteasomal inhibitors MG132, lactacystin and epoxomicin 
were entering the cells and inhibiting the UPS, the fluorescent probe MVB003 was 
used. This probe binds covalently and irreversibly with the N-terminal active site of the 
catalytic subunits of the proteasome, and emits red fluorescence. HTT exon 1 71Q-H 
ReNcellVM cells were grown on laminin coated glass coverslips for two weeks. 1% 
DMSO, 200 µM MG132, 200 µM lactacystin and 10 µM epoxomicin were added to the 
media for 24 hours. Following treatment, 1 µM of MVB003 was added to each coverslip 
for one hour at 37 degrees. Cells were also stained with Hoescht for 10 minutes, and 
then fixed and imaged. Results are shown in figure 4.20.    
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Figure 4.20: The UPS in dd14 HTT exon 1 71Q-H ReNcellVM cells is inhibited by 
MG132, lactacystin and epoxomicin. Probe MVB003 enters cells treated with only 
DMSO control and emits red fluorescence, confirming activation of the UPS. This red 
signal is absent in cells treated with MG132, lactacystin and epoxomicin, confirming 
that proteasomal inhibition has occurred.  
 
 
This confirms that the UPS is active in the 71Q-H cells, and is inhibited by MG132, 
lactacystin and epoxomicin; however, as seen from the results of the LDH assays, this 
inhibition does not lead to high levels of cell death.  
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4.5.2.12 Bafilomycin application in HTT exon 1 overexpressing ReNcellVM 
cells 
 
Bafilomycin is a widely used as an inhibitor of autophagy. Bafilomycin A1 inhibits 
lysosomal hydrolase activity required for lysosomal acidification, which is important for 
the final autophagosome-lysosome fusion event. This is known to occur at 
concentrations of 400 nM  (Sarkar et al, 2009), and therefore a range of doses were 
tested to include this (figure 4.21).  
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Figure 4.21: Bafilomycin dose response curve in dd14 HTT exon 1 29Q and 129Q 
ReNcellVM cells shows no cell death in response to treatment with high doses of 
bafilomycin, as assessed by LDH assay. (n=6 per dose). 
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Again, no increase in cell death is seen in response to bafilomycin, even at very high 
doses. This experiment was repeated with the addition of 200 µM of MG132 to the 
media in addition to increasing doses of bafilomycin, with results as shown in figure 
4.22.  
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Figure 4.22: Treatment of dd14 HTT exon 1 29Q and 129Q ReNcellVM cells with 
200 µM MG132 and increasing doses of bafilomycin. Cell death was determined by 
LDH assay. There was no significant effect of increasing bafilomycin dose in either cell 
line. There was a small but significant increase in cell death overall in the pathogenic 
129Q line compared to the control 29Q line (two-way ANOVA with Bonferroni 
correction, p<0.0001). (n=6 per dose). 
 
 
The effect of increasing bafilomycin dose was not significant in this experiment; 
however there was a significant difference between control (29Q) and pathogenic 
(129Q) lines, with slightly greater cell death observed in the pathogenic line. This may 
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indicate that cells expressing mHTT are more affected by high dose proteasomal 
inhibition. However in general terms, blocking both UPS and autophagy simultaneously 
for 24 hours still had minimal effect on cell viability; this would imply that our cells are 
able to tolerate severe disruption of protein homeostasis for up to 24 hours.  
 
Immunocytochemistry on the 29Q and 129Q line confirms that both bafilomycin and 
MG132 are entering the cells and affecting the distribution of proteins, including GFP 
(figure 4.23), and HTT as detected by the N-terminal anti-HTT antibody aa1-82 (figure 
4.24). This effect is particularly prominent in the 129Q line, and is discussed in more 
detail in chapter 5 (section 5.5.4). 
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Figure 4.23: GFP distribution in dd14 HTT exon 1 29Q and 129Q ReNcellVM cells 
following 24 hours of treatment with Bafilomycin and MG132. Inhibition of both 
autophagy and MG132 changes the distribution of GFP in both cell lines, and this is 
particularly prominent in the 129Q cells.  
Blue – Hoescht, Green – GFP 
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Figure 4.24: HTT distribution in dd14 HTT exon 1 29Q and 129Q ReNcellVM cells 
following 24 hours of treatment with Bafilomycin and MG132. Inhibition of both 
autophagy and MG132 changes the distribution of HTT in both cell lines and again, this 
is particularly prominent in the 129Q cells.  
Blue – Hoescht, White – HTT. 
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4.5.3 Effect of HTT exon 1 overexpression on the response of ReNcellVM 
neurons to chronic cell stress 
 
In order to allow more time for cytotoxicity to develop and for any potential 
compensatory mechanisms to fail, the response of 29Q and 129Q cells to five days of 
pathological stress was tested. Moderate and high doses of hydrogen peroxide (H2O2), 
MG132, epoxomicin and bafilomycin were used (epoxomicin has a favourable cost 
compared to lactacystin, and both are irreversible proteasomal inhibitors). Results are 
shown in figure 4.25. 
 
As expected, hydrogen peroxide continues to cause cell death in both lines at the high 
dose of 300 µM, but not at the lower dose of 30 µM. MG132 and epoxomicin both 
cause total or near total cell death at higher and lower doses, indicating that the cells 
are not able to tolerate UPS inhibition for longer periods of time. There was still minimal 
response to autophagy inhibition with bafilomycin. 
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Figure 4.25: Effect of chronic cell stress on dd14 HTT exon 1 29Q and 129Q 
ReNcellVM cells. Percentage cell death was determined by LDH assay after five days 
of treatment with toxins as shown. Chronic application of H2O2 causes cell death in 
both lines at the high dose of 300 µM, but not at the lower dose of 30 µM. Proteasomal 
inhibition with MG132 and epoxomicin did cause high levels of cell death after five 
days, but there remains minimal response to bafilomycin. Two-way ANOVA shows no 
significant differences between 29Q and 129Q lines under any of the conditions tested, 
with the exception of H2O2 at 300 µM, however this was felt to be a spurious result as 
previous experiments had not found any differences in the response to H2O2 between 
control and mutant lines. (n=6 wells per condition tested) (Epox=epoxomicin, 
Baf=bafilomycin). 
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To determine whether there was any evolution of CAG length-dependent differences in 
response to the proteasomal inhibitors between day 1 and day 5, a time-course of cell 
death was carried out. The above experiment was repeated with LDH assay performed 
at day 1, day 3 and day 5. Results are shown in figure 4.26 and 4.27. In the case of 
MG132 there are no significant differences between 29Q and 129Q lines at either 
dose, at any time point. At day 3 epoxomicin seemed to affect the 29Q control line 
more than the 129Q line at both doses, however on repeating the LDH assay at this 
time point, the finding was not replicated.  
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Figure 4.26: Cell death in HTT exon 1 29Q and 129Q cells treated with low and 
high dose MG132 over five days. Percentage cell death was determined by LDH 
assay after 1, 3 and 5 days of treatment with either 20 µM or 200 µM MG132. There 
are no significant differences between 29Q and 129Q lines at any time-point, at either 
dose (Two-way ANOVA with Bonferroni’s correction, n=6 per dose). 
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Figure 4.27: Cell death in HTT exon 1 29Q and 129Q cells treated with low and 
high dose epoxomicin over five days. Percentage cell death was determined by 
LDH assay after 1, 3 and 5 days of treatment with either 1 µM or 10 µM epoxomicin. 
Unexpectedly, there was significantly higher cell death observed in the control 29Q 
cells compared to the pathogenic 129Q lines at day three, both at low (p<0.001) and 
high doses of treatment (p<0.01) (Two-way ANOVA with Bonferroni’s correction, n=6 
per dose). However on repeating the LDH assay at this time point, the finding was not 
replicated. 
 
 
Therefore, although the cells did display expected levels of cell death in response to 
longer application of proteasomal inhibitors, there were no CAG length-dependent 
effects observed.  
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4.6 Discussion 
 
Overall the expression of mutant HTT exon 1 in the ReNcellVM cells had relatively 
minimal effect on both NSCs and neurons. There was a small but significant decrease 
in B3-tubulin expression in the ReNcellVM 129Q line, along with a trend towards larger 
nuclear size (though this did not reach significance). At baseline there was no 
increased cell death in the pathogenic cell lines, as measured by LDH, MTT, Alamar 
blue assays. Anti-activated caspase 3 imaging was marginally increased in the highly 
expressing ReNcellVM 71Q-H line. Surprisingly, there was a lack of CAG-dependent 
vulnerability to a range of toxins, tested both acutely and chronically.  
 
The general lack of overt cell death or toxicity of mHTT exon 1 in this cell line would 
seem to contrast with the findings of the studies mentioned in table 4.1. However, it 
may be that in human NSCs and neurons (rather than rodent derived cells or non-
neuronal cells), toxic effects take much longer to develop. HD is an exclusively human 
disease and even in severe cases of juvenile HD, it takes many years for symptoms to 
appear and neurodegeneration to occur. Another possible explanation for these results 
relates to the level of mHTT exon 1 overexpression in the lines; this is of particular 
relevance because wild-type huntingtin is known to have a neuroprotective effect in 
cells (Rigamonti et al, 2001). As determined by MSD assay (chapter 3) the matched 
panel of ReNcellVM 29Q, 71Q and 129Q lines have overexpression of HTT exon 1 at 
3-6 fold over endogenous HTT levels (with the 71Q-H line expressing at over 50 times 
endogenous levels). Generally, published papers that use transgenic cell models do 
not mention the level of overexpression in their system, but extremely high levels of 
mHTT exon 1 could be responsible for driving the observed toxicity reported in those 
studies. This is supported by the finding that the only line that displayed even marginal 
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compromise at baseline (as determined by anti-activated caspase 3 staining) was the 
highest expressing ReNcellVM 71Q-H line.  
 
The use of biochemical assays such as LDH, MTT and Alamar blue may lack the 
sensitivity required to pick up subtle differences in viability between the lines. The LDH 
assay detects gross impairments in cell viability, as it requires the plasma membrane to 
be “leaky” before LDH is released into the surrounding medium – this only occurs once 
the cells are dying/dead. The MTT and Alamar blue assays may similarly miss early 
pathogenic changes affecting neuronal viability. It may be that more sensitive 
measures, such as RNAseq or quantitative proteomics, are needed to detect CAG-
repeat length phenotypes in these cells. A recent paper by Kim et al found that 
differentiated Neuro-2a cells expressing Htt exon 1 with 18Q, 64Q or 150+Q had 
aberrant protein interactions (mediated through soluble oligomers) in the pathogenic 
lines despite there being no overt effect on cell viability (as assessed by LDH and MTT 
assays carried out after 48 hours) (Kim et al, 2016). 
 
Generally it was found that these transgenic cell lines lost their adhesion to laminin 
over time – on many occasions this lead to cells detaching as a sheet from the laminin 
coated well, at some point after ten days of differentiation. This would then render the 
plate unsuitable for imaging or biochemical assays, and necessitated repeating the 
experiment. Unfortunately the use of other coating agents (Matrigel, Geltrex) did not 
make any difference. Another experimental issue that caused difficulty was the 
“honeycombing” effect seen in these cells, as described above (section 4.5.1.1). This 
led to well to well variability in cell number across the 96 well-plate, despite the same 
seeding density – this may have led to less accurate readings on biochemical assays 
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of viability. In terms of imaging markers of cytotoxicity, nuclear cell count can be rapidly 
obtained across the plate using Columbus software, so any variability in cell number 
could be objectively measured and accounted for. Indeed the only finding of any mHTT 
exon 1 induced phenotype in unstressed cells was the increased activated-caspase 3 
staining in the 71Q-H line, detected on high content imaging. 
 
Caspase 3 is an effector of apoptosis that is activated by extrinsic (death ligand) and 
intrinsic (mitochondrial) pathways. On activation, it goes on to cleave and activate 
caspase 6 and 7, and also to cleave specific peptide bonds leading to protein 
degradation and cell death. In support of the findings in the ReNcellVM 71Q-H line, 
caspase 3 activation detected on Western blotting of cell lysates has been found to 
occur after 24 hours of mutant but not control length HTT exon 1 expression in PC12 
cells (Sahoo et al, 2016). The activation of caspase 3 is known to be inhibited by wild 
type Htt, and lowering wild-type Htt leads to an increase in caspase 3 activation. The 
interaction of mutant Htt with caspase 3 is however much weaker (Zhang et al, 2006), 
and this may explain the observation in the 71Q-H line.  This study also found that 
lowering endogenous huntingtin (with ensuing caspase 3 activation) led to increased 
cell death in N2a cells, but not in ST14 rat striatal cells (or ESCs and HeLa cells); this 
mirrors the selective cell vulnerability seen in HD. The lowering of wild-type Htt led to 
cell death in ST14 cells only when the cells were subjected to additional stress caused 
by the expression of N-terminal human mHTT. It also interesting that the authors did 
not find any increase in cell death following the expression of N-terminal human mHTT 
in ST14 cells under baseline conditions, as was also found in the pathogenic length 
HTT exon 1 ReNcellVM lines. 
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The absence of CAG-length dependent vulnerability to oxidative stress, proteasomal 
and autophagy inhibition was not expected. As mentioned previously, the lack of 
sensitivity of the LDH assay may have played a role in this, and would certainly miss 
any early DNA damage caused by H2O2 prior to cell death. There was minimal cell 
death in both pathogenic and control lines in response to proteasomal inhibitors 
(MG132, lactacystin, epoxomicin) applied for 24 hours, even at high doses – potentially 
the ReNcellVM line may be able to compensate for UPS inhibition in the short term. 
Chronic inhibition of the UPS over five days did produce high levels of cell death, 
indicating that any compensatory mechanisms may have been overwhelmed on 
prolonged exposure. On two occasions, statistical analysis did reveal slightly higher cell 
death in the pathogenic ReNcellVM line compared to control on treatment with acute 
high dose MG132 (figure  4.15 and 4.22). However this was not consistently found to 
be the case, and certainly on chronic proteasomal inhibition, no difference between 
pathogenic and control lines was found. Autophagy inhibition with bafilomycin did not 
cause cell death in either control or pathogenic line, even when applied for 5 days. 
However it could be seen on immunocytochemistry (figure 4.23 ad 4.24) that 
bafilomycin was entering the cells and affecting protein distribution even after 24 hours. 
There was increased HTT staining, particularly in the pathogenic line, suggesting the 
accumulation of HTT exon 1. This suggests that these cells are able to tolerate severe 
disruption of protein homeostasis, including the build-up of mutant HTT exon 1.  
 
Recent papers have described an effect of mutant HTT on early neurodevelopment. 
Neural differentiation in human ESCs engineered to have graded increases in CAG 
repeat length was affected in pathogenic lines by chromosomal instability and failed 
cytokinesis (Ruzo et al, 2018). HD iPSCs with large CAG expansions showed failure of 
neuro-ectodermal acquisition whilst shorter expansions showed abnormalities in neural 
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rosette formation and disrupted cytoarchitecture in cortical organoids (Conforti et al, 
2018). The finding that B3-tubulin expression (as quantified on high content imaging) is 
slightly reduced in the ReNcellVM 129Q line may be indicative of an adverse effect on 
neuronal differentiation in this line, and supports these recent findings.  
 
However, this last finding must be interpreted with caution as the entire HTT exon 1 
ReNcellVM panel, including the control GFP only line, did not differentiate into mature 
neurons, as evidenced by the lack of action potentials in these cells, and the co-
expression of B3-tubulin, GFAP and nestin. The relative immaturity of these cells may 
also have contributed to the general resistance to cellular stressors that was observed, 
as true neurons would likely be more sensitive to the effects of oxidative and 
excitotoxic stress, and disruption of protein homeostasis. The lack of CAG-length 
dependent effects on cell death might also be partly explained by this, as neurons are 
known to be the cell type most vulnerable to the effects of mutant HTT.  
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4.7 Summary 
 
 
The HTT exon 1 ReNcellVM allelic series did not display overt neuronal toxicity or 
increased vulnerability to toxins in the pathogenic lines. However a small decrease in 
B3-tubulin positive cells was seen in the ReNcellVM 129Q line on differentiation, and 
there was a marginal increase in anti-activated caspase 3 staining detected by high 
content imaging in the ReNcellVM 71Q-H line. There were no CAG-length dependent 
effects in cell death in response to modulation of protein homeostasis using UPS and 
autophagy inhibitors. 
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5 Effect of increasing CAG repeat length in HTT 
exon 1 protein in human neuronal cells 
 
5.1 Background 
 
Protein deposition is a feature of many neurodegenerative diseases, for example beta-
amyloid derived from amyloid precursor protein (APP) in Alzheimer’s disease (AD), tau 
in frontotemporal dementia (FTD) and alpha-synuclein in Parkinson’s disease (PD). 
The role of protein deposition in disease pathogenesis is often not clear, and such is 
the case in HD. Inclusions of HTT protein have long been observed in post-mortem 
brain tissue, where they are present in neurons (DiFiglia et al, 1997) and glia (Shin et 
al, 2005), and are recapitulated by animal and cell models of HD. Inclusion frequency 
and rate of formation are polyQ repeat length dependent, and inclusion size increases 
with disease duration (Hughes & Jones, 2014).  
 
Mutant HTT exon 1 is known to misfold and self-assemble via a series of aggregated 
species, progressing from monomeric forms into spherical oligomers, protofibrils, 
mature amyloid fibrils, and large fibril clusters or inclusions. The structures of these 
species are not fully resolved, nor the pathway of inclusion formation (Wetzel & Mishra, 
2014). Mature fibrils are thought to contain antiparallel β-sheets and a recent structural 
study has found that the amyloid core of mHTT exon 1 fibrils are made up of two kinds 
of β-hairpin strands which interact via interdigitation of side chains, and this may seed 
aggregation (Hoop et al, 2016). Using a combination of correlative light and electron 
microscopy (CLEM) and time-lapse fluorescence microscopy, Peskett et al have shown 
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that aggregates of huntingtin exon 1 exist in distinct liquid-like and solid-like forms. 
Liquid-like assembly formation is driven by polyQ and proline-rich regions of exon 1. 
These convert into solid-like assemblies in cells, which are highly structured at the 
nanoscale level and resemble aggregates that have been found in the brain tissue of 
HD patients (Peskett et al, 2018). 
 
The precise toxic species in HD is not known, and the contribution of HTT inclusion 
formation to neurodegeneration remains unclear. Marcellin et al have shown that levels 
of soluble monomeric full length mHtt remain constant with age in the HdhQ150 mouse, 
but the size of the oligomeric pool decreases and the level of insoluble inclusions 
increase (Marcellin et al, 2012). Inclusions have been shown to sequester essential 
cellular proteins such as transcription factors (CREB-binding protein), chaperones and 
proteasome components. The overexpression of a neuronal chaperone HSJ1a in R6/2 
mice significantly reduced mutant huntingtin aggregation and enhanced solubility, and 
led to improved neurological performance (Labbadia et al, 2012). Methylene blue has 
also been shown to reduce aggregation and improve phenotype in R6/2 mice (Sontag 
et al, 2012), although in this study oligomer formation was also reduced.  
 
In contrast a number of studies have found that promotion of HTT aggregation, for 
example by the chaperonin TRiC (Kitamura et al, 2006) and the small acidic protein 
prothymosin-α (Dong et al, 2012), have led to decreased toxicity in cell models of HD. 
A study by Tashiro et al showed that the prevention of correct folding of nascent GFP-
HTT exon 1 72Q protein by disrupting formation of the chaperone prefoldin, inhibited 
the formation of insoluble inclusions but led to an increase in oligomeric forms that 
were more toxic to cells (Tashiro et al, 2013). Tracking inclusion formation in individual 
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cells over time also found correlation with improved cell survival (Arrasate et al, 2004). 
Inclusions are found to appear very early in R6/2 mice, before any behavioural 
phenotype occurs (Gong et al, 2012). Inclusion formation has also been found to 
precede symptom onset in the HdhQ150 knock-in mouse model (Landles et al, 2010). 
Data from human brains post-mortem shows that the anatomic pattern of inclusion 
formation does not spatially correlate with the main sites of pathogenesis (Gutekunst et 
al, 1999). 
 
The subcellular location of inclusions may be of importance. In all mouse models, 
extra-nuclear inclusions have been found to vary in shape and size far more than 
nuclear inclusions. Extra-nuclear inclusions are composed of longer N-terminal 
fragments than their intra-nuclear counterparts (Hughes & Jones, 2014). R6/2 mice 
with super-long CAG repeats (>/= 335) have mHTT aggregation localised to the 
cytoplasm (as the transgenic protein is too large to past through the nuclear pore) and 
have delayed onset and less severe disease (Dragatsis et al, 2009).  In transgenic 
mice, the progression of perinuclear (rather than nuclear) inclusions was shown to be 
accompanied by cell-cycle activation, disruption of the nuclear envelope and culminate 
in cell death  (Liu et al, 2015).  
 
HTT inclusions may themselves be a heterogeneous population, with different forms 
having differing contributions to disease. Caron et al described the formation of 
two types of inclusions depending on phosphorylation state: fibrillar, which are tightly 
packed and do not exchange protein with the soluble phase, and globular, which are 
loosely packed, can readily exchange with the soluble phase. Tightly packed fibrillary 
inclusions that do not exit the insoluble phase are thought to exert less toxicity (Caron 
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et al, 2014). Different polyQ amyloid conformations form under different temperatures, 
and loop/turn structures with exposed polyglutamines were found to exert higher 
toxicity than structures with extended and buried β-sheets (Nekooki-Machida et al, 
2009).  
 
A detailed examination of inclusion formation using high content imaging in the 
ReNcellVM HTT exon 1 lines was undertaken, in order to establish the effect of 
increasing CAG repeat length in human neuronal cells with matched expression levels 
of HTT exon 1. The impact of inclusion formation on these cells was also investigated. 
Subsequently the effect of proteostasis modulation on HTT accumulation and 
clearance in HTT exon 1 overexpressing ReNcellVM was studied.  
 
 
The effect of increasing CAG repeat length on the processing of HTT exon 1 by 
autophagy and the UPS 
 
Autophagy and the ubiquitin proteasome system (UPS) are the two main mechanisms 
for protein clearance in cells, and there is cross-talk between the two systems. 
Autophagy is used for the bulk degradation of protein complexes and damaged 
organelles, whereas the UPS generally clears short-lived nuclear and cytoplasmic 
proteins.  
 
The term autophagy is used here to mean “macroautophagy”, in which the target 
cargoes are engulfed by double-membraned autophagosome precursors to form 
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completed autophagosomes. These are delivered to lysosomes along microtubules, 
and on fusion of the two structures, lysosomal hydrolases degrade its contents. Mutant 
HTT has been found to accumulate in vesicular structures in HD brains (Sapp et al, 
1997) indicating that it is a substrate for autophagy and subsequent studies have 
shown that both full-length (Shibata et al, 2006) and aggregated HTT (La Spada, 2012) 
are cleared by this process. mTOR is a negative regulator of autophagy and has been 
shown to be incorporated into mHTT aggregates, with subsequent enhancement of 
autophagy in cells (Ravikumar et al, 2004). The autophagy enhancer rapamycin 
increased mHTT clearance and improved phenotype in fly and mouse models of HD 
(Ravikumar et al, 2004). Conversely, impaired autophagy may contribute to HD 
pathogenesis. A failure of cargo loading into autophagosomes has been demonstrated 
in HD (Martinez-Vicente et al, 2010), and impaired uptake and degradation of mHTT 
fragments by lysosomes has been found (Qi et al, 2012). The enhancement of 
autophagy is a potential therapeutic avenue in HD which is currently being explored 
(Sasazawa et al, 2015). The effect of bafilomycin A1 was tested in the ReNcellVM HTT 
exon 1 lines, to determine the impact of increasing CAG repeat length in response to 
autophagy inhibiton.  
 
The UPS is responsible for the majority (80-90%) of protein clearance in eukaryotic 
cells, clearing both healthy and damaged or misfolded proteins. Elimination of proteins 
involves ubiquitination of the target protein, followed by degradation of the tagged 
protein by the 26S proteasome complex (Glickman & Ciechanover, 2002) (see section 
1.4.2. for more detail). Mutant HTT is thought to be broken down and cleared by the 
UPS, and inclusion bodies are rich in ubiquitin and proteasome components (DiFiglia et 
al, 1997). There is conflicting evidence with regards to how UPS function is affected in 
HD.  Seo et al found inhibition of the UPS in early and late stage HD brain regions, and 
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also in HD fibroblasts even on increased expression of proteasomal subunits (Seo et 
al, 2004). An increase in polyubiquitin chains, as a marker of UPS impairment, has 
been found in mouse models and HD patients (Bennett et al, 2007b). Using fluorescent 
reporters for the UPS, Wang et al have shown that mHTT compromised synaptic UPS 
activity in cultured neurons and mouse brains (Wang et al, 2008).  
 
However, others have found no relationship between the accumulation of protein 
aggregates and global UPS impairment in mouse models of HD (Bett et al, 2009b). 
Maynard et al also showed that although mHTT caused a general inhibition of the UPS 
in PC12 cells, this was not the case in mouse models of HD which had a largely 
operative UPS. Increased ubiquitin was observed but could be attributed to an 
accumulation of large ubiquitin conjugates, different from the conjugates observed 
upon UPS inhibition (Maynard et al, 2009). The cellular environment may also play a 
role as polyglutamine proteins have been shown to have no effect on the UPS in SH-
SY5Y cells under basal conditions, but the response of the UPS to cell stress was 
impaired (in the absence of cell death) (Ding et al, 2002). Thus the effect of mHTT on 
UPS function may be dependent on the expression levels, cellular context, model 
system, subcellular localisation and cell-type. Since the UPS is a highly ATP-
dependent system (Schrader et al, 2009), defective mitochondria transport that is 
known to occur in HD neurons (Reddy & Shirendeb, 2012) may lead to ATP deficiency 
in neurites and nerve terminals, thus impeding the local degradation of mHTT by the 
proteasome in these subcellular regions (Zhao et al, 2016).  
 
Whether a cause or a consequence of neurotoxicity in HD, impaired neuronal 
proteostasis may lead to the accumulation of any misfolded or old/damaged proteins 
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usually cleared through the UPS; this in turn may have far-reaching consequences on 
global cell health. The effect of the proteasomal inhibitor MG132 was tested in the 
ReNcellVM HTT exon 1 lines, to determine the impact of increasing CAG repeat length 
in response to UPS inhibition in neurons. 
  
Upregulation of the UPS is an attractive treatment pathway in HD, and the 
overexpression of ube3a, an ubiquitin E3 ligase, can activate the UPS and decrease 
mHtt aggregates in the brains of HD knock-in mice (Bhat et al, 2014). However, 
overexpression of proteasomal activator PA28 increased UPS function in control but 
not HD fibroblasts (Seo et al, 2004). In collaboration with Proteostasis Therapeutics Inc 
(PTI), a number of proteasomal enhancers (specifically USP14 inhibitors) were tested 
for their ability to clear pathogenic length HTT exon 1 from ReNcellVM neurons. 
Ubiquitin-specific protease 14 (USP14) is a deubiquitinating enzyme (DUB), that 
cleaves ubiquitin from ubiquitinated proteins. USP14 inhibitors antagonise this, thus 
leading to an increase in ubiquitinated proteins which are then targeted for proteasomal 
degradation. As mHTT exon 1 is generally thought to exert toxicity through a multitude 
of pathways, any reduction in its concentration would be of potential therapeutic value.  
 
 
 
 
 
 
Chapter 5 
 
220 
 
5.2 Aims 
 
1.  To establish the effect of increasing CAG repeat length on HTT protein in HTT 
exon 1 overexpressing ReNcellVM cells. 
 
2. To study the effect of proteostasis modulation on mHTT in HTT exon 1 
overexpressing ReNcellVM cells. 
 
 
 
5.3 Methods 
 
HTT exon 1 ReNcellVM NSCs were cultured and differentiated as described in section 
2.1.1 and 2.1.3. Samples were prepared for Western blotting as described in section 
2.4, and a range of HTT antibodies were tested to determine the optimum method for 
the detection of HTT exon 1. A table of all antibodies tested and the concentrations is 
included in appendix table A.1. Similarly, a range of HTT antibodies for 
immunofluorescence detection was tested (appendix table A.2); cells were grown on 
laminin coated glass coverslips, fixed, permeabilised and stained using a standard 
immunocytochemistry protocol as described in section 2.7.1. To test the effects of 
amyloid dyes thioflavin T (ThioT) and NIAD-4, cells were differentiated on coverslips, 
fixed, permeabilised and stained with S830 as standard. However, after the 
wash/removal of the secondary antibody, the dyes were then added to the coverslips. 
ThioT compound was dissolved in methanol to form a 0.1% solution. 500Ul of this was 
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added directly to the coverslip for 8 minutes as per protocol. A 0.05% solution was also 
tested. NIAD-4 was dissolved in DMSO to form a 1 mM solution, which was then 
diluted in PBS to form 10 µM and 100 nM solutions that were added to the coverslips 
for 30 minutes as per protocol. After removal of the respective amyloid dyes, Hoescht 
staining for nuclei was carried out as standard.  
 
To study the formation of HTT inclusion bodies in greater detail, a time-course analysis 
was carried out using high content imaging as described in section 2.7.2. Cells were 
seeded in a 96 well plate format onto laminin coated Perkin Elmer Cell Carrier plates 
for imaging. Cells were fixed at dd0, dd7 and dd14 respectively, followed by staining 
using the S830 anti-HTT antibody, and B3-tubulin or GFAP antibody (appendix table 
A.2). There were at least eight wells per condition tested (cell line and antibody 
combination). The plates were imaged on the Opera LX high content screening 
platform by Dr. Christin Luft at the UCL MRC Laboratory for Molecular Cell Biology 
(LMCB) with eighteen fields of view (fov) per well, and image analysis was carried out 
by Dr. Janos Kriston-Vizi (LMCB) using Image J and R. Data in the form of raw counts 
was then analysed on Prism by Dr. Rhia Ghosh and statistical analysis was carried out; 
two-way ANOVA with Bonferroni’s correction for multiple comparisons was applied to 
confirm differences between cell lines across different time points (section 2.10). To 
study the effect of inclusions on neurons, a combination of standard confocal 
microscopy on the Zeiss 710 confocal microscope (section 2.7.1) and high content 
image analysis of the full HTT exon 1 panel stained with anti-HTT aa 1-82 antibody and 
imaged on the new Opera Phenix (section 2.7.2) was carried out, followed by image 
analysis on Columbus (section 2.7.2.1) and statistical analysis using Prism software 
(section 2.10). 
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Super-resolution imaging of the HTT exon 1 ReNcellVM lines was carried out as 
follows: cells were differentiated on specific Ibidi glass plates (0.17 mm thickness) for 
imaging, fixed and stained using S830 (section 2.7.3). Imaging was carried out with Dr. 
Ed Smith at the King’s Nikon Centre, using the N-SIM Super Resolution System with 
corresponding N-SIM software. 
 
To test the effect of proteostasis modulation on the distribution of HTT exon 1 in the 
ReNcellVM HTT exon 1 cells, the full panel was again plated onto 96 well Perkin Elmer 
Cell Carrier plates and after 14 days of differentiation, either 1 µM bafilomycin A1 or 
200 µM MG132 was added to the media for 24 hours. Cells were then fixed and 
stained with aa1-82 as per standard protocol. Plates were imaged on the Opera 
Phenix, with image analysis on Columbus and statistical analysis on Prism.  The effect 
of proteasomal activation using USP14 inhibitors supplied by PTI on the clearance of 
HTT exon 1 was tested using Western blotting. The pathogenic exon 1 lines were 
grown in 6-well format, and treated with the provided compounds and control at DD14 
for 48 hours. Western blotting was optimised as described in the results section, and 
densitometry was carried out using Total Lab 100 (TL100) software. The density of 
HTT exon 1 bands was compared between control and active compounds, with 
statistical analysis (two-way ANOVA) carried out using GraphPad Prism. Following 
discussion with PTI, the experiment was repeated using the 71Q line only, this time 
using one-way ANOVA to assess for differences between control and active 
compounds.  
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5.4 Contributions 
 
The work described in this chapter was carried out by Dr. Rhia Ghosh with 
collaborators in the following areas: 
1. For the time-course of HTT inclusion formation, high content image acquisition using 
the Opera LX microscope and image analysis was carried out with the assistance of 
Dr. Robin Ketteler, Dr. Christin Luft and Dr. Janos Kriston-Vizi. Subsequently, with the 
arrival of the newer Opera Phenix microscope, both image acquisition and image 
analysis were carried out by Dr. Rhia Ghosh for all other high content imaging 
experiments described.  
2. Super-resolution imaging was carried out with the assistance of Dr. Ed Smith (HD 
Research Group) at the King’s Nikon Centre. 
3. Proteasomal enhancers (USP14 inhibitors) to test on HTT exon 1 ReNcellVM 
neurons were supplied by industrial collaborator Proteostasis Therapeutics Inc. (PTI). 
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5.5 Results 
 
5.5.1 Establishing a panel of HTT antibodies for protein detection in HTT 
exon 1 ReNcellVM cells 
 
In order to assess the impact of increasing CAG-repeat length on the behaviour of the 
HTT exon 1 protein in ReNcellVM cells, it is essential to have reliable methods for 
protein detection. A number of anti-HTT antibodies are now available, with variable 
target sites (table 5.1). Many of these are not commercially available and have 
restricted supply (including S830 and 4C9). The majority are directed towards the N-
terminal, and also have been raised in mouse (causing difficulty in co-staining 
experiments). Some of these antibodies detect mHTT only, in certain instances with 
some affinity to other polyQ-containing proteins. Others, that do not include the polyQ 
region in their epitope, do not distinguish between the normal and mutant forms of the 
protein. As expected, the binding of these antibodies is affected by the specific species 
or structure of the HTT protein; this must be taken into account when selecting 
antibodies for specific applications.  
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Antibody Species Immunogen/epitope 
S830 Sheep 
N-terminal of HTT aa 1-90, higher affinity for expanded 
polyglutamine lengths 
4C9 Mouse N-terminal proline rich region, aa 65-84 
aa1-82 (N82) Mouse N-terminal of HTT, aa 1-82 
MW1 Mouse N-terminal polyQ region 
3B5H10 Mouse N-terminal fragment of 171 amino acids containing 65Q 
2B7 Mouse N-terminal HTT aa 1-17 
ab109115 Rabbit N-terminal HTT aa 1-100 
1H6 Mouse N- terminal aa 81-190 
EM48 Mouse N-terminal HTT aa 1-256 (without PolyQ)  
MAB2166 Mouse HTT aa 181-810 
D7F7 Rabbit Residues around HTT Pro 1220  
MAB2170 Mouse HTT aa 1268-1666 
 
Table 5.1: Table of HTT antibodies with corresponding presumed epitopes. 
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5.5.1.1 Western blotting for HTT in HTT exon 1 ReNcellVM cells 
 
Initial Western blotting for HTT exon 1 in the ReNcellVM lines was carried out using the 
S830 and 4C9 antibodies, and has been described previously. As can be seen from 
figure 3.23 (chapter 3), the signal for the 29Q HTT exon 1 was considerably fainter 
than for the 129Q HTT exon 1 line that was confirmed to have matched expression 
levels by an MSD assay. On many occasions it was not possible to see any signal at all 
for this product on Western blotting, despite observing a good signal on 
immunofluorescence studies. Further Western blotting was therefore carried out using 
a number of different HTT antibodies, in order to determine which recognised particular 
HTT species in the ReNcellVM lines. NSCs of the matched 29Q and 129Q lines were 
used, along with a highly expressing 29Q line (29Q-H) which was thawed for this 
purpose. The results are shown in figure 5.1. 
 
S830 antibody detected the 129Q HTT exon 1 band at around 65 kDa as expected, 
and a relatively fainter 29Q HTT exon 1 band at 20 kDa. S830 is known to have 
preferential binding to mutant HTT and displays polyQ dependence, which may explain 
this finding. 4C9 antibody also detects both 129Q and 29Q exon 1, but the 29Q exon 1 
band is again relatively faint. This is surprising as 4C9 antibody binds to the polyproline 
region on HTT exon 1, and therefore binds both wild-type and mutant HTT; is not 
known to be polyQ dependent. Western blotting with aa1-82 hardly picked up 29Q HTT 
exon 1 in the matched expressing line, despite binding to this product on 
immunofluorescence studies. MW1 and 3B5H10 antibodies, both of which are directed 
against mutant HTT, were able to detect 129Q HTT exon 1 but not 29Q HTT exon1, 
and in addition there is much non-specific background visible with MW1. Both D7F7 
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and 2B7 antibodies gave a good signal for the endogenous full-length HTT protein. 2B7 
is directed against the extreme N-terminal of HTT and would be expected to detect 
both 29Q and 129Q HTT exon 1 equally well, however once again the 29Q HTT exon 1 
product was not detected using this antibody. However the same 2B7 antibody was 
used in the MSD assay in the detection of all the HTT exon 1 products.  
 
The lack of signal for the 29Q HTT exon 1 product on Western blotting raises the 
possibility that this product is being degraded in the cells, however its detection on both 
immunofluorescence studies and MSD assays rules this out. The Western blotting 
process involves steps that unfold the protein; therefore the epitope for antibody 
binding may be affected compared to immunofluorescence techniques that are more 
likely to preserve the native protein conformation. It is also possible that the 29Q HTT 
exon 1 protein may not transfer well, or only bind the transfer membrane very weakly, 
being washed away during the staining and washing steps. The lack of reliable 
detection of the 29Q HTT exon 1 product on Western blotting precluded this method for 
making comparisons between lines in the HTT exon 1 panel. 
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Figure 5.1: Western blots with panel of HTT antibodies in HTT exon 1 29Q, 29Q-H 
(high expressor) and 129Q ReNcellVM NSCs. Black arrow: 129Q exon 1, Grey 
arrow: 29Q exon 1, Yellow arrow: Full length endogenous HTT 
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5.5.1.2 Immunofluorescence detection of HTT in HTT exon 1 ReNcellVM cells 
 
A number of HTT antibodies were also tested for the immunofluorescence (IF) 
detection of HTT exon 1 in these lines, with the results shown below. EM48 is a well-
known antibody used for the detection of mHTT inclusions on IF (Carty et al, 2015), 
and shows the presence of mHTT inclusions in the pathogenic 71Q-H line by day 14 of 
differentiation (dd14).  S830 can also be seen to bind to these aggregates, confirming 
that they are indeed mHTT inclusion bodies (IBs). In addition, a diffuse cytoplasmic 
stain is visible with S830 that is not seen in the GFP-only line (figure 5.2). This is likely 
to be soluble HTT exon 1, not incorporated into inclusions. S830 antibody does not 
seem to detect wild-type HTT.  
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Figure 5.2: Immunofluorescence co-stain of dd14 GFP only and 71Q-H HTT exon 
1 ReNcellVM cells with EM48 and S830 antibody. Both antibodies are seen to bind 
to HTT inclusions in the 71Q-H line, and in addition, S830 detects soluble cytoplasmic 
mHTT exon 1. Green – S830, Red – EM48, White – GFP, Blue - Hoescht. 
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Different HTT antibodies have the potential to recognise different HTT species, 
depending on protein conformation. A series of co-stains with S830 antibody was 
therefore carried out, with findings as follows (figure 5.3): 
 
1. 4C9 antibody displays a similar pattern of staining to S830, however is less sensitive 
than S830 (when tested on the GFP-only line, 4C9 did not detect to wild-type 
endogenous HTT.   
 
2. Both MW1 and 3B5H10 stain soluble mutant exon 1 and not aggregates. 3B5H10 is 
thought to specifically recognise a monomeric species that predicts neurodegeneration, 
whereas MW1 recognises an extended unfolded PolyQ “linear lattice” (Miller et al, 
2011). High levels of non-specific background staining were observed with both these 
antibodies. 
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Figure 5.3: Immunofluorescence co-staining of dd14 HTT exon 1 71Q-H 
ReNcellVM cells S830 and another HTT antibody as shown (from left to right 4C9, 
MW1, 3B5H10).  4C9 displays a similar pattern of staining to S830, but appears less 
sensitive. Both MW1 and 3B5H10 stain soluble mutant exon 1 and not aggregates. 
Green – S830, Red – HTT antibody as shown, White – GFP, Blue - Hoescht. 
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Due to the restricted supply of S830 and 4C9 antibody, the commercially available aa1-
82 antibody was also tested (figure 5.4). It also binds to inclusions, though is also less 
sensitive than S830. Cytoplasmic HTT exon 1 staining also appears to have a more 
granular appearance.  
 
 
Figure 5.4: Immunofluorescence co-stain of dd14 GFP only and 71Q-H HTT exon 
1 ReNcellVM cells with S830 and aa 1-82 antibody. aa 1-82 binds to HTT inclusions 
but is less sensitive than S830 and appears to produce more granular cytoplasmic HTT 
exon 1 staining. Blue – Hoescht, White – S830 or aa 1-82 as labelled. 
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The anti-HTT 2170 antibody recognises full length wild-type HTT in the cells and 
displayed diffuse cytoplasmic staining in both GFP only and 71Q-H lines. It does not 
bind to HTT exon 1 which lacks this more C-terminal epitope. There was no co-
localisation with inclusions, suggesting that the IBs are not binding or sequestering the 
wild-type protein (figure 5.5). The extremely N-terminal antibody 2B7, which had 
worked well in detecting full length endogenous HTT on Western blotting, was not 
effective when used for immunocytochemistry in HTT exon 1 ReNcellVM cells.  
 
Therefore it is possible to specifically detect mHTT inclusion bodies, soluble mutant 
HTT exon 1 and wild-type HTT in these cells.  
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Figure 5.5: Immunofluorescence co-stain of dd14 GFP only and 71Q-H HTT exon 
1 ReNcellVM cells with S830 and 2170 antibody. 2170 antibody recognises full 
length wild-type HTT in the cells and displays diffuse cytoplasmic staining in both lines. 
There is no co-localisation with inclusions. Green – S830, Red – HTT antibody 2170, 
White – GFP, Blue - Hoescht. 
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5.5.1.3 Alternative methods for imaging HTT inclusions in HTT exon 1 
ReNcellVM cells 
 
Previous studies have reported that HTT inclusions form a heterogenous population, 
and different species may have different effects within neurons (Caron et al, 2014). In 
this particular study Thioflavin T (ThioT) was used to demonstrate the existence of at 
least two inclusion types: fibrillar or globular.  ThioT is an amyloid dye which binds to β-
sheet structures and fluoresces green (482 nm) on excitation. Following the staining of 
dd14 HTT exon 1 129Q ReNcellVM cells with S830, ThioT was used as per protocol to 
visualise any amyloid-like inclusions formed by HTT exon 1. It was hoped that any such 
structures would fluoresce in the green channel more brightly than the background 
GFP, in order to allow visualisation. Unfortunately no bright green spot-like structures 
were seen and ThioT was deemed not to be useful for further experiments in these 
cells (Figure 5.6). Another fluorescent probe specific for β-sheet structures is NIAD-4, 
which binds to amyloid-β and displays far-red emission (Woerner et al, 2016). This dye 
was also tested on these cells, but again did not bind to any HTT inclusions in the cells, 
as can be seen from the complete lack of any detection in the far red channel (figure 
5.6). The lack of binding of both these dyes may indicate that the inclusions formed by 
mHTT exon 1 in these lines are not amyloid in nature.  
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Figure 5.6: Amyloid staining in dd14 HTT exon 1 129Q ReNcellVM cells. Neither 
thioflavin T (top panel) nor NIAD-4 (bottom panel) reveals the presence of amyloid, 
suggesting that HTT inclusions in ReNcellVM do not contain β-sheet structures. Blue – 
Hoescht, Green – GFP, White – S830.   
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5.5.2 HTT inclusions in HTT exon 1 ReNcellVM cells 
 
Having tested a range of HTT antibodies, it was decided that S830 was the most 
suitable to use for further analysis of mHTT inclusion formation; this is due to its 
sensitivity in detecting mHTT IBs, and also its ability to detect at least one other form of 
HTT exon 1 (soluble HTT exon 1, corresponding to the diffuse cytoplasmic staining). 
The full HTT exon 1 ReNcellVM panel was fixed and stained with S830 and B3-tubulin, 
both in NSC form and at dd14 (figure 5.7). From these representative images it can be 
observed that NSCs do not contain inclusions, except in the mostly highly pathogenic 
HTT exon 1 71Q-H ReNcellVM “positive control” line. In addition, upon differentiation 
IBs form in a small proportion of the matched expressing pathogenic HTT exon 1 (71Q 
and 129Q) ReNcellVM lines too.  
 
The different patterns of S830 staining in the pathogenic 71Q-H line are shown in 
Figure 5.8. It is notable that when present inclusions are mostly found within the 
nucleus, but in some cells a cluster of smaller peri-nuclear inclusions can be seen. 
Inclusion formation appears to be an “all or nothing” phenomenon; cells either contain a 
number of intranuclear IBs or none at all. The diffuse cytoplasmic stain is again 
observed, thought to be soluble HTT exon 1. Cells with intra-nuclear IBs are found to 
have lower levels of this this diffuse cytoplasmic staining, suggesting that in those cells 
most HTT exon 1 present has entered the nucleus and been incorporated into 
inclusions.  
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Figure 5.7: HTT inclusion formation in full HTT exon 1 ReNcellVM panel at dd0 
and dd14. Neural stem cell IBs are only found in the HTT exon 1 71Q-H ReNcellVM 
cells. In addition, upon differentiation IBs form in a small proportion of HTT exon 1 71Q 
and 129Q ReNcellVM lines. Blue: Hoescht, Green – GFP, Red – B3-tubulin, White – 
S830 HTT antibody.  
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Figure 5.8: Different patterns of HTT staining in dd14 HTT exon 1 71Q-H 
ReNcellVM cells labelled with S830 HTT antibody. Blue: Hoescht, White – S830 
HTT antibody.  
 
 
5.5.2.1 Time-course of mHTT inclusion formation 
 
In order to further analyse the formation of mHTT inclusions over time in the HTT exon 
1 lines, the full panel was seeded into three 96 well plates and fixed at dd0 (NSC 
stage), dd7 and dd14 respectively, with 16 wells per cell line (technical replicates). 
Following staining with S830, plates were imaged on the Opera LX high content 
imaging microscope. Image analysis was carried out in conjunction with Dr. Janos 
Kristen-Vizi, using ImageJ and R. Further statistical analysis was carried out using 
GraphPad Prism software, with results as shown below.  
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Intra-nuclear inclusions 
Following differentiation the pathogenic lines (71Q, 129Q and 71Q-H) started to form 
S830 positive intra-nuclear HTT inclusions (figure 5.9), and by day 7 (dd7) significant 
CAG-repeat length dependent differences were seen, as neither the matched 
expressing HTT exon 1 29Q line nor the GFP-only line contain IBs (figure 5.10). In the 
NSC state, only the 71Q-H line has significant numbers of inclusion containing nuclei 
(though occasional abnormal nuclei are seen in the 71Q and 129Q lines of the 
matched panel too) (figure 5.9). The increase in IB containing cells over time in the 
pathogenic lines is not due to a corresponding drop/death of cells without IBs (figure 
5.11). Overall, the percentage of dd14 neurons that contains IBs is low, ranging from 
0.5-1.0% in the 71Q and 129Q lines, and increasing to 3.0% in the 71Q-H line. Thus 
inclusion formation can be found to be proportional to CAG-repeat length and the level 
of HTT exon 1 expression, as has been found in other studies (Scherzinger et al, 
1999). 
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Figure 5.9: Development of nuclear inclusions over time in HTT exon 1 
ReNcellVM cells. The percentage of cells with nuclear IBs increases over time in the 
pathogenic lines (71Q, 129Q and 71Q-H). Two-way ANOVA with Bonferroni’s 
correction as shown, n=16 per condition.  
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Figure 5.10: Formation of nuclear IBs in HTT exon 1 ReNcellVM cells is CAG-
repeat length dependent. By dd7, differences between lines in the percentage of cells 
with inclusions appear, with only the 71Q, 129Q and 71Q-H lines developing nuclear 
IBs. The 71Q-H line forms a significantly higher percentage of nuclear IB containing 
cells than all other lines. Two-way ANOVA with Bonferroni’s correction as shown, n=16 
per condition (all other comparisons were not significant).  
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Figure 5.11: Total nuclear count per well over time in HTT exon 1 ReNcellVM 
cells. Two-way ANOVA with Bonferroni’s correction confirms no significant difference 
between DD7 and DD14 in any cell line (n=16 per condition). 
 
 
The number of inclusions per inclusion-containing nucleus is also higher in the positive 
control 71Q-H line compared to both the other pathogenic lines, with a trend towards 
increased number in the 129Q compared to the matched 71Q line (though this did not 
reach significance) (figure 5.12). This measurement also significantly increased over 
time in the 71Q and 129Q lines, but not in the positive control line (figure 5.13).  
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Figure 5.12: Number of IBs per inclusion containing nucleus in pathogenic HTT 
exon 1 ReNcellVM lines is highest in the 71Q-H line, which has the highest 
concentration of mHTT exon 1. The increasing trend between 71Q and 129Q lines is 
not statistically significant. Two-way ANOVA with Bonferroni’s correction as shown, 
n=16 per condition. 
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Figure 5.13: Number of IBs per inclusion containing nucleus increases over time 
in the pathogenic HTT exon 1 ReNcellVM lines, although this measure does not 
reach statistical significance in the 71Q-H line. Two-way ANOVA with Bonferroni’s 
correction as shown, n=16 per condition. 
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Peri-nuclear inclusions 
In line with the increase in intra-nuclear IBs on differentiation, the number of peri-
nuclear inclusions decreases in the two most pathogenic lines (129Q and 71Q-H) 
(figure 5.14). However this has not been found in the 71Q line, and this result may be 
affected by the difficulty in setting up accurate spot counting algorithms for peri-nuclear 
inclusions on ImageJ, as generally the peri-nuclear inclusions have a much smaller 
area than intra-nuclear inclusions and counts can be spuriously increased by non-
specific background staining artifact. 
 
Figure 5.14: The number of perinuclear inclusions decreases over time in the two 
most pathogenic 71Q-H and 129Q HTT exon 1 ReNcellVM lines, however this has 
not been found in the 71Q line. Two-way ANOVA with Bonferroni’s correction as 
shown, n=16 per condition. 
Chapter 5 
 
248 
 
Soluble HTT exon 1  
Diffuse cytoplasmic S830 staining (thought to represent soluble HTT exon 1) increases 
over time, particularly in the pathogenic lines (Figure 5.15). Again, this was found to be 
less prominent, or absent, in cells which have inclusion containing nuclei.  
 
Figure 5.15: Cytoplasmic soluble HTT exon 1 increases over time in the HTT 
exon 1 ReNcellVM cells, particularly in the pathogenic 71Q, 129Q and 71Q-H lines. 
Soluble HTT exon 1 is thought to correspond to diffuse cytoplasmic staining of S830 
antibody, which is not present in the GFP only line. Two-way ANOVA with Bonferroni’s 
correction as shown, n=16 per condition. 
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5.5.2.2 The effect of mHTT inclusions on neurons 
 
As mentioned, the overall proportion of cells containing mHTT inclusions was low, even 
in the 71Q-H line. Therefore it was not possible to ascertain their effect globally on the 
neuronal culture. However, it could be seen on immunofluorescence that cells 
containing nuclear IBs often had reduced expression of cell type markers and abnormal 
morphology, with a more rounded cellular appearance compared to the surrounding 
neuronal culture (figure 5.16). This finding was supported by high content image 
analysis (Columbus) which revealed that the intensity of B3-tubulin staining in the 
pathogenic lines was significantly reduced in nuclear IB containing cells compared to 
cells without nuclear IBs (two-tailed t-test, p<0.05).  
 
 
Figure 5.16: Cells with nuclear inclusions have reduced expression of cell 
markers as shown by immunocytochemistry of dd14 129Q ReNcellVM cells. A more 
rounded cell morphology is also observed.                
White – S830 antibody; Red – B3-tubulin; Green – GFP; Blue - Hoescht 
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It was difficult to co-stain with S830 and markers of cell toxicity, due to the GFP 
expression blocking the 488 nm channel in these lines. HTT is intracellular and 
therefore it is necessary to permeabilise cells post-fixing in order to expose antigens for 
HTT-antibody binding. The permeabilisation procedure caused any cell viability 
markers added to live cells (such as propidium iodide), to leach out. However, it can be 
seen from figure 5.17 that there was no obvious effect of nuclear IB formation on 
Hoescht staining, in terms of abnormal nuclear morphology or formation of apoptotic 
bodies. This was confirmed using anti-activated caspase 3 staining, which was not 
present in untreated/unstressed cells with nuclear inclusions. 
 
 
Figure 5.17: Nuclei containing inclusion bodies have normal morphology as 
demonstrated in dd21 HTT exon 1 71Q-H ReNcellVM cells at x60 magnification. Blue – 
Hoescht, White – S830. 
 
However high content image analysis (Columbus) with measurement of nuclear area 
revealed that nuclei with inclusions are slightly bigger than those without (figure 5.18). 
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This may be simply the spatial effect of the inclusions themselves, or may be due to an 
osmotic effect, drawing water into the nuclei and expanding their size. This in turn may 
lead to impaired nuclear functioning, including transcriptional dysregulation that is 
known to occur in HD.  
 
 
Figure 5.18: Nuclear area in pathogenic HTT exon 1 ReNcellVM lines. Columbus 
analysis of nuclear size in dd14 71Q, 129Q, 71Q-H stained with Hoesht and anti-HTT 
S830 antibody revealed significantly increased size of nuclei containing inclusion 
bodies.  
One-way ANOVA with Bonferroni correction. **=p<0.01, ***=p<0.001. n=16 per cell line 
(with and without inclusions) 
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5.5.3 Super-resolution imaging of HTT exon 1 ReNcellVM lines 
 
In order to examine the nuclear inclusions in more detail, and to further ascertain the 
nature of the diffuse cytoplasmic staining, super-resolution imaging of the HTT exon 1 
ReNcellVM lines was carried out. Cells were differentiated on specific glass plates 
(0.17mm thickness) for imaging, fixed and stained using S830. Imaging was carried out 
with Dr. Ed Smith at the King’s Nikon Centre, using the N-SIM Super Resolution 
System with corresponding N-SIM software. This achieves resolution of 100-120 nm 
and the results are shown in figure 5.19.  
 
These images reveal smaller intra-nuclear inclusions not previously seen on standard 
confocal microscopy, and a range of IB size is observed. This is consistent with a 
previous super-resolution study which suggests that IBs increase in size over time with 
the addition of more huntingtin monomers, and a range of sizes are therefore present 
at the same time (Duim et al, 2014). The all-or-nothing nature of inclusion formation is 
again highlighted, with the majority of nuclei completely clear, but affected nuclei full of 
inclusions. The cytoplasmic diffuse S830 is still seen in all lines except for the GFP only 
line, and therefore likely corresponds to soluble HTT exon 1. This is confirmed to be 
absent in cells with nuclear IBs. 
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Figure 5.19: Structured illumination microscopy images of dd21 HTT exon 1 71Q-
H ReNcellVM. (a,b) Multiple smaller nuclear inclusions not previously appreciated with 
standard confocal microscopy can be seen. (c,d) Cytoplasmic HTT staining is less 
prominent in cells with nuclear inclusions. 
Blue - Hoescht; Red - S830; White - S830. Scale: Width 31.94 µm, Height 31.94 µm, 
Depth 5.00 µm 
 
 
 
Chapter 5 
 
254 
 
5.5.4 Effect of proteostasis modulators on mHTT in ReNcellVM lines  
 
5.5.4.1 Effect of MG132 and Bafilomycin on distribution of HTT exon 1  
 
The panel of HTT exon 1 cells was seeded onto 96 well plates for imaging, and after 14 
days of differentiation, cells were treated with 200 µM MG132, 1 µM bafilomycin or 
DMSO control for 24 hours with 8 wells (technical replicates) tested per line for each 
treatment. Due to the restricted supply of S830 antibody, plates were fixed and stained 
with HTT antibody aa1-82, imaged on the Opera Phenix and analysed using Columbus 
software. Example images from these plates are shown in figure 4.24 (chapter 4), with 
further images of the 129Q line shown below (figure 5.20).  
 
It is clear that MG132 and bafilomycin both alter the distribution of HTT in the 129Q 
cells. As expected, the effect of autophagy inhibition with bafilomycin serves to 
increase the amount of mHTT in the neurons, with higher levels of aa1-82 staining 
observed both in the nucleus and axons. However proteasomal inhibition with MG132 
appears to cause increased HTT levels in the nuclear and perinuclear regions of only a 
few cells, with very little HTT observed in axons.  
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Figure 5.20: Distribution of mHTT exon 1 following treatment with MG132 and 
bafilomycin in dd14 HTT exon 1 129Q ReNcellVM cells. 
Blue – Hoescht, White – aa1-82 antibody. 
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Quantification of HTT staining using Columbus proved difficult. The plates displayed 
enormous variability in cell number between different fields of view (fov), even within 
the same well. This is due to the “honeycomb” effect mentioned previously. Many fields 
of view had no cells at all. Therefore when calculating the measure of aa1-82 staining 
intensity by dividing the overall intensity per fov by the nuclear count (for 
normalisation), the zero value divisor led to an infinite error result. This was discussed 
with engineers from Perkin Elmer, in order to find a way of excluding such fields of view 
from the analysis. However, ultimately the software was not able to perform this 
function. An alternative method of aa1-82 staining analysis was suggested, by creating 
a nuclear mask around each nucleus and measuring the average (mean) intensity in 
this area. This method was used to quantify the treatment effect of MG132 and 
bafilomycin in the cells, with results as shown in figure 5.21. Baseline levels of HTT in 
the GFP only line appear to be much higher than expected and are not as high as 
expected in the 71Q-H line. This is likely to be because the quantification method used 
misses the aa1-82 staining in the axons. However, within line comparisons of the 
treatment effect show that MG132 does not significantly alter the total levels of HTT 
within the cell, whereas bafilomycin does lead to a significant increase in all lines. 
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Figure 5.21: Quantification of total HTT staining in the HTT exon 1 ReNcellVM 
lines following administration of proteasomal inhibitor MG132 and autophagy 
inhibitor bafilomycin was carried out using Columbus software. Treatment with 
MG132 (top panel) has no significant effect on the total levels of HTT; Two-way 
ANOVA with Bonferroni’s correction. Treatment with Bafilomycin (bottom panel) 
significantly increases total HTT levels in all lines; Two-way ANOVA with Bonferroni’s 
correction (***=p<0.001), n=8 per condition.  
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5.5.4.2 mHTT exon 1 clearance by proteasomal activators 
 
Upregulation of the UPS is an attractive therapeutic option in HD. In a collaboration 
with Proteostasis Therapeutics Inc (PTI), a number of USP14 inhibitors were tested for 
their ability to clear HTT exon 1 from ReNcellVM neurons. PTI supplied five active 
compounds and one scrambled control, which was initially blinded to us. On receipt, 
the compounds were reconstituted in DMSO to achieve a final concentration of 5 mM. 
Following guidance from PTI, final doses of 1 µM, 3 µM and 10 µM were tested for 
each compound.  
 
Initially as a preliminary experiment only the 129Q line was tested; cells were 
differentiated in 6-well plates to dd14, followed by the addition of test compounds for 48 
hours. Cells were then harvested and samples prepared for Western blotting with 
measurement of total protein levels. Twenty micrograms of total protein was loaded per 
lane and blotting was carried out for HTT exon 1 (using aa1-82 antibody) and actin as a 
loading control. The membrane was then stripped and reprobed with HTT antibody 4C9 
and PSMb5 (a subunit of the 20S proteasome complex) as loading control. Results are 
shown in figure 5.22 below.  
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Figure 5.22: Western blotting of dd14 HTT exon 1 129Q ReNcellVM cells following 
treatment with PTI compounds at doses as shown. Detection of HTT exon 1 was 
carried out using HTT antibody aa1-82 (left), and 4C9 (right). A comparison of actin 
loading control (left) and the 20S proteasome subunit PSMb5 (right) is also shown.  
 
 
Densitometry was carried out and aa1-82:4C9 ratio was normalised to compound PTI-
N (as instructed by collaborators PTI). The same procedure was carried out for 
4C9:PSMb5 ratio, but with some missing data due to the reduced quality of the re-
probed membrane. However from comparing these preliminary results at the 10 µM 
dose it can be seen that both methods give rise to similar findings (figure 5.23).  
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Figure 5.23: Densitometry of bands at 10 µM PTI compound dose from Western 
blots shown in Figure 5.22. This preliminary experiment shows that both methods using 
anti-HTT aa1-82 and 4C9 antibody give rise to similar results. 
 
 
 
It was therefore decided to carry out a full experiment testing all compounds and doses 
on 71Q, 129Q and 71Q-H lines at dd14 (figure 5.24). Densitometry of bands in shown 
in figure 5.25, with results normalised to PTI-UB which was revealed by PTI to be the 
control scrambled compound.  
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Figure 5.24: Western blots of HTT exon 1 detected by 4C9 antibody (green), and 
PSMb5 (red) across the three pathogenic HTT exon 1 ReNcellVM lines (71Q, 129Q, 
71Q-H) following 48 hours of treatment with PTI compounds as doses shown above. 
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Figure 5.25: Densitometry results of Western blots shown in Figure 5.24, normalised to 
PTI-UB control. Bottom right panel shows combined results (mean+SEM) of all three 
pathogenic lines. Two-way ANOVA with Bonferroni’s correction shows no significant 
difference between the compounds at any of the doses tested.  
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These results were discussed with the PTI scientific team, who were hopeful that in the 
71Q line there had been a lowering of 71Q exon 1 with their newer USP14 inhibitors 
PTI UD/UE and UN. These compounds had previously only been tested in transiently 
transfected cells, and not in a system with steady state levels of pathogenic protein. 
The possibility of the compounds not working to clear the longer 129Q exon 1 or being 
“swamped” by the high expression of 71Q exon 1 in the 71Q-H line was suggested. 
Therefore, two further Western blots of the 71Q line treated with the PTI compounds at 
3.3 µM were carried out (technical replicates) (figure 5.26), with corresponding 
densitometry in figure 5.27. This showed that treatment with PTI-UE at 3.3 µM 
significantly lowered levels of 71Q exon 1 in this line.  
 
  
Figure 5.26: Further Western blotting (technical replicates) of HTT exon 1 71Q 
ReNcellVM line treated with 3.3 µM dose of PTI compounds.  
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Figure 5.27: Densitometry of Western blots of HTT exon 1 71Q ReNcellVM line treated 
with 3.3 µM dose of PTI compounds (shown in figure 5.26). Combined results (bottom 
right panel) show mean+SEM. PTI-UE is found to significantly lower 71Q exon 1 levels 
in these cells (One-way ANOVA with Bonferroni’s correction, **=p≤0.01, ***=p≤0.001, 
n=3). 
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Based on these results, three further 6-well plates of the 71Q line were differentiated 
and treated with DMSO (control), 3.3 µM PTI-UB (control), PTI-UD, PTI-UE and PTI-
UN as well as a media only control. The results are shown in figure 5.28 and figure 
5.29 respectively.   
 
 
Figure 5.28: Western blotting of further HTT exon 1 71Q ReNcellVM cells (biological 
replicates) treated with 3.3 µM dose of PTI compounds.  
 
 
 
Figure 5.29: Densitometry of Western blots of HTT exon 1 71Q ReNcellVM line treated 
with 3.3 µM dose of PTI compounds (figure 5.28). Results show mean+SEM. Left 
panel: results normalised to media only control, Right panel: results normalised to PTI-
UB control. In both panels, analysis of results with one-way ANOVA showed no 
significant differences between treatments (n=3).  
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The results were also combined with the 71Q line results from the previous experiment, 
in order to increase to n=4, however this made no difference to the overall results. 
Therefore the USP14 inhibitors supplied did not lower levels of HTT exon 1 in 
this cell model, and were not tested further.  
 
 
 
5.6 Discussion 
 
Increasing CAG repeat length in HTT exon 1 in ReNcellVM cells was found to cause 
nuclear inclusion body (IB) formation in the pathogenic lines.  The number of cells 
containing IBs increased on differentiation, and was highest amongst the matched 
expressing lines in the 129Q line (the longest CAG-repeat length). Raised expression 
levels of HTT exon 1 also led to increased IB formation, with the 71Q-H line displaying 
the most inclusion forming cells by two weeks.  Thus the development of inclusion 
containing cells can be seen to be proportional to CAG-repeat length and the level of 
HTT exon 1 expression in these lines, as has been previously shown in vitro 
(Scherzinger et al, 1999).  
 
Overall, only a small proportion of cells (up to 3% in the highly expressing 71Q-H line) 
developed intra-nuclear IB. It is not clear why some cells in particular were susceptible 
to inclusion formation, particularly since it could be seen from the GFP expression that 
cells with IBs were not more highly expressing mHTT exon 1 than the surrounding 
culture (the mHTT exon 1 construct is linked via an IRES site to GFP and therefore 
GFP expression is proportional to mHTT exon 1 expression). SIM imaging confirmed 
that nuclear inclusion formation appears to be an “all-or-nothing” process in these cells 
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and that the soluble cytoplasmic HTT exon 1 is reduced or absent in cells with nuclear 
IBs. Hence there looks to be a shift in mHTT exon 1 distribution from cytoplasm to 
nucleus, with associated IB formation, in a small number of cells. It is possible that on 
prolonged culture greater numbers of cells would accumulate inclusions, as HD is a 
progressive disease with onset generally in adult-life. Post-mortem studies of HD brain 
cortex have found neuronal inclusions in 3-6% of neurons in adult-onset patients and 
38-52% in JHD patients. Cortex from a patient with pre-symptomatic HD had no 
nuclear inclusions (DiFiglia et al, 1997).  
 
In this study inclusion formation was not associated with cell death, as there was no 
drop in cell count over time. Nuclei containing IBs did not appear to have abnormal 
morphology (except for a slight increase in overall nuclear area), and cells with 
inclusions did not have higher levels of activated caspase-3 staining. However it was 
not possible to track inclusion formation in specific neurons longitudinally over time and 
so the possibility that IB containing cells die and are replaced by others cannot be 
excluded. A longitudinal study tracking live cells over time has previously been carried 
out and did not find that inclusion formation led to cell death, rather it has a protective 
effect in neurons, possibly by reducing levels of soluble diffuse mHtt which was thought 
to be the toxic species (Arrasate et al, 2004). 
 
Immunofluorescence studies of the ReNcellVM lines showed that IBs do not recruit or 
bind full length endogenous mHTT. Cells with nuclear IBs were however noted on to be 
more rounded in shape and have reduced expression of cell markers, which was 
confirmed on image quantification with Columbus. This may suggest that cells with 
nuclear IBs become “inert” and do not differentiate as well as the surrounding culture. 
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This would be consistent with recent studies suggesting that inclusion formation is 
neither harmful nor protective but triggers a state of cellular quiescence, and shifts cells 
from a fast cell death by apoptosis due to soluble mHtt exon 1, to a slow death by 
necrosis due to co-aggregation with other proteins (Ramdzan et al, 2017). For future 
work to ascertain the effect of nuclear IBs on cells, or to determine which cellular 
factors favour IB formation, it would be useful to develop a method of separating such 
cells from the surrounding culture. This has previously been achieved in Neuro2a (N2a) 
cells expressing fluorescently tagged mHTT exon 1, using pulse-shape analysis 
(PulSA) by flow cytometry (Ramdzan et al, 2012), however mHTT exon 1 in the 
ReNcellVM cells does not contain a tag.  
 
A wide range of nuclear IB sizes was observed in the cells. This is consistent with 
previous studies suggesting that IBs are comprised of a heterogeneous population, 
including amyloid aggregates with a β-sheet structure (Caron et al, 2014; Nekooki-
Machida et al, 2009), and inclusions at various stages of maturity (Duim et al, 2014). In 
the ReNcellVM, inclusions did not stain with NIAD-4 (or Thioflavin T) suggesting that 
they do not contain amyloid. However, intracellular inclusions may be difficult for these 
dyes to access, and variable response of in vitro amyloid to ThioT has been reported 
(Chen et al, 2002). The intracellular location of mHTT inclusions also precluded live-cell 
imaging of inclusion formation in the ReNcellVM lines. Many previous studies have 
utilised fluorescent proteins such as GFP tagged or fused onto the HTT protein, 
however, the presence of the tag may affect the behaviour of the protein of interest and 
therefore this approach was not used.  
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Having determined that mHTT exon 1 exists in a number of forms in the HTT exon 1 
ReNcellVM lines, the impact of proteostasis modulation on the accumulation, 
distribution and clearance of mHTT exon 1 was then investigated. Bafilomycin A1 is a 
vacuolar ATPase inhibitor which interferes with the autophagosome–lysosome fusion, 
possibly because lysosomal acidification is required for this step (Yamamoto et al, 
1998). Treatment with bafilomycin resulted in increased HTT staining throughout the 
whole neuron (nucleus, cytoplasm and axons) across all ReNcellVM lines. This was 
also confirmed on high content image analysis with Columbus. This suggests that 
autophagy is at least partly responsible for the clearance of mHTT from these cells, 
and is in support of a previous finding that the degradation of polyQ expanded peptides 
is particularly dependent on autophagy (Tsvetkov et al, 2013).  
 
Surprisingly proteasomal inhibition with MG132 did not lead to increased levels of HTT 
in the ReNcellVM lines. However, on visual inspection of the images a striking 
redistribution of HTT exon 1 could be seen, with increased staining in nuclear and 
perinuclear regions, with no axonal/cytoplasmic signal. This may suggest that 
clearance of mHTT occurs via different mechanisms in different cellular compartments 
(Zhao et al, 2016), and is particularly UPS dependent in nuclear/perinuclear areas 
rather than axonal or cytoplasmic regions. There is also the possibility that MG132 
affects the mechanisms that govern the trafficking of the HTT protein itself within 
neurons.  
 
Proteasomal enhancement is a potential therapeutic avenue in HD and the 
overexpression of ubiquitin E3 ligase decreased mHTT aggregates in the brains of HD 
mice (Bhat et al, 2014). However, the USP14 inhibitors provided by Proteostasis 
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Therapeutics Inc (PTI) did not clear HTT exon 1 from the pathogenic ReNcellVM lines. 
There are many potential reasons for this including lack of target (USP14) 
engagement, or overwhelming the UPS by a general increase in ubiquitinated proteins. 
Another possibility is that mitochondrial dysfunction (which is known to occur in HD 
models) may preclude proteasomal enhancement because the UPS is a highly ATP-
dependent system. Indeed, mitochondrial deficits have been observed in the 
ReNcellVM HTT exon 1 lines by Dr. Wood-Kaczmar (unpublished data). 
 
 
 
5.7 Summary 
 
HTT exon 1 ReNcellVM neurons developed nuclear inclusion bodies in a manner 
proportional to CAG-repeat length and the level of mHTT exon 1 overexpression. Cells 
containing nuclear IBs displayed decreased or absent soluble cytoplasmic mHTT exon 
1, and reduced expression of cell markers. Although autophagy and proteasomal 
inhibition altered the distribution of mHTT within neurons, enhancement of the UPS 
with USP14 inhibitors had no effect on the clearance of mHTT exon 1 from ReNcellVM 
neurons.  
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6 Trafficking of huntingtin in HTT exon 1 
ReNcellVM neurons and in iPSC-derived 
medium spiny neurons  
 
6.1 Background 
 
Mutant huntingtin exerts a dominant toxic effect through a multitude of pathogenic 
mechanisms; among others, these include transcriptional dysregulation, abnormal 
mitochondrial transport and function, and impaired vesicular trafficking. It is not clear 
which of these pathways lends the greatest contribution to neurodegeneration in 
Huntington’s disease, particularly to the loss of striatal medium spiny neurons (MSNs) 
that is characteristic of HD. An understanding of the trafficking of the HTT protein itself, 
and how this is altered by the polyglutamine expansion mutation, might shed light on 
which of these mechanisms is the most important. Aberrant trafficking of the mutant 
protein may also play a role in pathogenesis.   
 
Initial studies of subcellular localisation of HTT and mHTT were hampered by the lack 
of well characterised HTT antibodies or human neuronal cell models, and yielded 
conflicting results. N-terminal fragments of mHTT formed aggregates in the cytoplasm 
and nucleus, but full length HTT (both wild-type and mutant) was only found in the 
cytoplasm (Cooper et al, 1998). An absence (or near absence) of nuclear HTT was 
also reported by other groups (Persichetti et al, 1995; Trottier et al, 1995). However 
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further immunofluorescence studies found that full-length wild type HTT could be 
detected in the nucleus of multiple mammalian cell lines (De Rooij et al, 1996; 
Dorsman et al, 1999), although neuronal intra-nuclear inclusions could only be 
detected by N-terminal antibodies in HD autopsy brain (Dorsman et al, 1999).  
 
More recent studies have suggested that the trafficking of HTT is dependent on the cell 
context.  Under basal conditions, huntingtin is thought to be an endoplasmic reticulum 
(ER)-associated protein, which attaches through its N-terminal membrane binding 
domain. On ER stress, HTT can dissociate and translocate to and from the nucleus. 
Loss of ER targeting of mHTT results in increased nuclear entry of mHTT and 
increased toxicity (Atwal et al, 2007). This has also been found to occur in response to 
reactive oxygen species (ROS) stress, which triggers structural change of the N17 
domain resulting in HTT dissociation from the ER membrane, increased N17 
phosphorylation, and nuclear targeting (DiGiovanni et al, 2016). Using novel 
chromobodies, HTT was shown to localise to sites of DNA damage within the nucleus 
of retinal epithelial cells, where it acts as a scaffold for proteins of the DNA damage 
response pathway, in a process which is deficient in HD patient fibroblasts (Maiuri et al, 
2017). HTT also localises to early endosomes and forms cytosolic puncta, termed 
huntingtin stress bodies (HSBs) as part of a rapid cell stress response, and this is 
associated with the arrest of endosomal trafficking which conserves ATP use. Mutant 
HTT displays defective recovery from this stress response (Nath et al, 2015).   
 
Nuclear huntingtin also increases at certain points during the cell cycle (Martín-Aparicio 
et al, 2002), and localises to the mitotic spindle during cell division (Godin et al, 2010). 
Within the nucleus, huntingtin has been localised to chromatin (Benn et al, 2008). 
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Stress dependent phosphorylation at Ser13 and Ser16 targets full-length HTT to 
chromatin-dependent sub-regions of the nucleus, the mitotic spindle and cleavage 
furrow during cell division (Atwal et al, 2011). Huntingtin has also been shown to 
transport to the nuclear compartment during the meiotic stage of spermatogenesis (Im 
et al, 2014).  
 
The entry or exit of proteins to and from the nucleus is a tightly controlled process. 
Smaller proteins (50-60kDa) may pass by passive diffusion though the nuclear pore 
complex (NPC), but larger proteins require a nuclear localisation signal (NLS) to enter 
via a facilitated diffusion mechanism. The NPC spans the nuclear envelope and is the 
main transport conduit between the nucleus and cytoplasm. It is made up of many 
subunit proteins called nucleoporins (NUPs), which have functions including nuclear 
import and export, RNA export and membrane anchoring. NUPs have been shown to 
be severely mislocalised in a number of HD cell models, leading to general deficits in 
both active and passive nucleocytoplasmic transport (Grima et al, 2017). Conversely, 
HTT itself is known to contain a nuclear localisation signal (NLS) near its N-terminus, 
between aa 174-207 (Desmond et al, 2012), and two nuclear export signals (NES), one 
at its C-terminus (Xia et al, 2003) and one within the N17 domain (Maiuri et al, 2013).  
This may explain the rapid pathology in the R6/2 mouse, which expresses aa 1-81 of 
Htt and does not contain the NLS; this small N-terminal fragment therefore can pass 
unrestricted into the nucleus by passive diffusion through the NPC. With CAG repeat 
lengths >335 in the R6/2 mouse a larger N-terminal fragment is generated, which 
cannot pass through the NPC by passive diffusion, and also does not contain the NLS; 
therefore cytoplasmic rather than nuclear inclusions are formed which may account for 
the striking improvement in phenotype that is seen (Dragatsis et al, 2009).  
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Hence multiple lines of evidence suggest that alterations in the trafficking of mutant 
HTT may play a role in disease pathogenesis. Therefore using an approach of 
subcellular fractionation followed by measurement of HTT levels in different cell 
compartments, the trafficking of HTT was studied in HTT exon 1 overexpressing 
ReNcellVM neurons and also in iPSC-derived MSNs. By studying both cell models, 
comparisons between the behaviour of HTT exon 1 and endogenous full length HTT 
could be made, in addition to evaluating differences any between mutant and wild-type 
HTT.  
 
 
6.2 Aims 
 
1. To determine any differences in the subcellular trafficking of control (29Q) and 
mutant length (129Q) HTT exon 1 in HTT exon 1 overexpressing ReNcellVM neurons. 
 
2.  To determine any differences in subcellular trafficking between wild type and mutant 
HTT in iPSC-derived MSNs. 
 
 
6.3 Methods 
 
HTT exon 1 overexpressing ReNcellVM cells and iPSC-derived MSNs were 
differentiated as described in section 2.1.3 and 2.2.6 respectively. In order to ensure 
correct differentiation of MSNs, immunocytochemistry was carried out (section 2.7.1) 
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with images taken on the Opera Phenix microscope as previously described (section 
2.7.2). Subcellular fractionation was carried out as per the protocol outlined by Thermo 
(section 2.9). A sample of each fraction was used to check for adequate separation 
using Western blotting (section 2.4.2) with antibodies to various compartment markers 
(appendix table A.1). Measurement of mutant and total HTT levels was carried out at 
Evotec, using the Erenna Singulex human huntingtin protein detection assay (section 
2.5). Graphical representation and statistical analysis was carried out using Prism 
software (section 2.10).  
 
 
6.4 Contributions 
 
The work described in this chapter was carried out by Dr. Rhia Ghosh, with the 
following exceptions: 
The measurement of HTT levels using the Erenna Singulex assay was carried out at 
Evotec by Drs Frank Herrman, Michaela Pirsch and Chantal Bazenet. 
The antibody staining and imaging of cells displayed in Figures 6.5 and 6.6 was carried 
out by Dr. Alison Wood-Kaczmar (due to Dr. Rhia Ghosh commencing maternity 
leave).  
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6.5 Results 
 
6.5.1 Trafficking of huntingtin protein in HTT exon 1 overexpressing  
ReNcellVM neurons 
 
To study the trafficking of HTT exon 1 in ReNcellVM neurons, subcellular  fractionation 
was carried out in dd14 neurons in the 29Q (control) and 129Q (mutant) lines, followed 
by measurement of total and mutant HTT levels in the resulting fractions with the 
Erenna Singulex human huntingtin protein detection assay. 
 
6.5.1.1 Subcellular fractionation of HTT exon 1 overexpressing ReNcellVM 
neurons 
 
Subcellular fractionation was used to separate ReNcellVM neurons into cytoplasmic, 
membrane-bound, soluble nuclear, chromatin bound and cytoskeletal fractions. This 
was followed by Western blotting to check for the presence of respective compartment 
markers in each fraction, to ensure satisfactory separation. Initial fractionation attempts 
produced very little material in each fraction (due to loss of material at each separation 
stage), with incomplete separation of nuclear, chromatin bound and cytoskeletal 
fractions. To compensate for this, the amount of starting material was increased to one 
confluent T175 flask. Solution buffers were doubled from the nuclear fractionation 
stage onwards, with the addition of an incubation step with 1 Ul benzonase to 
encourage separation of the chromatin bound fraction from the soluble nuclear fraction. 
It was decided that the cytoskeletal fraction (the final product after completion of the 
protocol) was not of sufficient purity to warrant further study.  
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Following optimisation of the fractionation protocol, ReNcellVM 29Q and 129Q cells 
were differentiated to dd21. A proportion of these cells were used to prepare whole cell 
pellets. The remainder underwent cell fractionation, of which a proportion of each 
fraction was used for Western blotting to ensure adequacy of separation. Results are 
shown in figure 6.1 and figure 6.2. ReNcellVM 29Q fractions displayed appropriate 
enrichment of compartment markers in each fraction on Western blotting. ReNcellVM 
129Q fractions were also well separated, however there was no signal for the nuclear 
compartment marker PMS2 (a mismatch repair endonuclease) in the soluble nuclear 
fraction. This may be because of the limited sample availability for this particular 
fraction (the majority of which was reserved for testing of HTT levels).  
 
Whole cell pellets and fractions of cytoplasm, membrane-bound, nuclear and chromatin 
bound samples for the HTT exon 1 ReNcellVM 29Q and 129Q lines were sent to 
Evotec for quantitative measurement of HTT levels.  
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Figure 6.1: Subcellular fractionation of dd21 ReNcellVM 29Q neurons. Western 
blotting with cell compartment markers shows good separation of the cytoplasmic 
marker HSP90 in lane S1, the membrane bound compartment marker calreticulin in 
lane S2, the nuclear marker PMS2 in lane S3, and the chromatin bound compartment 
marker histone 3 in lane S4. There is some overlap between fractions, which is to be 
expected. 
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Figure 6.2: Subcellular fractionation of dd21 ReNcellVM 129Q neurons. Western 
blotting with cell compartment markers shows good separation of fractions with HSP90 
(cytoplasmic marker), calreticulin (membrane bound compartment marker) and histone 
3 (chromatin bound) enriched in respective lanes. However the nuclear marker PMS2 
cannot be visualised in lane S3 – this is likely due to the small amount of material 
isolated for this fraction. 
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6.5.1.2 Measurement of total and mHTT levels in HTT exon 1 ReNcellVM 
neurons and cell fractions 
 
The Erenna Singulex human huntingtin protein detection assay was used to quantify 
levels of soluble total and mHTT in whole cell pellets and cell fractions of 29Q and 
129Q ReNcellVM dd21 neurons. This ultrasensitive single-molecule counting (SMC) 
mHTT immunoassay has previously been used to detect femtomolar levels of mHTT in 
the CSF of premanifest HD gene carriers (Wild et al, 2015). The antibody pair 
2B7/MW1 is used to detect levels of mutant HTT, and 2B7/4C9 is used to detect levels 
of total HTT. The latter is known to be the less sensitive assay. Readings were taken in 
triplicate for each line and results are shown in figure 6.3 and figure 6.4 respectively.   
 
As expected, mHTT exon 1 is detected in the ReNcellVM 129Q line, but not in the 
control ReNcellVM 29Q line. mHTT is found in all compartments in the mutant line, and 
the concentration of mHTT in the nucleus is seen to be extremely low in comparison to 
the cytoplasm and membrane-bound compartments. This is consistent with 
observations from immunofluorescence studies (chapter 5), particularly since this 
assay detects only soluble and not aggregated forms of mHTT.   
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Figure 6.3: Mutant HTT levels in ReNcellVM 29Q and 129Q neurons and cell 
fractions. Using the 2B7/MW1 Singulex assay mHTT exon 1 is detected in all fractions 
of the mutant 129Q line, but not in the control 29Q (as is expected). The concentration 
of mHTT in the nucleus is extremely low in comparison to the cytoplasm and 
membrane-bound compartments. (n=3, technical replicates).   
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Measurement of total HTT levels again shows the presence of HTT in all fractions of 
the 129Q line (this is likely to be mostly HTT exon 1, though this assay would also 
detect endogenous full-length HTT). HTT is also seen in the cytoplasmic, membrane 
bound, and nuclear fractions of the control 29Q line.  
 
The total HTT concentration in the cell (whole cell pellet) was significantly higher in the 
129Q line than the 29Q line (unpaired t-test). This was surprising as these lines were 
initially confirmed to have very closely matched expression levels of HTT exon 1 on 
MSD assay (chapter 3, section 3.5.3.2). Due to this difference in whole cell HTT 
concentration in 29Q and 129Q lines, further between-line comparisons of 
compartmental HTT concentration were not made. As a proportion of whole cell HTT 
levels, the nuclear HTT concentration is lower in the 29Q than the 129Q line (2.6% vs 
5.5%). This may suggest that mHTT 129Q HTT exon 1 accumulates in the nucleus 
more readily than control length 29Q HTT exon 1. 
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Figure 6.4: Total HTT levels in ReNcellVM 29Q and 129Q neurons and cell 
fractions. Using the 2B7/4C9 Singulex assay HTT exon 1 is detected in all 129Q 
fractions, including nuclear and chromatin bound fractions. The presence of HTT is 
also confirmed in the nucleus of the control 29Q line. n=3 (technical replicates).  
Chapter 6 
 
284 
 
6.5.2 Trafficking of huntingtin protein in iPSC-derived MSNs 
 
The trafficking of HTT protein in iPSC-derived MSNs was then studied using the same 
approach as for the HTT exon 1 ReNcellVM neurons. In this case, MSNs express HTT 
from the endogenous locus only, so HTT levels would be expected to be much lower. 
Control length (20Q) and the longest mutant length (73Q) iPSCs were utilised to 
enhance the chance of observing mutant HTT driven differences between the lines. 
Three clones of each line were used as biological replicates to account for clonal 
variability. After differentiation of iPSCs into MSNs, subcellular fractionation was carried 
out, followed by measurement of total and mutant HTT levels as previously described. 
 
6.5.2.1 Differentiation of iPSC-derived MSNs  
 
Three clones of the control iPSC line (designated 20Q clone 1, 20Q clone 2 and 20Q 
clone 3) and mutant 73Q iPSC line (designated 73Q clone 1, 73Q clone 2 and 73Q 
clone 3) were differentiated in 10 cm dishes to generate sufficient material. A 
proportion of cells were grown in Ibidi glass-bottom wells for imaging purposes. These 
iPSC lines were derived from a related family as described in chapter 3; in the case of 
these two particular lines, an unaffected mother (control) and affected son (carrying an 
HTT mutation with 73 CAG repeats). MSN differentiation was carried out for at least 36 
days (as per protocol), and cultures have been shown to be comprised of 50% MSNs 
from this time (Arber et al, 2015). A portion of cells were fixed and stained to ensure 
correct differentiation, with results of one control and one mutant (73Q) clone as shown 
in figure 6.5 and figure 6.6. Work is currently on-going in the lab to quantify the 
proportion of MSNs generated using high-content imaging. 
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Figure 6.5: Immunocytochemistry of control 20Q clone 2 cell cultures at dd36. 
Many cells display DARPP-32 staining with characteristic MSN morphology. High 
densities of clustered nuclei are observed, due to ongoing cell proliferation during 
differentiation. Prominent B3-tubulin staining confirms that the majority of the culture is 
neuronal. Blue – Hoescht (nuceli), White – anti-B3-tubulin antibody, Green – anti-
DARPP-32 antibody.  
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Figure 6.6: Immunocytochemistry of mutant 73Q clone 2 cell cultures at dd36. 
Mutant neurons also display DARPP-32 staining, confirming that they also differentiate 
into a predominantly neuronal culture with a high proportion of MSNs. Clusters of nuclei 
are observed, due to ongoing cell proliferation during differentiation. Blue – Hoescht 
(nuceli), White – anti-B3-tubulin antibody, Green – anti-DARPP-32 antibody.  
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6.5.2.2 Subcellular fractionation of iPSC-derived MSNs 
 
Subcellular fractionation was carried out using the optimised protocol, and Western 
blotting with compartment markers carried out to ensure adequate separation of 
cytoplasmic, membrane-bound, nuclear and chromatin-bound fractions. Results are 
shown in figures 6.7 - 6.12. Whole cell pellets were also prepared.  
 
20Q clone 1 and 2, and 73Q clone 2 and 3 MSN fractions displayed appropriate 
enrichment of compartment markers on Western blotting, suggestive of good 
separation of the different fractions. 20Q clone 3 and 73Q clone 1 MSN fractions also 
showed good separation of all fractions except for the nuclear fraction, which showed 
no signal on Western blotting with nuclear compartment markers PMS2 or MLH1.  This 
is likely due to the limited amount of sample produced during nuclear fractionation, of 
which the majority therefore was reserved for the quantification of HTT levels.  
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Figure 6.7: Subcellular fractionation of 20Q clone 1 MSNs (dd49). Western blotting 
with cell compartment markers shows enrichment of the cytoplasmic marker HSP90 in 
lane S1, the membrane bound compartment marker calreticulin in lane S2, the nuclear 
marker MLH1 in lane S3, and the chromatin bound compartment marker histone 3 in 
lane S4.  
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Figure 6.8: Subcellular fractionation of 20Q clone 2 MSNs (dd43): Western blotting 
with cell compartment markers shows enrichment of the cytoplasmic marker HSP90 in 
lane S1, the presence of membrane bound compartment marker calreticulin in lane S2, 
the nuclear marker MLH1 in lane S3, and the enrichment of chromatin bound 
compartment marker histone 3 in lane S4. 
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Figure 6.9: Subcellular fractionation of 20Q clone 3 MSNs (dd39). Western blotting 
with cell compartment markers shows enrichment of the cytoplasmic marker HSP90 in 
lane S1, the presence of membrane bound compartment marker calreticulin in lane S2, 
and the enrichment of chromatin bound compartment marker histone 3 in lane S4. No 
signal with nuclear marker MLH1 was obtained, and this was also found to be the case 
with PMS2 antibody. No other compartment markers are visible in lane S3 which 
suggests that insufficient material was loaded for Western blotting. 
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Figure 6.10: Subcellular fractionation of 73Q clone 1 MSNs (dd38). Western 
blotting with cell compartment markers shows enrichment of the cytoplasmic marker 
HSP90 in lane S1, the presence of membrane bound compartment marker calreticulin 
in lane S2, and the enrichment of chromatin bound compartment marker histone 3 in 
lane S4. No signal with nuclear marker MLH1 was obtained, and this was also found to 
be the case with PMS2 antibody. No other compartment markers are visible in lane S3 
which suggests that insufficient material was loaded for Western blotting. 
Chapter 6 
 
292 
 
 
Figure 6.11: Subcellular fractionation of 73Q clone 2 MSNs (dd45). Western 
blotting with cell compartment markers shows enrichment of the cytoplasmic marker 
HSP90 in lane S1, the membrane bound compartment marker calreticulin in lane S2, 
the nuclear marker MLH1 in lane S3, and the chromatin bound compartment marker 
histone 3 in lane S4. 
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Figure 6.12: Subcellular fractionation of 73Q clone 3 MSNs (dd47). Western 
blotting with cell compartment markers shows enrichment of the cytoplasmic marker 
HSP90 in lane S1, the membrane bound compartment marker calreticulin in lane S2, 
the nuclear marker MLH1 in lane S3, and the chromatin bound compartment marker 
histone 3 in lane S4. 
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6.5.2.3 Measurement of total and mHTT levels in iPSC-derived MSNs and cell 
fractions 
 
The Erenna Singulex human huntingtin protein detection assay was used to quantify 
levels of total and mHTT in whole cell pellets and cell fractions of MSN control 20Q and 
mutant 73Q lines. The three epistemic replicates (clones) of the control 20Q and 73Q 
line were analysed, with the results as shown in figure 6.13 (mHTT) and figure 6.14 
(total HTT). 
 
Mutant huntingtin is confirmed to be present in the 73Q line but not in the control line. 
Within the 73Q line, mHTT is present in all fractions tested although the concentration 
detected in the chromatin bound fraction is low enough to be considered background 
noise. The presence of endogenous soluble mutant huntingtin is observed in the 
nucleus of human HD MSNs, where it is found at a much lower concentration than 
seen in cytoplasm and membrane-bound compartments, a pattern that was also 
observed in the 129Q HTT exon 1 mutant ReNcellVM line.  
 
The total HTT assay detects wild-type HTT in the control MSN line, and both mutant 
and wild-type HTT in the 73Q MSN line. Results show that the highest concentration of 
HTT is in the cytoplasm and membrane-bound fractions in both lines. Soluble HTT is 
again found in the nuclear fraction of both control and mutant MSN lines, at a much 
lower level, and suggests the presence of soluble wild-type huntingtin in the nucleus of 
human control MSNs. 
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Figure 6.13: Mutant HTT levels in control and 73Q MSNs and MSN cell fractions. 
mHTT is detected in all fractions of the mutant 73Q line, though levels shown in the 
chromatin-bound fraction are likely to be background noise. As expected, no mHTT is 
found in the control MSN line. The concentration of mHTT in the nucleus is extremely 
low in comparison to the cytoplasm and membrane-bound compartments. (n=3, 
biological replicates).   
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Figure 6.14: Total HTT levels in control and 73Q MSNs and MSN cell fractions. 
HTT is detected in both line in all fractions, though ultra-low levels in the chromatin 
bound fraction is likely to be background noise. The concentration of soluble HTT is 
highest in cytoplasm and membrane-bound compartments, with much lower levels 
found in the nucleus. There are no significant differences between the two lines in any 
of the cell fractions (Two-way ANOVA with Bonferroni’s correction, n=3 (biological 
replicates)).  
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The total HTT assay uses a combination of 2B7 and 4C9 antibodies to detect all HTT 
present, both mutant and wild-type (provided the N-terminal is present). 4C9 binds to 
the polyproline region on the N-terminal and is not polyQ length dependent – therefore 
between-line comparisons can be made and statistical analysis carried out. Two-way 
ANOVA of the results revealed no significant difference between the HTT concentration 
of control and 73Q MSNs in any of the fractions tested. 
 
The total HTT concentration was much lower (at least ten-fold in the case of control 
lines and 20-30 fold in the case of the mutant lines) in the nucleus of the MSN samples 
compared to the HTT exon 1 ReNcellVM lines, suggesting that in both control and 
mutant ReNcellVM lines, the HTT exon 1 protein is the principle component of the 
nuclear fraction.  
 
 
6.6 Discussion 
 
Subcellular fractionation followed by the measurement of HTT levels using the Erenna 
Singulex assay was used to study the trafficking of HTT in HTT exon 1 overexpressing 
ReNcellVM neurons and in iPSC-derived MSNs. Using this approach, some soluble 
wild-type HTT was found in the nucleus of human MSNs, and soluble mHTT was 
detected in human HD MSNs. A similar pattern was found in the HTT exon 1 
overexpressing ReNcellVM line, with both soluble 29Q HTT exon 1 (control) and 129Q 
HTT exon 1 (mutant) present in the nucleus. In all cases, the concentration of nuclear 
HTT was considerably lower than that in the cytoplasm. This finding is consistent with 
previous studies that have shown the presence of wild-type and mutant HTT in the 
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nucleus of mammalian cell lines, but at a lower concentration than in the cytoplasm (De 
Rooij et al, 1996; Dorsman et al, 1999). 
 
In the ReNcellVM lines, the concentration of nuclear mutant 129Q HTT exon 1 was 
over double that of 29Q HTT exon 1 (as measured by the total HTT 2B7/4C9 assay, as 
a proportion of the whole cell pellet HTT level). This would suggest that mutant HTT 
exon 1 accumulates more readily in the nucleus than control HTT exon 1, although it 
should be noted that the presence of “wild-type” HTT exon 1 (in contrast to full-length 
HTT) has never been confirmed in control human neurons. This assay does not detect 
aggregates or inclusions, but it is possible that mHTT oligomers that are formed along 
the pathway to IB generation in the 129Q line are detected by this assay. Mutant HTT 
oligomeric species may not be able to exit the nucleus (due to increased 
size/conformation), and therefore the concentration of soluble mHTT is higher in the 
nuclear compartment of the 129Q line compared to the 29Q control. Another possibility 
is that due to a conformational change in the 129Q HTT exon 1, the N17 nuclear export 
signal (Maiuri et al, 2013) is less accessible. A previous study has found that small N-
terminal HTT fragments interact with the nuclear pore protein translocated promoter 
region (Tpr), which is involved in nuclear export. PolyQ expansion and aggregation 
decreases this interaction, impairs nuclear export of N-terminal mHTT and increases 
the nuclear accumulation of mHTT (Cornett et al, 2005).  
 
No significant differences were found between the trafficking of wild-type and mutant 
HTT in the control and mutant MSN lines, with the distribution of soluble HTT similar 
across all cell compartments in both cases. This may suggest that the pathogenic 
pathways triggered by mHTT are due to its aberrant interactions within key cellular 
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pathways, rather than any deficit or alteration in the trafficking of the HTT protein itself.  
Another possibility is that differences in HTT trafficking are only apparent in the context 
of cell stress and this experiment was performed in unstressed neurons. Multiple lines 
of evidence now suggest that nuclear localisation of wild-type HTT occurs in response 
to cell stress (Atwal et al, 2007; DiGiovanni et al, 2016), where it localises to sites of 
DNA damage and acts as a scaffold for proteins of the DNA repair pathway, in a 
process that is impaired in HD cells (Maiuri et al, 2017). Localisation of wild-type HTT 
to early endosomes also occurs as part of a rapid stress response and mutant HTT 
displays defective recovery from this (Nath et al, 2015). 
 
It is notable that although mutant 129Q HTT exon 1 seems to accumulate in the 
nucleus more readily than control 29Q HTT exon 1, the levels of total HTT were not 
higher in the nuclei of mutant compared to control MSNs. This may be due to the fact 
that N-terminal HTT overexpression models exhibit phenotypes on a much faster 
timescale than full-length HTT models. Mutant HTT exon 1 is considerably smaller than 
full length mHTT and may enter the nucleus more readily, with higher expression levels 
leading to faster build-up. Alternative splicing is thought to lead to the generation of 
mHTT exon 1 from full-length mHTT, a process that may be occurring in the 73Q MSN 
line (Neueder et al, 2017; Sathasivam et al, 2013); however it is possible that more 
time would be needed to accumulate biologically significant levels of mHTT exon 1 in 
this manner.   
 
One issue that was encountered in using this approach to study HTT trafficking was 
that the technical replicates of HTT measurement using the Erenna Singulex assay 
showed some variability, and in the case of the MSNs, there was also variation 
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between clones. This variation was present even in the whole cell pellets and therefore 
is not due to the fractionation technique. In addition, subcellular fractionation is not 
completely precise, with loss of cell material during the fractionation steps. In making 
between-lines comparisons however, this effect is partly mitigated.  
 
Another issue is that the proportion of MSNs generated in culture was not quantified 
prior to subcellular fractionation of the global culture. This work is currently on-going in 
the lab, but previous studies have reported that this differentiation protocol generates 
cultures with 50% MSNs (Arber et al, 2015). MSNs are GABAergic striatal projection 
neurons derived from the progenitor zone of the lateral ganglionic eminence (LGE); 
LGE progenitors may be defined by the combinatorial expression of several 
transcription factors including FoxP1, FoxP2, CTIP2, Nolz1, Dlx2 and Gsx2, all of 
which regulate fate specification of MSNs. The presence of mature MSNs is generally 
demonstrated by the presence of DARPP-32 staining, but mature MSNs also express 
CTIP2, GAD 65/67; neuronal identity can be confirmed by co-staining with MAP2 or 
NeuN markers. MSNs also have a distinct appearance comprising a branching, 
multipolar morphology with numerous spines. Quantification of MSNs using 
immunofluorescence staining with combinations of markers, prior to fractionation, 
would have been useful to understand the degree to which this study represents the 
trafficking of HTT within actual MSNs, as it is not possible currently to separate these 
MSNs from the surrounding culture prior to experimentation.  
 
Live-cell imaging would be a useful approach to study HTT trafficking in neurons; 
however in both the HTT exon 1 overexpressing ReNcellVM neurons and the iPSC-
derived MSNs, there is no fluorescent tag to allow visualisation of the HTT protein. The 
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presence of such a tag fused onto the HTT protein may also alter its dynamics, and 
would not in any case allow visualisation of the endogenous HTT within the MSNs. 
Recently a novel approach using HTT intrabodies fused to fluorescent proteins has 
been utilised to study HTT trafficking in human retinal epithelial cells; intrabodies are 
expressed within the cell and can be manipulated to bind to HTT within particular cell 
compartments (Maiuri et al, 2017). In the future, such a method may allow the 
visualisation of endogenous wild-type and mHTT within patient derived cells. 
 
 
6.7 Summary 
 
A study of HTT trafficking in the HTT exon 1 overexpressing ReNcellVM lines has 
shown that mutant (129Q) HTT exon 1 accumulates in the nucleus more readily than 
control (29Q) HTT exon 1. However, there were no significant differences between the 
trafficking of wild-type and mHTT in the control and mutant iPSC-derived MSN lines. 
Soluble HTT, both wild-type and mutant, was detected in the nucleus of control and HD 
MSNs respectively. 
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7 Conclusions and future work 
 
Over thirty years have passed since the discovery of the causative genetic mutation in 
Huntington’s disease (Huntington's Disease Collaborative Research Group, 1993), but 
a full understanding of the mechanisms by which the consequent neuronal 
degeneration occurs remains incomplete. HTT CAG-repeat length is the key 
determinant of disease status and is inversely correlated with age at disease onset; an 
understanding of how increasing CAG-repeat length drives increasing neurotoxicity will 
likely further our knowledge of HD pathogenesis and help to guide research efforts in 
HD therapeutics.  This thesis describes the development of novel HTT allelic series 
human neuronal cell models of HD, and subsequent experiments to determine the 
effect of CAG-repeat length on neuronal phenotypes and on the HTT protein itself.  
 
 
7.1 Conclusions and main findings 
 
7.1.1 Generating a HTT allelic series neuronal cell model of Huntington’s 
disease  
 
HD is a human neurodegenerative disease and therefore it is likely that cell culture 
models comprising human neurons are most likely to recapitulate the true pathogenic 
mechanisms underpinning disease. Increasing HTT CAG-repeat length on an 
otherwise constant genetic background eliminates any genetic heterogeneity that might 
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also affect disease-associated phenotypes. Consequently attempts were made here to 
create an isogenic HTT allelic series in the human neural stem cell (NSC) ReNcellVM 
line using rAAV vectors to knock in increasing CAG repeat lengths into the endogenous 
HTT locus. For a number of potential reasons this approach was not successful; the 
rate of homologous recombination in the ReNcellVM line was much lower than 
expected (Khan et al, 2011; Khan et al, 2010) and it is possible that the length of the 
desired insertion sequence may have been too long relative to the length of the 
guidance homology arms. In addition, pools of cells initially containing the positively 
integrated vector lost this over subsequent passages or freeze/thaw, perhaps due to a 
selective advantage of wild-type cells in the speed of cell division/doubling time and/or 
in their tolerance of cell stress. Indeed there is evidence that mHTT affects mitotic 
spindle formation (Godin et al, 2010) and cells expressing mHTT are known to be more 
sensitive to stress (Zhang et al, 2010). 
 
Next, efforts were made to optimise and characterise a human neural stem cell HTT 
exon 1 overexpression model of HD. An allelic series containing HTT exon 1 with 29Q, 
71Q and 129Q repeats with relatively matched expression levels was generated in 
ReNcellVM NSCs. This panel was shown to differentiate into B3-tubulin positive cells, a 
proportion of which displayed HTT inclusion bodies in the pathogenic lines (71Q and 
129Q). HTT exon 1 and N-terminal fragment models of HD have many advantages 
over full-length HTT models. Mutant phenotypes develop over a much faster timescale 
and are therefore more amenable for study, as has been demonstrated by the R6/2 
mouse model (Mangiarini et al, 1996), and HTT exon 1 cell models of rat striatal 
progenitors (Colby et al, 2006) and human neuroblastoma cells (Ho et al, 2001). An 
abnormal splicing mechanism (Sathasivam et al, 2013) for the generation of mHTT 
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exon 1 has been shown in patient derived fibroblasts and post-mortem human brain 
tissue (Neueder et al, 2017),  and many studies have indicated the importance of HTT 
exon 1 in HD pathogenesis (DiFiglia et al, 1997); (Barbaro et al, 2015; Landles et al, 
2010).  
 
To complement this HTT exon 1 model, a full length HTT model was also generated in 
iPSCs derived from a genetically related HD family comprising three siblings with 
juvenile HD carrying HTT with 56, 67 and 73 CAG repeats respectively, and their 
unaffected mother (as control). These lines were shown to differentiate into a high 
proportion of MSNs, the predominant cell type that is affected in HD. Induced PSCs 
derived from patients are the most genetically precise disease model, but comparison 
between control and HD lines may be hampered by background genetic heterogeneity 
of the donors. In generating new HD-iPSC lines using fibroblasts from the same family, 
it was hoped that the impact of genetic heterogeneity would be diminished when 
making between-line comparisons of neuronal phenotypes. Previous studies in HD-
iPSC derived neurons have reported subtle differences compared to control iPSCs in 
terms of protein expression, differentiation efficiency and neurite length (Chae et al, 
2012), as well as in lysosomal function (Camnasio et al, 2012) and caspase 3/7 activity 
(Zhang et al, 2010). In addition, HD-iPSC lines have been shown to display 
neurodevelopmental abnormalities on differentiation (Conforti et al, 2018).  
 
In recent years, advances in iPSC research have led to improvements in 
reprogramming techniques (Fusaki et al, 2009) and neuronal differentiation protocols 
(Arber et al, 2015). In addition, the development of CRISPR (clustered regularly 
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interspaced short palindromic repeats)/Cas9 (CRISPR-associated system 9) nuclease 
for precision genome editing has revolutionised the field of molecular biology. Indeed 
this technique has recently been used to create the first isogenic HTT allelic series in 
human embryonic stem cells (hESCs) (Ruzo et al, 2018). Use of CRISPR/Cas9 to 
create an isogenic HTT allelic series in the ReNcellVM line is also feasible, and such a 
line would be highly suitable for high content screening of therapeutic compounds due 
to its robust and rapid neuronal differentiation.  
 
7.1.2 Effect of increasing HTT exon 1 CAG repeat length on human 
neuronal phenotypes 
 
Having optimised a HTT exon 1 overexpressing allelic series in the ReNcellVM line, the 
effect of increasing CAG-repeat length on neuronal phenotype and the response to cell 
stress was then studied. A small decrease in B3-tubulin positive cells was seen in the 
129Q ReNcellVM on neuronal differentiation, and there was a marginal increase in 
anti-activated caspase 3 staining in the highly expressing 71Q-H ReNcellVM line, as 
detect by high content imaging and analysis. Surprisingly, the HTT exon 1 ReNcellVM 
allelic series did not display overt neuronal toxicity or increased vulnerability to toxins in 
the pathogenic lines. 
 
The lack of obvious overt pathogenic neuronal phenotypes in this line may reflect the 
fact that the symptoms of HD take many years to manifest, even in patients who have 
juvenile HD. Neuronal cultures derived from the HTT exon 1 ReNcellVM lines displayed 
persistent GFAP and nestin staining and were therefore relatively immature/not true 
neurons (section 3.5.3.3), and it is possible that an extended period of cell 
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culture/aging is needed before neuronal toxicity is evident the pathogenic lines. In 
addition, the HTT exon 1 ReNcellVM lines have relatively low levels of HTT exon 1 
overexpression (levels are often not published in papers using other transgenic HTT 
exon 1 models) and wild-type huntingtin is known to have a neuroprotective effect 
(Rigamonti et al, 2001).  
 
The finding that B3-tubulin expression is slightly reduced in the 129Q ReNcellVM line 
may hint towards adverse neuronal differentiation in this line, although the finding that 
none of these cell lines differentiated into true neurons should be borne in mind. In 
support of this, recent papers have described an effect of mutant HTT on early 
neurodevelopment, in terms of chromosomal instability and failed cytokinesis (Ruzo et 
al, 2018), as well as impaired neuro-ectodermal acquisition and disrupted 
cytoarchitecture (Conforti et al, 2018). The increased anti-activated caspase 3 staining 
in the highly expressing 71Q-H ReNcellVM line is backed by studies showing that 
caspase 3 activation is detected on Western blotting of cell lysates after 24 hours of 
mutant but not control length HTT exon 1 expression in PC12 cells (Sahoo et al, 2016). 
Activated caspase 3 is a key effector of apoptosis and its increased presence in 71Q-H 
ReNcellVM cells may be a marker of early toxicity in this line. 
 
7.1.3 The effect of increasing CAG repeat length on HTT exon 1 protein in 
human neuronal cells 
 
HTT exon 1 ReNcellVM neurons developed nuclear HTT inclusion bodies (IBs) in a 
manner proportional to CAG-repeat length and the level of HTT exon 1 overexpression, 
confirming previous findings (Scherzinger et al, 1999). Interestingly, only a small 
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percentage of cells developed IBs, even in the highly expressing 71Q-H line. Super-
resolution imaging confirmed that nuclear inclusion formation is an “all-or-nothing” 
process with an apparent shift in HTT exon 1 distribution from cytoplasm to nucleus 
that accompanies IB formation. Why certain cells should be susceptible to this process 
is not clear, however it is possible that on prolonged culture greater numbers of cells 
would accumulate IBs as HD is generally an adult-onset, progressive disease. 
 
Neuronal inclusion formation was not associated with cell death or increased levels of 
activated caspase-3 staining, suggesting that they are not intrinsically harmful 
(Arrasate et al, 2004). Cells with nuclear IBs were however noted to be more rounded 
in shape and have reduced expression of cell markers, suggesting that cells with 
nuclear IBs become “inert” and do not differentiate as well as the surrounding culture. 
This is consistent with recent studies suggesting that inclusion formation is neither 
harmful nor protective but triggers a state of cellular quiescence (Ramdzan et al, 2017). 
A wide range of nuclear IB size was observed in the ReNcellVM cells, supporting 
previous studies which suggest that IBs are comprised of a heterogeneous population 
including amyloid aggregates with a β-sheet structure (Caron et al, 2014; Nekooki-
Machida et al, 2009) and inclusions at various stages of maturity (Duim et al, 2014).  
 
Having determined that mHTT exon 1 exists in a number of forms in the HTT exon 1 
ReNcellVM lines, the impact of proteostasis modulation on the accumulation, 
distribution and clearance of mHTT exon 1 was investigated. Treatment with the 
autophagy inhibitor bafilomycin resulted in increased HTT staining throughout the 
whole neuron (nucleus, cytoplasm and axons), whereas proteasomal inhibition with 
MG132 led to a striking redistribution of HTT exon 1, with increased staining in nuclear 
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and perinuclear regions, and no axonal/cytoplasmic signal. This may suggest that 
clearance of mHTT occurs via both autophagy and the UPS, and is particularly UPS 
dependent in nuclear/perinuclear areas. Alternatively, MG132 may be affecting HTT 
trafficking, either directly or indirectly. Unfortunately, proteasomal enhancement with 
USP14 inhibitors provided by Proteostasis Therapeutics Inc (PTI) did not clear mHTT 
exon 1 from the pathogenic ReNcellVM lines, despite previous studies suggesting this 
as a promising therapeutic approach in HD (Bhat et al, 2014). This may be due to a 
lack of target (USP14) engagement in these cells, or overwhelming the UPS with a 
general increase in ubiquitinated proteins.  
 
7.1.4 Trafficking of huntingtin in HTT exon 1 ReNcellVM neurons and in 
iPSC-derived medium spiny neurons  
 
The trafficking of HTT between different cellular compartments in HTT exon 1 
overexpressing ReNcellVM neurons was studied using subcellular fractionation 
followed by the measurement of soluble HTT levels using the Erenna Singulex assay. 
This revealed that mutant (129Q) HTT exon 1 accumulated in the nucleus more readily 
than control (29Q) HTT exon 1, but in both cases the concentration of nuclear HTT was 
considerably lower than that of the cytoplasm. This finding was not unexpected (De 
Rooij et al, 1996; Dorsman et al, 1999); mutant HTT exon 1 may be less readily 
exported from the nucleus due to its propensity to form mHTT oligomers en route to IB 
generation.  PolyQ expansion and aggregation has been previously shown to decrease 
the interaction of small N-terminal HTT fragments with the nuclear pore protein, leading 
to impaired nuclear export and nuclear accumulation of mHTT (Cornett et al, 2005).  
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The same experimental approach was used in control and mutant (73Q) iPSC-derived 
MSNs and revealed no significant difference between the trafficking of full-length wild-
type and mHTT in these cells. Soluble HTT, both wild-type and mutant, was detected in 
the nucleus of control and HD MSNs respectively, again at a much lower concentration 
than that of the cytoplasm. However it is worth noting that the MSNs that were studied 
using this approach were part of a global cell culture, and were not quantified prior to 
subcellular fractionation. Previous studies have suggested this differentiation protocol 
generates 50% MSNs as defined by DARPP-32 staining (Arber et al, 2015); however 
even at this proportion any MSN specific findings may be missed and at present it is 
not possible to separate intact MSNs from the surrounding culture. Future experiments 
on these iPSC lines will require some form of immunofluorescence quantification in 
order to ascribe differences to MSNs specifically. 
 
It is possible that differences in HTT trafficking between wild-type and mutant protein 
may only be apparent under conditions of cell stress; wild-type HTT undergoes nuclear 
localisation in response to cell stress (Atwal et al, 2007; DiGiovanni et al, 2016), where 
it localises to sites of DNA damage and acts as a scaffold for proteins of the DNA 
repair pathway, in a process that is impaired in HD cells (Maiuri et al, 2017). Wild-type 
HTT also localises to early endosomes as part of a rapid stress response and mutant 
HTT displays defective recovery from this (Nath et al, 2015). 
 
The utility of using both HTT exon 1 and full-length HTT iPSC-derived models is 
highlighted by this study of HTT trafficking, in which different results were observed in 
each model. The ReNcellVM HTT exon 1 model exhibited a mutant trafficking 
phenotype by two weeks of differentiation, whereas this was absent in the more 
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genetically precise iPSC-derived MSN model. This may reflect the fact that N-terminal 
HTT overexpression models exhibit phenotypes on a much faster timescale than full-
length HTT models. However, there is also the possibility that HTT exon 1 cell models 
exhibit phenotypes that are not present or different in full-length HTT cell models; 
repeating this experiment in MSNs following prolonged culture would distinguish 
between these two possibilities.  
 
 
7.2 Insights and future work 
 
Over ten years have passed since the discovery that iPSCs could be generated by the 
expression of four key factors in somatic cells (Takahashi et al, 2007). Since that time 
iPSC models have been generated for many neurodegenerative diseases, and 
differentiation protocols have been optimised to generate a range of neuronal cell types 
(Arber et al, 2015; Shi et al, 2012). The advantages of iPSC based modelling are that 
the cells represent one of the most genetically precise cell models to date, and that 
once generated, they form a renewable resource for the entire research community. 
They may in the future also provide a source of neurons for transplantation into 
patients, either from healthy donor cells or from autologous fibroblasts modified to 
correct the causative genetic mutation. However, neuronal differentiation protocols are 
generally still long and complex, as they attempt to recapitulate various stages of 
neuronal development. In addition they do not display overt mutant phenotypes on 
timescales compatible with standard research protocols, though they may allow the 
study of some of the earlier, subtler phenotypes that precede neurodegeneration.   
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Recently the direct reprogramming of human fibroblasts into striatal MSNs has been 
achieved through the ectopic expression of brain-enriched microRNAs (miRNAs) miR-
9/9* and miR-124 (miR-9/9*-124), co-expressed with transcription factors enriched in 
the developing striatum (Victor et al, 2014). The method has also been applied to 
HD patient fibroblasts, and the resulting HD MSNs readily displayed HD-associated 
phenotypes, including the formation of mHTT aggregates, DNA damage, 
spontaneous neuronal death in culture, and a decline in mitochondrial function 
(Victor et al, 2018). Unlike iPSC-derived MSNs, HD-associated phenotypes are 
thought to result from the retention of the cellular age-related features when directly 
reprogramming cells; this includes epigenetic changes, oxidative stress, and any 
DNA damage already sustained by the donor cell. These elements are lost when 
reprogramming fibroblasts into iPSCs by traditional means.  
 
In the case of HD, there remains a role for HTT exon 1 or N-terminal fragment 
overexpression models that overcome some of these limitations of iPSCs. In particular, 
such models lend themselves to high content screening of therapeutics as they can be 
easily generated in cells that are amenable to high throughput cell culture and 
generally have more overt disease phenotypes. However many potential therapeutic 
agents show promise in early stages of drug testing and then fail in human trials, and 
this may in part be because the models used for testing are not fully representative of 
the disease state.  A combined approach using HTT exon 1 models for initial 
compound screening, followed by more targeted iPSC-based experiments may be the 
most suitable approach for the future. 
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Technology for high content screening (HCS) has advanced rapidly in recent years. 
HCS refers to the automated and rapid measurement of multiple cell parameters with 
cell imaging, in a high throughput manner. Most commonly HCS is used in drug 
discovery to visually identify phenotypic changes in response to various test 
compounds. However HCS can also be used to identify and quantify biological and 
pathogenic processes (Carty et al, 2015), and in this thesis was used to demonstrate 
CAG-repeat length dependent changes in IB formation in the ReNcellVM line. The 
acquisition of thousands of images in an automated manner allows for objective and 
robust statistical analysis of the results, and can identify rarer phenotypes in a small 
percentage of cells. The disadvantage is the need to optimize differentiation of cells in 
96- or 384-well plates that are amenable to confocal imaging, however with 
improvements in general cell culture protocols, this will likely be overcome in the near 
future.   
 
The long-standing debate over the role of HTT inclusions in the pathogenesis of HD 
has still not been fully resolved, with studies suggesting that they may be harmful, 
protective or neutral.  In this study IBs were found to be associated with increased 
nuclear size and reduced expression of cell markers but not with increased cell death. 
As HTT is an intracellular protein, it was not possible to visualize inclusion formation in 
living ReNcellVM cells, or to separate IB containing cells from the surrounding culture. 
Previous studies have achieved this using cell models containing fluorescently tagged 
HTT exon 1 with pulse-shape analysis (PulSA) by flow cytometry (Ramdzan et al, 
2012), however it is possible that the presence of a tag affects the behaviour and 
dynamics of the HTT protein. Recently a novel approach using HTT intrabodies fused 
to fluorescent proteins has been utilised to study HTT trafficking in human retinal 
epithelial cells (Maiuri et al, 2017). This approach could be used to study inclusion 
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formation in the HTT exon 1 ReNcellVM line, and also in iPSC-derived MSNs. 
Combined with live-cell imaging techniques, HTT intrabodies could also be an 
alternative method to study HTT trafficking in the MSN lines in the future.  
 
It is clear that HD pathogenesis involves a variety of cellular mechanisms and a 
number of key questions remain; this includes the reason for the specific striatal 
degeneration that is observed, why only certain cells develop HTT inclusions, and the 
factors that trigger the actual onset of disease or neurodegeneration in patients after a 
period of clinically normal neurodevelopment and brain function. The answer to these 
questions and further insights into HD pathogenesis may provide alternative avenues 
to therapies for HD, as there are currently no disease-modifying treatments available.  
However a promising approach that is currently undergoing clinical trials in patients is 
the lowering of HTT levels using anti-sense oligonucleotides delivered by intra-thecal 
injection.  This would minimise all the downstream negative effects of mHTT protein 
expression, and the drug has been shown to be safely tolerated in a Phase 1/2a trial in 
early stage HD patients (Tabrizi et al). Whilst the search for small molecule 
therapeutics continues, HTT lowering offers real hope to HD patients for a viable 
treatment in the coming years.  
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Appendix 
 
A.1 Media components 
Unless stated otherwise, all cell culture reagents were from purchased Gibco and 
supplementary chemicals were from Sigma-Aldrich. 
 
A.1.1  Neural stem cell medium 
NSC medium comprised Dulbecco’s Modified Eagle's Medium (DMEM): Nutrient 
Mixture F-12 (F12) supplemented with:  
0.03% Human albumin solution  
5 µg/ml Transferrin (human recombinant)  
16.2 µg/ml Putrescine dihydrochloride 
5 µg/ml Insulin (human recombinant) 
400 ng/ml L-thyroxine 
337 ng/ml Tri-iodo-thyronine 
60 ng/ml Progesterone 
2mM L-glutamine 
40 ng/ml Sodium selenite 
10 Units/ml Heparin sodium 
10 ng/ml Corticosterone 
10 ng/ml basic Fibroblast growth factor (bFGF) [Peprotech] 
20 ng/ml Epidermal growth factor (EGF) [Peprotech] 
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A.1.2 Neural differentiation medium 
 
The basic neural differentiation medium was the same as the NSC medium listed 
above, but without bFGF or EGF. For ReNcell VM differentiation, the concentration of 
L-glutamine was reduced to 0.5 mM after 2 weeks.  
 
A.1.3 HEK culture medium 
HEK culture medium comprised DMEM:F12 with:  
2 mM L-glutamine  
10% fetal bovine serum (FBS) [Invitrogen] 
100 U/ml penicillin 0.1 mg/ml streptomycin [Invitrogen] 
 
A.1.4 HCT116 culture medium  
This comprised McCoy’s 5A modified medium with:  
2 mM L-glutamine  
10% FBS  
50 U/ml penicillin 50 ug/ml streptomycin 
 
A.1.5 Fibroblast culture medium 
Fibroblast culture medium comprised DMEM with glutamax and 4.5g/L of glucose and 
1mM pyruvate with:  
10% foetal bovine serum (FBS) 
50 U/ml penicillin, 50 ug/ml streptomycin  
2.5 ml/L amphotericin B  
The amphotericin was added just prior to use for the first two weeks of cell culture, after 
which its addition was no longer required. 
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A.1.6 N2B27 differentiation medium for MSNs 
 
This comprised 2/3 volume DMEM:F12 medium and 1/3 volume Neurobasal with:  
1:100 L-Glutamine 
1:150 N2 
1:150 B27 (without vitamin A until dd26 and with vitamin A post dd26) 
0.1 mM B-mercaptoethanol 
 
 
A.2 Antibodies for Western blotting and confocal microscopy 
 
A.2.1 Western blotting 
 
Appendix Table A.1: Primary and secondary antibodies used in Western blotting 
Primary antibody Dilution Species Supplier 
S830 (Anti-HTT) 1:2000 Sheep Bates (in house) 
4C9 (Anti-HTT) 1:1000 Mouse CHDI 
aa 1-82 (N82) (Anti-HTT) 1:500 Mouse Merck 
MW1 (Anti-HTT) 1:1000 Mouse Merck 
3B5H10 (Anti-HTT) 1:2000 Mouse Merck 
D7F7 (Anti-HTT) 1:1000 Rabbit Cell Signaling 
Technology 
2B7 (Anti-HTT) 1:750 Mouse CHDI 
MAB2166 (Anti-HTT) 1:1000 Mouse Merck 
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Green fluorescent protein (GFP) 1:2000 Rabbit Santa-Cruz 
Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) 
1:10,000 Rabbit Merck 
Beta-actin  1:10,000 Mouse Merck 
Beta-actin  1:5000 Rabbit Merck 
Beta 3 tubulin (B3T) 1:5000 Rabbit Abcam 
Glial fibrillary acidic protein (GFAP) 1:5000 Rabbit Abcam 
Nestin 1:5000 Mouse Abcam 
Microtubule-associated protein 2 (MAP2) 1:1000 Rabbit Merck 
Human HuD neuronal protein (HuD) 1:500 Rabbit Merck 
Oligodendrocyte transcription factor 1 (Olig 1) 1:250 Mouse Merck 
Neurofilament (NF200) 1:250 Mouse Merck 
Heat shock protein 90 (HSP90) 1:1000 Mouse Abcam 
Calreticulin 1:500 Rabbit Abcam 
Mismatch repair endonuclease PMS2 (PMS2) 1:200 Rabbit Merck 
MutL homolog 1 (MLH1) 1:1000 Mouse Merck 
Histone 3 (H3) 1:5000 Mouse Cell Signaling 
Technology 
Secondary antibody Dilution Species Supplier 
IRDye 800CW anti-goat  1:10,000 Donkey LI-COR 
IRDye 680LT anti-mouse 1:10,000 Goat LI-COR 
IRDye 680LT anti-rabbit 1:10,000 Goat LI-COR 
IRDye 800CW anti-mouse 1:10,000 Goat LI-COR 
IRDye 800CW anti-rabbit  1:10,000 Goat LI-COR 
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A.2.2 Confocal microscopy (including high content screening) 
 
Appendix Table A.2: Primary and secondary antibodies used for confocal microscopy 
and high content screening 
Primary antibody Dilution Species Supplier 
S830 (Anti-HTT) 1:250-500 Sheep Bates (in house) 
EM48 (Anti-HTT) 1:50-100 Mouse Merck 
aa 1-82 (Anti-HTT) 1:200-500 Mouse Merck 
4C9 (Anti-HTT) 1:500 Mouse CHDI 
MW1 (Anti-HTT) 1:500 Mouse Merck 
3B5H10 (Anti-HTT) 1:500 Mouse Merck 
MAB2170 (Anti-HTT) 1:500 Mouse Merck 
Beta 3 tubulin (B3T) 1:500 Rabbit Abcam 
Glial fibrillary acidic protein (GFAP) 1:500 Rabbit Abcam 
Nestin 1:600 Mouse Abcam 
Caspase 3 1:100 Rabbit Abcam 
Microtubule-associated protein 2 (MAP2) 1:200 Rabbit Sigma 
Dopamine- and cAMP-regulated 
phosphoprotein, 32 kDa (DARPP-32) 
1:500 Rabbit polyclonal Abcam 
Forkhead box protein P1 (FOXP1) 1:500 Mouse monoclonal Abcam 
Secondary antibody Dilution Species Supplier 
Anti-goat IgG (H+L) Alexa Fluor 546  
 
1:10000 Donkey Thermo 
Anti-rabbit IgG (H+L) Alexa Fluor 633 
 
1:10000 Goat Abcam 
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Anti-rabbit IgG (H+L) Alexa Fluor 488 1:10000 Goat Abcam 
Anti-rabbit IgG (H+L) Alexa Fluor 568 1:10000 Goat Abcam 
Anti-mouse IgG (H+L) Alexa Fluor 568 
 
1:10000 Donkey Abcam 
Anti-mouse IgG (H+L) Alexa Fluor 633 
 
1:10000 Goat Abcam 
Anti-mouse IgG1 Alexa Fluor 488 1:10000 Goat Abcam 
Anti-mouse IgG2 Alexa Fluor 568 1:10000 Goat Abcam 
 
 
 
 
A.3 Solutions and buffers 
 
Lysis buffer to prepare Exon 1 overexpressing ReNcells for Western blotting: 
PBS  
1% Triton X-100  
0.5% sodium deoxycholate (SDS) 
1x protease inhibitor cocktail [Roche] (1 tablet diluted in 500 µl of H20 makes a 100x 
solution that can be kept for 2 weeks at -20°C) 
 
5x sample buffer to prepare lystaes for Western blottin): 
0.625M Tris pH 6.8  
50% glycerol  
10% (w/v) SDS  
Trace Bromophenol blue  
10% β-mercaptoethanol (added in the fume hood) 
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This 5x sample buffer can be stored at -20°C and freeze-thawed. The solution is diluted 
in water to make 1x sample buffer. 
 
10x running buffer for Western blotting:  
0.25M Tris pH 8.6 
1.92M Glycine  
1% SDS  
The solution is diluted in water to make 1x running buffer. 
 
1x transfer buffer for Western blotting. To make 1 L: 
100 ml of 10x transfer buffer: 
0.25M Tris pH 8.6  
1.92M Glycine  
200 ml methanol 
700 ml ddH20
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